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ABSTRACT
ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is a neurological disease mainly characterized by 
progressive motor neuron degeneration and muscle atrophy that lead to premature death. 
It is not yet fully understood in terms of etiology and, as a consequence, it is still orphan 
of cures. This project was aimed at studying some of the main reliable causal events 
leading to motor neuron degeneration in ALS, i. e. AMP A receptor (AMPAR)- 
dependent excitotoxicity, neuroinflammation and intracellular protein aggregation.
1) We investigated the intracellular mechanisms that are induced in motor neurons by 
AMPAR-mediated excitotoxicity, demonstrating that different death pathways were 
activated depending on the intensity of the initial stimulus to the receptor. Low AMPAR 
agonist concentrations induce, indeed, the typical intracellular events of the apoptotic 
pathway, while higher concentrations trigger to non-apoptotic motor neuron death.
2) We analysed the intracellular effect of mediators of the inflammatory signalling, i.e. 
TNF-a and IL-8, and their interaction with the AMPAR-dependent excitotoxic 
pathway. We demonstrated that IL-8-induced motor neuron death is specifically 
mediated by the CXCR2 chemokine receptor. TN F-a exerts both neurotoxicity and 
neuroprotection against AMPAR-mediated cell death. The presence of mature and 
active glial population is determinant in mediating TNF-a effect.
3) We studied the effect of intracellular a-synuclein accumulation in motor neurons, 
revealing a dual concentration-dependent effect since micromolar protein concentrations 
are neurotoxic, while nanomolar concentrations induce neuroprotective effect against 
oxidative stress.
In light of such results, we tested the effectiveness of potentially neuroprotective drugs 
which could interfere with the intracellular death mechanisms of motor neurons. We 
found that Erythropoietin (EPO) and different non-erythropoietic EPO derivatives 
(CEPO, ASIALOEPO and HBP) have specific neuroprotective properties against the
2
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apoptotic AMPAR-dependent death pathway. Reparixin, an orally active chemokine 
receptor (CXCR1/2) inhibitor was successfully tested against the EL-8-dependent motor 
neuron death.
All together these results add further useful information to define the complex ALS 
etiology and provide interesting pharmacological approaches which could be relevant 
for the treatment of the pathology.
3
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INTRODUCTION 
Chapter 1 - ALS
1.1 History
Amyotrophic lateral sclerosis is a severe neurological disease associated with 
degeneration and loss of motor neurons at different levels of the motor system. 
“Amyotrophic” refers to muscle weakness, atrophy and fasciculation that account for 
the effect on motor neurons. “Lateral sclerosis” relates to the rigidity of the lateral 
columns of the spinal cord in autopsy specimens due to gliosis of the cortico-spinal 
tracts (Rowland & Shneider 2001). The French neurobiologist Jean-Martin Charcot 
first clearly identified the disease (also known as “Maladie de Charcot”) in 1869 
(Charcot 1869). ALS is also colloquially known in the United States as Lou Gehrig’s 
disease, named after the New York Yankee baseball player who developed the disease 
in the 1930s. Many other well known individuals have been affected by the pathology 
during recent years, including professional Italian soccer players who have seen a ten­
fold increased incidence of ALS (Belli & Vanacore 2005). The Nobel-prize-winning 
astrophysicist Stephen Hawking, suffering from an unusually slowly progressing form 
of the disease, is an example demonstrating how selective the neuronal loss can be. He 
has no cognitive impairment, but an almost complete paralysis of his arms, legs and the 
muscles necessary for speech (schematic summary of the main features of the disease 
reported in Fig. 1.1). On the other hand, ALS is a very heterogeneous disease displaying 
a huge complexity in terms of genetic, biochemical and clinical features. Indeed, despite 
developments in histopathological techniques, the introduction of clinical 
neurophysiology, and the use of neuroimaging techniques, the diagnosis of ALS still 
requires the skills of an experienced neurologist with techniques that were available at 
the turn of the nineteenth century. Pathogenic mechanisms of the disease are still 
unknown and a variety of potentially toxic events could account for the onset of the
14
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Fig. 1.1 Schematic recapitulation of the main events involved in ALS.
disease. As a consequence of this complexity and heterogeneity, potential biomarkers 
have never been assessed and therapeutic strategies are hard to devise. In fact, although 
numerous compounds have been tested in clinical trials, as yet only riluzole has been 
proven effective for the treatment of ALS (Miller et al. 2007). However, riluzole 
showed only a little survival benefit (Miller et al. 2007, Zoccolella et al. 2007) and 
patient care has to be supported by palliative therapies throughout the entire course of 
the pathology. In summary, given this evidence of general failure, from the basic 
research to the therapeutic approach, a great effort is required in order to change the fate
15
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of this still incurable and fatal disease. Multidisciplinary studies, both on patients and
animal models as well as at the cellular level with the use of tissue or cell cultures
should be a challenge to obtain more knowledge about the pathogenic mechanisms of
the disorder and to devise effective therapies.
1.2 Epidemiology
A wide rate variability in the incidence of ALS was reported since epidemiological 
studies were based on variable sizes of the study populations and on the use of different 
diagnostic criteria and methods of case ascertainment (Swash 2000). More 
homogeneous results have been recently reported from population-based registries, 
when similar diagnostic criteria and case ascertainment methods were adopted, 
indicating the incidence of ALS from 1.7 to 2.5 per 100,000 population per year in 
industrialized European countries (Beghi et al. 2007, Logroscino et al. 2005). A great 
variety of disease variants and ALS-like syndromes has been reported over the years 
leading to up to 10% of misdiagnosed ALS patients. The absence of biological markers 
of the disease and the complexity of the clinical features concur to render ALS a 
member of a group of heterogeneous disorders, some of which have common clinical 
features while others show different clinical and pathological progression of the disease 
(Beghi et al. 2007). Increased age of onset, low forced vital capacity, rapid symptom 
progression and bulbar site of onset have all been indicated as adverse prognostic 
factors. However, the rate of disease progression varies greatly among patients. Clinical 
observations suggest an individual rate of disease progression in most patients. A direct 
relationship between rate of progression, as determined by isometric myometry (Brooks 
1991), and patient survival was shown in many patients enrolled in therapeutic trials 
(Armon et al. 2000, Smith et al. 1993).
16
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ALS has an extremely low incidence under age 30 and is almost absent under 20 years.
The risk increases highly between 50 and 60 years of age with a clear increase with age
until the seventh decade (Beghi et al. 2006). However, there is still insufficient evidence
to conclude that ALS is an age-related or an aging-related disease. The difficulty in
defining ALS in the elderly, due to misdiagnosis with other clinical conditions as well
as the presence of numerous comorbidities affecting muscle strength and motion, makes
this question even more difficult to answer. The only study (performed in Rochester,
Minnesota, US; Yoshida et al. 1986) which showed an exponential increase in the
incidence of the disease was performed in a small sample of patients. A more recent
study (performed on a larger sample) showed a peak in the 60- to 69-year age group,
consistent with several other populations (Sorenson et al. 2002).
Males are usually affected more than females (1.6:1), although most recent publications
report a significant decrease in the male/female ratio in the 1990s (incidence of ALS in
Europe shown in Fig. 1.2).
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Fig. 1.2 Age specific incidence of ALS for males and females in four European 
population-based registries (taken from Logroscino et al. 2008).
A host of environmental factors have been investigated with alternating fortunes as 
potential risk factors for ALS (Armon 2001, Mitchell 2000). These include conjugal 
ALS (i.e., the disease has occasionally been reported in husband and wife), correlation
17
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with antecedent poliomyelitis or concurrent neoplasms (adenocarcinoma, lymphoma,
adenoma), exposure to (heavy) metals (including lead, mercury and selenium), to
solvents or to electrical or electromagnetic fields, mechanical trauma, heavy physical
activity, and living in rural areas or using chemical substances in agriculture.
Interestingly, cigarette smoking was the only risk factor supported by fairly good
epidemiological evidence (Armon 2003). This finding indicates that the increasing
incidence of ALS in women can be related to changing in the contemporary lifestyle
which includes exposure to risk factors previously limited to males.
Recent observations of ALS cases in professional soccer players brought into the
spotlight the debate whether it could be considered an occupational disease and what are
the pathological reasons for its increased incidence in this specific group of athletes. A
study on 24,000 Italian professional soccer players who played between 1960 and 1997,
found out a tenfold increase in ALS risk since eight soccer players died from the
pathology, while the number of cases expected was 0.61 (Belli & Vanacore 2005). This
observation was confirmed by recent findings in a cohort of 7325 professional football
players (Chio et al. 2005) revealing an overall standardized morbidity ratio of 6.5. The
position played and the duration of the practice was significantly correlated with the
disease risk, with midfielders showing the highest incidence. In addition, the risk was
highest in individuals playing 5 years or longer (15.2). A plethora of possible risk
factors associated with the participation in competitive sports has been suggested from
the literature over the last years. The Body Mass Index and the increased muscularity of
the athletes, exposure to herbicides or fertilizers used on playing fields, the frequent
occurrence of microtrauma, exposure to dietary supplements or drugs used to enhance
sporting performances, have all been proposed as possible events involved in the
abnormal incidence of this pathology among the professional soccer players (Chio et al.
2005).
18
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Oxidative stress is also associated with strenuous physical activity, and reactive oxygen
species are involved in neurodegeneration. In fact, there is indirect evidence of an
increased production of reactive oxygen species (ROS) when combining strenuous
exercise with other factors (dietary habits, drugs, ischemia followed by reperfusion)
(McArdle et al. 2001). Oxidative stress can potentially induce detrimental changes in
crucial metabolic functions including nucleic acid damage (Cleveland & Rothstein
2001, Julien 2001). However, despite these apparently striking findings no conclusive
results have been obtained by individual studies on a single risk factor in the
pathogenesis of ALS. A multidisciplinary study seems to be the only practical approach
to providing biological support for the epidemiologic evidence and to identify sport-
related abnormalities possibly linked to ALS.
Increased risk of ALS was present in Western Pacific areas, especially between the 
Chamorros, the indigenous population of Guam and other Mariana Islands. The 
recognition of ALS cases among different ethnic groups with similar socio-cultural 
habits enforced the hypothesis of the influence of environmental factors, including 
elements in the soil and water, nutrition and exposure to migratory birds. The role of 
methylaminoalanine in these foci is of particular interest. Research suggests a 
cyanobacterial origin for methylaminoalanine in cycad seeds with resultant 
biomagnification in the food chain (Ince & Codd 2005).
Approximately 5-10% of ALS cases are familial usually showing an autosomal- 
dominant pattern of inheritance. Autosomal-recessive forms have also been described, 
particularly from highly consanguineous populations in north Africa (Figlewicz &
Orrell 2003). Mutations in the copper/zinc superoxide dismutase (SOD1) gene on 
chromosome 21 accounts for 10% to 20% of autosomal dominant patients. A number of 
other genes that cause familial amyotrophic lateral sclerosis (fALS) has also been
19
PhD Thesis, M. De Paola
INTRODUCTION - Chapter 1-1.3 
discovered and are discussed in detail in Chapter 1.5. Other linkages have also been
reported in people with fALS but the genetic lesion in most of these affected individuals
remains unknown.
1.3 Clinical features and diagnosis
Although it is now considered a multisystem disease with an important extra motor 
component, ALS remains a typical motor disorder (Oey et al. 2002, Isaacs et al. 2007). 
The clinical features of amyotrophic lateral sclerosis are strictly dependent on the 
progressive loss of both glutamatergic (motor cortex) and cholinergic (brain stem and 
anterior horns of the spinal cord) motor neurons. In general, the disease course is 
characterized by progressive neurodegeneration, muscle weakness with denervation and 
paralysis (main CNS regions and muscles affected by the pathology in Fig. 1.3),
Upper motor neurons 
in motor cortex
Brain
Brain stem lower 
motor neurons 
controlling speech  
and swallowing
B rain stem
Cortocospinal 
tract from upper 
motor neurons
-  Spina
Lower motor 
neurons controlling 
limb and respiratory muscles
Brain
Brainstem
Leg
m uscles
Face and  
tongue
Arm
m uscles
Intercostal
m uscles
Fig. 1.3 Main regions of the CNS and muscular system affected by ALS
(modified from Goodall & Morrison, 2006).
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culminating in the patient’s death within 3 to 5 years from symptom onset, primarily
due to respiratory failure (Mitchell & Borasio 2007).
Although there is a formal separation between sporadic (sALS) and familial groups, 
both forms show similar clinical and pathological features and seem to share common 
pathophysiological mechanisms (Ince et al. 1998b). The onset of the clinical phase is 
revealed by functional changes in ALS patients and possible abnormalities in isokinetic 
muscle tests at a time when isometric strength is not yet reduced in these patients (de 
Carvalho et al. 2003). At the symptomatic phase ALS patients show changes in 
isokinetic strength as well as early changes in isometric strength. During this phase, 
pathology is usually reported to be more severe in the anatomical areas where ALS had 
initially started but progressively increases even in regions to which the symptoms had 
spread (Ince et al. 1998a). Patients presenting bulbar onset show slurring of speech 
(dysarthria), difficulty swallowing (dysphagia), or both. Bulbar involvement is 
associated with upper and lower facial weakness and poverty of palatal movement with 
wasting, weakness, and fasciculation of the tongue. When upper motor neurons are 
mainly involved, patients present emotional lability (also known as pathological 
laughing or crying), brisk jaw jerk, and dysarthria. Cervical-onset patients present 
upper-limb symptoms, either bilateral or unilateral. Proximal weakness with difficulty 
in shoulder abduction (e.g., hair washing, combing, etc) and profuse arm fasciculation 
and distal weakness with impairment of activities requiring pincer movements are 
shown. Lumbar onset implies degeneration of the anterior-horn cells of the lumbar 
enlargement and is associated with lower motor neuron symptoms and signs in the legs, 
such as a tendency to trip (foot drop) or difficulty on stairs.
Although involvement of other systems is not considered in ALS clinical observations, 
recent studies have revealed the concomitant presence of unrelated symptoms, including
21
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sensory dysfunction, autonomic nervous system abnormalities, mood alterations and
cognitive abnormalities (Daube 2000, Mulder et al. 1983).
The progressive atrophy of respiratory muscles results in respiratory failure, the most 
common cause of death in ALS patients. Measurements of forced vital capacity are 
useful to identify early respiratory problems (Borasio & Voltz 1997). Dyspnoea at rest 
is the earlier hallmark of respiratory failure. As the respiratory difficulty increases, 
attacks of sleep apnoea do not allow patients to sleep supine. During the development of 
the disease, when respiratory forced activity is completely lost, patients need assisted 
ventilation (Gelanis 2001).
Diagnosis of ALS is usually based on clinical evaluations supported by 
electrophysiological assessments. As a consequence of the lack of a specific test or 
biological markers, up to 10% of patients initially diagnosed with ALS might be 
affected by different disorders (Bradley et al. 2004).
Progressive spinal muscular atrophy, cervical radiculomyelopathy, thoracolumbar-sacral 
disc disease, multifocal motor neuropathy, chronic inflammatory demyelinating 
neuropathy, adult-onset spinal muscular atrophy, myasthenia gravis, spinobulbar 
muscular atrophy (Kennedy’s disease), multiple sclerosis, cerebrovascular disease, and 
multiple system atrophy have been misdiagnosed as ALS (Traynor et al. 2000, Visser et 
al. 2002). The factors that guide clinicians to the correct diagnosis include the lack of 
progression, the development of atypical symptoms, and the results of additional 
investigations. In fact, for the correct identification of ALS, signs of upper and lower 
motor neuron involvement and a progressive spread of neurological signs from the 
bulbar or spinal region of onset towards other areas are required.
Assessment of disease progression is also difficult. Several different functional scales, 
new neurophysiological tests, and imaging techniques have been developed but none
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of these has sufficient diagnostic or prognostic certainty (Mitsumoto et a l  2007,
Winhammar et al. 2005). To date, the most useful clinical measures are vital capacity
(Czaplinski et al. 2006) and the revised ALS functional rating scale (Cedarbaum et a l
1999, Kaufmann et a l 2005). Functional rating scales are excellent primary outcome
measures since the complexity of ALS clinical features requires a pragmatic
classification containing precise diagnostic criteria. Such determination was first
devised in El Escorial (Madrid) in 1990 (Brooks 1994). The “El Escorial” scale is based
on different parameters, clinical features that allow classification of the probability of a
patient having ALS, according to the degree of clinical certainty in relation to other
pathologies, such as multiple sclerosis, cervical myelopathy and other similar
neuromuscular disorders (Brooks 1994). The “El Escorial” scale includes four degrees
of certainty for the diagnosis of ALS. They can range from "clinically definite" to
"clinically suspected". In 1994 neuropathological analyses were included in the “El
Escorial” diagnostic criteria (World Federation of Neurology Research Group on
Neuromuscular Disease Subcommittee on Motor Neuron Disease). The list of
neuropathological features supporting the diagnosis included selective atrophy of the
motor cortex, greyness and atrophy of anterior spinal nerve roots compared with normal
roots, grains of the lateral columns of the spinal cord and atrophy of skeletal muscles.
Features that rule out the diagnosis of ALS or suggest the presence of an additional
disease were considered to be plaques of multiple sclerosis or a focal cause of
myelopathy.
Because of the inability to confirm a diagnosis of ALS exclusively by gross 
examination of the brain and spinal cord tissues, light and electron microscopy analyses 
are needed. Although it represents a valid criterion to diagnose ALS, this approach 
cannot evaluate the progression of symptoms. To determine a more efficient protocol to
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score the progression of symptoms, “El Escorial” criteria have subsequently been
revised and to date the ALS Functional Rating Scale (ALS FRS) is the most widely
used in clinical trials. Although intended as an aid to research and slightly more
restrictive than the burden of proof usually applied in clinical practice, these criteria do
provide a structured approach to assessment of people suspected of having amyotrophic
lateral sclerosis, which can enhance objectivity in clinical practice and facilitates
clinical studies. The ALS FRS is a ten-item scale with five different scores for each
item. The total score is obtained by the sum of scores for each single item and increases
proportionally to the symptomatological worsening. The evaluation of three bulbar
functions (speech, salivation and swallowing), one respiratory function (breathing),
three upper-extremity (handwriting, cutting food and dressing), one truncal function
(turning in bed) and two lower-extremity (walking and climbing stairs) are included in
ALS FRS (ALS CNTF Treatment Study group-no authors listed).
The aim of this scale is: I) to provide a unique, simple, reproducible, sensitive and
specific protocol to test the possible efficiency of drugs during clinical trials; II) to
better characterize and separate the evolution of symptoms among the different forms of
ALS; III) to define the different stages of disease for a population of patients who might
have all types of onset.
1.4 Histo- and cyto-pathological hallmarks
In the study of neurodegenerative diseases, knowledge of the descriptive 
neuropathology is essential to draw out the clinical pattern of the disease, to 
differentiate among distinct pathologies sharing similar symptoms and to understand 
whether neuropathological observations found in animal models are similar to the 
human condition. From a pathological point of view ALS is mainly characterised by 
degeneration and loss of motor neurons associated with gliosis. Intracellular inclusions
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were found in degenerating neurons and glia. Abnormalities in mitochondria and axons,
and alterations in neurofilament composition were revealed in ALS patient specimens
and in transgenic mice with a mutation in SOD1. The main neuropathological
alterations in both upper glutamatergic as well as lower cholinergic motor neurons are
described in detail below.
Upper motor neurons and cortico-spinal tract
In the cerebral cortex a marked decrease in large pyramidal motor neurons has been 
predominantly observed in the motor area. However, neuronal abnormalities are not 
confined to the motor cortex; in fact, a lesser degree of damage was also reported in the 
premotor areas, sensory cortex and temporal cortex. Quantitative histological studies of 
cortical motor neurons revealed changes in size with shortened and fragmented 
dendrites. Accumulation of neurofilaments and ubiquitinated proteins are common 
before motor neuron death (Kiernan & Hudson 1991). Demyelination, due to axonal 
degeneration of descending large myelinated fibers of cortical motor neurons, is a 
common feature in the cortico-spinal tract of ALS patients. Moreover, cortico-spinal 
fibres showed a marked axonal swelling and spheroids containing packed 
neurofilamentous material and other cellular debris are found (Chou 1992).
Lower motor neurons
A marked loss of spinal motor neurons showing a patchy and focal pattern was found 
in the anterior horn of ALS patients (Tsang et al. 2000). Quantitative histological 
studies showed that large motor neurons are selectively involved. In these cells neuronal 
shrinkage or atrophy precedes neuronal death and also involves alterations to axons and 
dendrites. Loss of Nissl substance (chromatolysis), vacuolization and lipofuscin 
deposits are sometimes detectable in the remaining anterior horn motor neurons
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(Kiernan & Hudson 1991). Since spinal motor neurons represent the best-studied and
characterized group of cells affected by the pathology, a detailed description of
ultrastructural alterations found in these neurons is reported below.
Neurofilament alterations
Cytoskeletal components direct several processes of eukaryotic cells, including mitosis, 
cell motility, endocytosis, and the maintenance of cellular shape. Moreover, in neurons, 
cytoskeletal organisation is fundamental to connect the cellular body to the periphery, 
axons and dendrites, and to regulate the transport of a large number of molecules by an 
extensive network of microtubules and filaments (Bloom & Goldstein 1998). 
Neurofilaments are the most abundant filamentous component in neurons. They are 
divided into three different classes, light neurofilaments (NF-L) medium neurofilaments 
(NF-M) and heavy neurofilaments (NF-H) depending on their molecular size (Al- 
Chalabi & Miller 2003). In healthy motor neurons neurofilaments are expressed in the 
perikaryon and are then transported toward the periphery in a not-phosphorylated form. 
Neurofilament phosphorylation is a crucial event for the assembling of single 
neurofilaments taking place when they reach the target cellular localization. This 
mechanism is essential for the extension of axons and to maintain the integrity of 
neuronal morphology (Shea et al. 2003). In recent years a growing body of evidence 
suggests that various neurodegenerative diseases share a similar process in which 
neurofilaments are phosphorylated and accumulated in the cell body of dying neurons 
(Taylor et al. 2002, Zhao et al. 2001). A common pathological feature, observed in 
autoptic samples of ALS patients, is the presence of a marked accumulation of 
intermediate filaments in the perikaryon of motor neurons and in their axons (Gambetti 
et a l 1983, Hirano et a l 1984). Immunostaining experiments with monoclonal 
antibodies directed against the three different forms of neurofilaments showed a 5 to 10
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fold increased immunopositivity in motor neurons from ALS patients compared to those
from control patients (Rouleau et al. 1996). Abnormal neurofilaments accumulation in
the perikaryon occurs in two distinct patterns: homogeneously diffuse or focally
accumulated in various shapes. Neurofilaments are not the unique category of
cytoskeletal components present in ALS inclusion bodies. Peripherin is another protein
detected in the majority of inclusions in motor neurons of ALS patients (Corbo & Hays
1992, Migheli et al. 1993). Peripherin is normally expressed in peripheral sensory
neurons but is almost absent in the motor neurons (Escurat et al. 1990, Troy et al.
1990). However, peripherin gene expression can be up regulated by nerve injury and
inflammatory cytokines (Wong & Oblinger 1990).
Intracellular inclusions
Several types of inclusion bodies that were found in the perikarya of anterior horn 
motor neurons are immunoreactive to ubiquitin (Leigh et al. 1989). Ubiquitin is a 76- 
amino acid-protein that is involved in an ATP-dependent nonlysosomal proteolysis of 
abnormal or short-lived proteins (Leigh et al. 1991). Although ubiquitin inclusions in 
lower motor neuron are unique to ALS tissues, ubiquitin-immunoreactive intraneuronal 
inclusions were often observed in the upper motor neurons (Morris et al. 2001) and are 
not specific to this disease (Wilson et al. 2001). By immunoelectron microscopy 
observation, it was shown that these ubiquitin-reactive inclusions are composed of small 
10-15 A linear fragments whose exact identity remains undiscovered (Okamoto et al. 
1991a). Lewy-body-like hyalin inclusions were originally described as a characteristic 
feature of posterior columns and spinocerebellar tracts in ALS patients, but furthermore 
they have also been found in the soma and in the proximal axons of anterior horn motor 
neurons (Murakami 1990). These inclusions measure 7 to 20 ^min diameter and are 
surrounded by a lighter, slightly basophilic halo and contain a dense eosinophilic core
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of granules associated with a patchy shaped aggregate of filaments. These filaments are
not immunoreactive to any cytoskeletal components such as neurofilaments, tubulin,
microtubule-associated protein 2, or phosphorylated tau protein. These inclusions are
similar to those described in the Lewy bodies in Parkinson’s disease.
Bunina bodies are hystologically described as small, eosinophilic, irregularly shaped, 2
to 3 |xm in diameter and exclusively found in the perikaryon. Ultrastructurally, they are
electron dense amorphous structures surrounded by lysosomal vesicles, endoplasmic
reticulum fragment, lipofuscin granules and other debris.
An intriguing relationship between bunina bodies and Golgi apparatus fragments has 
been hypothesised because of the presence in the bunina bodies of marked 
immunoreactivity for anti-cystatin C antibody, a protein highly expressed in the Golgi 
apparatus (Okamoto et al. 1991b).
Mitochondrial alterations
Abnormalities in mitochondrial morphology and alterations in electron transport chain 
activities were found both in muscle samples from patients with ALS and in the 
transgenic SOD1 mouse model of the pathology. When analysed by electron 
microscopy, muscle mitochondria showed ultrastructural abnormalities including 
increased size, paracrystalline inclusions and abnormal cristae (Mourelatos et al. 1996). 
Similar observations come from the G37R and G93A mouse models where membrane- 
bound vacuoles in axons, dendrites and motor neurons appeared to be derived from 
degenerating mitochondria (Bendotti et al. 2001, Kong & Xu 1998, Wong et al. 1995). 
A fine ultrastructural examination of the synapses in ALS patients showed 
mitochondrial alterations in the anterior horn motor neurons (lumbar spinal cord) not 
only in degenerated neurons, but, to a lesser extent, in neurons that appear normal. 
Mitochondrial abnormalities include dense conglomerates of aggregated, dark
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mitochondria and presynaptic vesicles, and also bundles of neurofilaments, and a
marked increase in presynaptic vesicles. These observations suggest that a substantial
synaptic alteration, including mitochondrial changes, occurs in the early stages of
anterior horn neuron death process in ALS patients (Swerdlow et a l  1998).
Impairment of mitochondrial function was observed in skeletal muscle biopsies from
patients with ALS (Borthwick et al. 1999, Wiedemann et a l  1998), and altered
respiration was described in muscle mitochondria of patients with early stage sALS
using the skinned fiber technique (Echaniz-Laguna et a l 2002). Loss of citrate synthase
activity (a mitochondrial marker) as well as decreased activities of respiratory chain
complexes I and III, II and HI, and IV suggested a loss of mitochondria in spinal cords
of patients with ALS (Wiedemann et a l  2002). Mitochondrial respiration, electron
transport chain, and adenosine triphosphate synthesis were defective in G93A mice at
the onset of the disease (Mattiazzi et a l  2002). In the same animal model, mitochondrial
electron transport chain activities were decreased in the spinal cord ventral horn prior to
disease onset and during disease progression (Jung et a l  2002). These alterations in
mitochondrial function in G93A SOD1 mice appeared to be specific and preferentially
targeted to the central nervous system (Kirkinezos et a l  2005).
Mitochondrial respiration is the main source of reactive oxygen species (ROS) in the
cell, and ROS levels tend to increase when respiration is impaired (Wei et a l  1998).
Both the involvement of mitochondria and the association of SOD1 with ALS suggest
that oxidation of macromolecules could have a role in the pathogenesis of ALS. In
patients with sALS, both lipid and protein oxidation are enhanced in the spinal cord
motor neurons and glial cells, suggesting that the formation of these products is
implicated in motor neuron degeneration (Shibata 2001). Markers of oxidative stress
and immune activation were significantly elevated in post-mortem ALS tissue in the
CNS (Siciliano et a l  2002) and abnormally increased blood levels of ROS and lactate
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production may indicate a close relationship between mitochondrial function and
oxidative stress in ALS (Simpson et a l 2004). These increases in ROS and products of
oxidation have been observed both in post-mortem samples and in experimental models
for ALS and may result from an altered metabolism of copper and iron ions (Carri et al.
2003).
Axonal alterations
As in other neurodegenerative diseases, axonal swelling represents a common event 
detectable in ALS. In ALS patients the axons are swollen and typically show well- 
defined structures that are identified as spheroids (Carpenter 1968). These structures are 
eosinophilic bodies and are usually greater than 20 pm in diameter. They contain 
packed 10-nm-thick neurofilaments. Like intraneuronal neurofilament accumulations, 
spheroids are phosphorylated. However, spheroids have not been found exclusively in 
ALS tissues and many other neurological diseases are characterized by the presence of 
phosphorylated neurofilaments and neurofilamentous conglomerates (Chou 1992, 
Manetto et al. 1988).
Protein aggregates
As reported for other neurodegenerative diseases, like Alzheimer's disease, prion 
disease, Kennedy and Huntington’s disease, protein accumulation in motor neurons of 
ALS patients may be caused by the formation of aggregates due to an alteration in the 
process of misfolded protein degradation (Ross & Poirier 2004). The mutant SOD1 
protein was reported to sequester chaperones that are required for promoting the correct 
folding of many proteins, whereas ubiquitin-mediated protein degradation might be 
inhibited by these aggregates. Aggregates intensely immunoreactive for SOD1 are
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found in the motor neurons of fALS patients carrying SOD1 mutations, and ubiquitin
deposits have been reported in lower motor neurons in both sALS and fALS patients.
The evidence of a large amount of ubiquitin positive aggregates in motor neurons of
ALS patients strengthens the hypotheses that a failure in the ubiquitin-proteasome
system can be responsible for protein accumulation (Migheli et a l  1999, Valentine &
Hart 2003).
a-Synuclein is a small (14 kDa) protein mainly expressed in the brain and 
predominantly concentrated in presynaptic nerve terminals. At physiological 
concentrations a-synuclein is an unfolded protein with no ordered secondary structure 
but it is well known that it can undergo polymerisation into fibrils associated with the 
formation of toxic aggregates (Moran et a l  2001). a-Synuclein aggregates are 
associated with several neurodegenerative diseases including Parkinson’s disease, 
Alzheimer’s disease, Lewy body dementia, multiple system atrophy and it has been 
recently associated with ALS (Bennett 2005). Aggregates of a-synuclein have been 
observed in neuronal spheroids, astrocytes, Schwann cells and in cortico-spinal axon 
tract fibers and glia in brain and spinal cord of ALS patients (Doherty et a l  2004, 
Mezey et a l 1998). In addition an increased expression of a-synuclein has been 
detected in the anterior horn in the spinal cord of SODG93A transgenic mice, an animal 
model of ALS (Chung et a l  2003).
1.5 Etiology
Despite extensive research, the pathogenic mechanisms of ALS are still unknown and 
this is probably the main reason that could account for the lack of effective treatments. 
The process of motor neuron degeneration looks complex and multifactorial and 
remains poorly understood in terms of a unifying causal hypothesis suggesting, indeed, 
that it might be a common end-stage phenotype of different causes. As for other
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complex diseases, the etiology of ALS is likely to involve both genetic and
environmental factors (overview of the main factors involved in ALS etiology in Fig.
1.5.1).
Exogenous factors Genetic factors
• toxins • SOD1
• viruses • Alsin and senataxin
• metals • Genetic risk factors
Astrocyte Excitotoxicity
Mitochondrial
dysfunction
Abnormal protein 
aggregation
Microglial cell
Oxidative stress
Impaired 
axonal transport
Apoptosis
Motor neuron
Neuroinflammation
Fig. 1.5.1 Overview of the main mechanisms contributing to ALS pathogenesis
(taken from Goodall & Morrison, 2006).
Genetic forms
Between 5 and 10% of ALS cases are familial, most often compatible with autosomal 
dominant inheritance. The disease progression and features are clinically and 
pathologically very similar between the familial and the sporadic cases, suggesting that 
they share common pathogenic mechanisms. Many current studies are focused on the 
detection of genetic factors in ALS, to seek loci and genes responsible for the familial
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forms and to identify genetic polymorphisms as risk factors in the more common sALS.
A key discovery in the field was the identification of mutations in the Cu/Zn superoxide
dismutase 1 (SOD1) gene as the cause of approximately 20% of fALS and therefore 2%
of all cases (Rosen et al. 1993). SOD1 is part of the cellular defence against oxidative
stress; it catalyses the conversion of superoxide anions into hydrogen peroxide, which is
then further metabolised. More than a hundred mutations in SOD1, distributed
throughout the gene, have been found in fALS patients (Borchelt et al. 1994). It is still
not known why the mutant form of this abundant and ubiquitously expressed enzyme
should be particularly toxic to motor neurons and causes ALS. Extensive study has
provided strong evidence for a toxic gain of function rather than a loss of enzymatic
function of the mutant enzyme. SOD1 enzymatic activity varies greatly depending on
which mutation is present and does not correlate with disease severity, with some
mutant forms maintaining full activity (Borchelt et al. 1994). Knockout mice do not
develop overt ALS (Reaume et al. 1996), while transgenic mice overexpressing mutant
forms of the SODl protein (mSODl) develop an adult-onset progressive motor
neuropathy phenotype (Gurney et al. 1994).
Double-trans genic mice containing both mutant and wild-type SODl were produced and 
showed a phenomenon whereby human wild type SODl exacerbates ALS-like disease 
in different transgenic mice. This phenomenon is accompanied by a conversion of the 
human wild type SODl from a soluble form to aggregates of dimers and multimers 
(Deng et al., 2006). Analysis of transgenic mice expressing familial amyotrophic lateral 
sclerosis (ALS)-linked mutations in the enzyme superoxide dismutase (SODl) have 
shown that motor neuron death arises from a mutant-mediated toxic property or 
properties (Bruijn et al., 1998). Transgenic rats overexpressing various human mSODl 
genes have also now been developed, showing features similar to the human disease 
(Howland et al. 2002, Nagai et al. 2001). There are many theories as to why mSODl is
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toxic, including enhanced oxidative stress from aberrant free radical production, and
protein misfolding leading to abnormal aggregation. There are also data indicating a
non-cell-autonomous toxic pattern of m SO D l. In fact, motor neuron-specific expression
of mSODl does not produce ALS in mice and neurodegeneration is delayed or
eliminated when motor neurons expressing mSODl are surrounded by wild-type cells
(Clement et al. 2003, Pramatarova et al. 2001).
Genetic linkage studies in pedigrees in which motor neuron disorder phenotypes are 
segregated have identified other disease-causing loci and genes. For example, mutations 
in alsin cause autosomal recessive juvenile-onset forms of ALS and the upper motor 
neuron variant primary lateral sclerosis, and mutations in senataxin cause a slowly 
progressive autosomal dominant disorder. Alsin encodes a protein with three putative 
guanine-exchange factor domains that may activate small GTPases and have a role in 
signal transduction (Yang et al. 2001). Several groups have now generated alsin knock­
out mouse models, but only mild neurological changes have been reported in these 
animals to date (Cai et al. 2005, Hadano et al. 2006). Senataxin contains a DNA/RNA 
helicase domain, which may suggest mutations cause a defect in RNA processing (Chen 
et al. 2004).
Genetic association studies in ALS helped to identify the main pathways affected by the 
pathology. Genetic polymorphisms associated with ALS include deletions or insertions 
in the neurofilament heavy chain gene, deletions in the promoter of vascular endothelial 
growth factor (VEGF), mitochondrial DNA deletions, a polymorphism in the 
haemochromatosis gene HFE and, recently, mutations in the angiogenin gene (Dhaliwal 
& Grewal 2000, Figlewicz et al. 1994, Goodall et al. 2005, Greenway et al. 2006, 
Lambrechts et al. 2003).
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Pathogenic hypotheses
Different pathogenic mechanisms have been proposed to contribute to ALS onset. 
Current works focuse largely on excitotoxicity and mitochondrial alterations with 
consequent oxidant stress. The excitotoxic hypothesis has led to the identification of 
riluzole, a glutamate-release inhibitor, as the first licensed disease-modifying treatment 
for amyotrophic lateral sclerosis (reviewed by (Miller et al. 2007). Attempts to develop 
antioxidant strategies for the disorder have, by contrast, been disappointing (Orrell et al. 
2005). Viral hypotheses drawing from the role of polio virus in poliomyelitis have been 
pursued extensively without positive evidence emerging. Other pathogenic hypotheses 
have been related to neurofilament alterations, protein aggregation and an 
immunoinflammatory process.
Excitotoxicity
Glutamate-induced excitotoxicity is the best-characterized factor in the ALS 
pathogenesis. Glutamate is the main excitatory neurotransmitter in the mammalian 
CNS, acting through both ligand-gated ion channels (ionotropic receptors) and G- 
protein coupled (metabotropic) receptors. The ionotropic glutamate receptors are 
multimeric assemblies of four or five subunits, named AMPA, NMDA or Kainate 
receptors, dependently on their pharmacology structural similarities. The subunits share 
a common basic structure with an extracellular N-terminus and intracellular C- 
terminus. NMDA receptors (NMDAR) are composed of assemblies of NR1 and NR2 
subunits, the last being one of four separate gene products (NR2A-D).Expression of 
both subunits is required to form functional channels. In addition to glutamate the 
NMDAR requires the co-agonist glycine to bind to NR1 subunit to activate the receptor. 
At resting membrane potentials, NMDAR are inactivate because of a voltage-dependent 
block by magnesium ions. Sustained activation of AMPAR depolarises the post-
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synaptic membrane, releasing the channel inhibition and thus allowing NMDAR
activation and the following influx of calcium and other ions.
AMPAR are composed of subunits GluRl-4, products from separate genes. The ligand- 
binding domain is made up from N-terminal regions while the C-terminus contains 
binding sites for proteins involved in AMPAR trafficking and targeting. Native 
AMPAR channels are impermeable to calcium, a function controlled by the GluR2 
subunit. The calcium permeability of the GluR2 subunit is determined by the post- 
transcriptional editing of the GluR2 mRNA at the so called Q/R editing site. Glutamine 
(Q) - containing GluR2 is calcium permeable while arginine (R) - containing GluR2 is 
not. Different editing forms of the subunits as well as different subunit assembly of the 
receptor confer to AMPAR peculiar properties within the different cells.
Kainate receptors (Abhyankar et a l)  are built from multimeric assemblies of GluR5-7 
and KA1-2 subunits. They undergo both splice variation and RNA editing, conferring to 
the receptor different pharmacological and functional properties. Little is known about 
the specific physiological and/or pathological role of this receptor since kainate is also 
active on AMPAR and exerts many of its effect through the activation of both KAR and 
AMPAR. For this reason the two receptors are usually considered as common 
AMPA/KA receptors in neurodegenerative studies.
Excitotoxicity is the process by which amino acid neurotransmitters such as glutamate 
become toxic when present at supraphysiological concentrations inducing 
overstimulation of postsynaptic glutamate receptors (representation of the main cellular 
alterations induced by excitotoxicity is shown in Fig. 1.5.2). This overstimulation can 
generate an excessive influx of Ca2+ and Na+ into the neurons and the following 
activation of damaging pathways ultimately leading to cell death (Choi 1987). Both 
glial and neuronal glutamate transporters play a pivotal role in avoiding excitotoxicity 
by removing the excess of glutamate released into the synaptic cleft from presynaptic
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neurons and, consequently, by preventing the overstimulation of postsynaptic glutamate
receptors. Evidence of alterations in glutamate homeostasis both in patients and in
animal models have accumulated over the years. Increased levels of glutamate have
been found in the CSF of 40% of sALS patients (Spreux-Varoquaux et al. 2002).
Abnormal glutamate metabolism and selective loss of the glial glutamate transporter
(EAAT2) in the anterior hom of affected spinal cord regions in ALS patients were
reported (Rothstein et al. 1995).
In addition, a significant decrease in glutamate reuptake from cerebral and spinal 
synaptosomes from autoptic samples has been measured (Rothstein et al. 1992). 
Glutamate overstimulation produces its neurotoxic effect acting through the N-methyl- 
D-aspartate (NMDA) receptor and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA)/kainate ionotropic receptors. However, while the NMDA receptor 
seems to mediate most acute neuronal injury, AMPA/kainate receptors (AMPARs) 
seem to be associated with detrimental effects produced following a slower and 
prolonged overstimulation.
This latter mechanism appears to be more related to chronic processes, such as 
neurodegenerative diseases and ALS (Weiss & Choi 1991).
AMPARs are cation-conducting complexes; the receptors are composed of four 
subunits (GluRl-4) and are always constituted as an heteromeric protein. The 
alternative assembly of the different subunits produces important differences in the 
electrophysiological properties of AMPAR (Jonas & Bumashev 1995). A possible 
mechanism of excitotoxicity due to post-transcriptional editing of the calcium 
impermeable subunit (GluR2) of AMPAR has been postulated (Takuma et al. 1999).
Ca permeability is largely determined by the GluR2 subunit, receptors incorporating 
an edited GluR2 subunit show a limited Ca2+ permeability in comparison with GluR2- 
lacking channels or containing the unedited form of GluR2.
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Fig. 1.5.2 Glutamatergic transmission in the CNS under physiological (a) or 
pathological (b) conditions (taken from Goodall & Morrison, 2006)
This effect is related to the presence of an arginine in its pore-forming segment in 
GluR2, in a position occupied by a glutamine in the other AMPAR subunits (Bumashev 
et a l  1992, Hume et a l  1991). This critical arginine residue is formed at the pre-mRNA 
stage by RNA editing (Sommer et a l  1991). The relative Ca2+ permeability of native
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AMPARs in neurons is inversely correlated with the rate of edited GluR2 and the
divergence in relative Ca2+ permeability of AMPAR between different neuronal cell
types could be an important constituent of selective vulnerability (Pellegrini-Giampietro
et al. 1997). It has been widely demonstrated that different neuronal cell types can
diverge in GluR2 expression, in the rate of GluR2 editing and in the desensitisation
properties of their AMPAR (Raman et al. 1994) and such differences may be related to
the selective vulnerability of motor neurons that occurs in ALS.
The prolonged elevation of motor neuron intracellular calcium (which seems to
represent the irreversible step of the degenerative pathway, Lukas & Jones 1994) starts a
complex cascade of correlated intracellular events such as the activation of numerous
enzymes (nucleases, cytosolic proteases and kinases, lipases etc.; Favaron et al. 1990,
Mills & Kater 1990, Orrenius et a l  1989) and calcium-dependent protein interactions,
which can compromise cellular homeostasis.
Furthermore, exposure of mitochondria to high concentrations of intracellular free 
calcium levels leads to increased free radical production and causes impairment of 
neuronal energy metabolism, which may sensitise neurons to excitotoxic cell death 
(Arundine & Tymianski 2003, Dykens 1994).
Mitochondrial alterations and oxidative stress
Mitochondrial main activities involve providing energy through oxidative 
phosphorylation, maintaining calcium homeostasis, producing free radicals and 
regulating cell death pathways. Mitochondrial respiration is the main source of reactive 
oxygen species (ROS) in the cell, and ROS levels tend to increase when respiration is 
impaired (Wei et al. 1998). Morphological and ultrastructural abnormalities of 
mitochondria in SALS were initially observed in autopsies. Subsarcolemmal aggregates 
of abnormal mitochondria were found in skeletal muscle and in intramuscular nerves
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(Afifi et a l 1966, Atsumi 1981). Mitochondrial morphological abnormalities were also
detected in proximal axons (Hirano et al. 1984) and in the anterior horns of the spinal
cord in sALS patients (Atsumi 1981, Sasaki & Iwata 1996). Increased mitochondrial
volume and elevated calcium levels within the mitochondria were found in muscle
biopsies of ALS patients (Siklos et a l  1996). Deficits in the activities of mitochondrial
respiratory chain complex I (Wiedemann et al. 1998) and complex IV (Vielhaber et a l
2000) have been identified in the skeletal muscle and in the spinal cord of sALS patients
(Borthwick et al. 1999, Wiedemann et al. 2002). The observation of increased resting
cytosolic calcium and reduced response to uncouplers of oxidative phosphorylation in
lymphocytes from sALS patients accounts also for impairment of mitochondrial
functions (Curti et a l 1996).
The evidence of mitochondrial alterations together with the involvement of mutations of 
SODl in ALS cases support the hypothesis that oxidation of macromolecules could 
have a role in the pathogenesis of ALS. In patients with sALS both lipid and protein 
oxidation are enhanced in the spinal cord motor neurons and glial cells, suggesting that 
the formation of these products is implicated in motor neuron degeneration (Shibata et 
a l 2001). Markers of oxidative stress and immune activation were significantly elevated 
in post-mortem tissue in the CNS (Simpson et al. 2004), and abnormally increased 
blood levels of ROS and lactate production (Siciliano et a l  2002) were found in ALS 
patients. Increase in ROS and products of oxidation have been observed also in 
experimental models for ALS and may result from an altered metabolism of copper and 
ferrous/ferric ions (Carri et a l  2003). mSODl transgenic mice, indeed, show elevated 
levels of protein and lipid oxidation at both pre- and post-symptomatic stages (Gajewski 
et a l  2003).
Cell culture studies have been conducted to determine the functional significance of 
mitochondrial (mt) DNA changes in ALS using cytoplasm hybrid (cybrid) cell lines.
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Patient’s and control platelets (containing no nucleus) were fused with neuroblastoma
cells (with depleted mitochondria) to create cybrid cells differing only in their mtDNA.
The ALS cybrid cells had several defects including altered mitochondrial ultrastructure,
decreased complex I activity and decreased calcium storage by the mitochondria
(Paradies et al. 2000).
Vacuolated mitochondria are a striking and early feature of disease in some strains of 
mSODl mice, including the most commonly used G93A model. The degree of 
vacuolation correlates with the decline in muscle strength (Crapo et al. 1992). Studies 
using in vitro cellular models have also shown that mSODl disrupts mitochondrial 
morphology and function (Fridovich 1997, Kira et al. 2002).
Correlations between oxidative stress and other proposed disease mechanisms such as 
excitotoxicity and axonal transport defects have been proposed. Excitotoxicity- 
dependent increased intracellular calcium may lead to increased nitric oxide formation. 
Peroxynitrite, generated by the reaction of superoxide anions and nitric oxide, can 
subsequently be the trigger of oxidative damage (Rao & Weiss 2004). Nitration may 
also target neurofilament proteins, disrupting their phosphorylation and affecting axonal 
transport (Torreilles et al. 1999).
Neurofilament alterations
Both in sporadic and in familial forms, neurofilament alterations represent a 
pathological hallmark of ALS (Julien & Beaulieu 2000). Neurofilament proteins 
(neuron-specific intermediate filaments) are the most abundant structural protein in 
mature motor neurons, and aggregates of neurofilament proteins in the cell body and 
proximal axons of motor neurons are commonly seen in ALS. Neurofilament heavy 
chain gene deletions were found in 1% of sALS cases (Al-Chalabi et al. 1999,
Figlewicz et al. 1994) supporting a direct involvement of neurofilaments in the
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pathogenesis of ALS. However, how this aberrant expression of neurofilament can lead
to a selective damage for motor neurons is still unclear.
Experiments in transgenic mice revealed a key role for neurofilaments in normal motor 
neuron function. Mice overexpressing human wild-type or mutant neurofilament protein 
develop motor neuropathies and undergo massive motor neuron cell death (Cote et al. 
1993, Lee et a l  1994, Xu et al. 1993). Peripherin and a-internexin are two intermediate- 
filament proteins that co-localise with neurofilaments and form part of the axonal 
inclusion bodies in ALS. Overexpression of peripherin or a-internexin in transgenic 
mice causes motor neuron degeneration (Beaulieu et al. 1999, Ching et al. 1999). 
Peripherin is encoded by a single gene and has splice variants of 56, 58 and 61 kDa. 
Peripherin 61 is toxic to primary motor neuron cultures, even at low levels, and has 
been detected in the spinal cord of sALS patients (Robertson et al. 2003). When 
considering the role played by neurofilaments in ALS pathology it is important to note 
that the formation of intraneuronal aggregates which are highly enriched in 
phosphorylated neurofilaments, is a peculiarity of motor neurons in ALS patients. This 
increase in highly phosphorylated neurofilaments could also suggest that the failure in 
the metabolism of neurofilaments may be the first step in a series of processes leading 
to neurofilament accumulation, axonal strangulation and neuronal cell death. However, 
it has been also suggested that upstream defects, such as, axonal transport deficit, 
glutamate induced excitotoxicity, SODl mutation or inflammatory response, might 
cause the disorganisation of neurofilaments in the cell body; in which case 
neurofilament alteration would represent more of an effect than a cause of the disease 
(Ackerley et al. 2000, Asahara et al. 1999).
Aberrant protein aggregation
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Abnormal protein aggregates are recurrent etio-pathological signs of ALS and include
Bunina bodies, ubiquitinated inclusions and neurofilament inclusions. As reported for
other neurodegenerative diseases, like Alzheimer's disease, prion disease, Kennedy and
Huntington’s disease, protein accumulation in motor neurons of ALS patients may be
caused by the formation of aggregates due to an alteration of the process of misfolded
protein degradation (Ross & Poirier 2004).
SODl
The mutant SODl protein was reported to sequester chaperones that are required for 
promoting the correct folding of many proteins, whereas ubiquitin-mediated protein 
degradation might be inhibited by those aggregates. Aggregates intensely 
immunoreactive for SODl are found in the motor neurons of fALS patients carrying 
SODl mutations, and ubiquitin deposits have been found in lower motor neurons in 
both sALS and fALS patients. The evidence of a large amount of ubiquitin-positive 
aggregates in motor neurons of ALS patients strengthens the hypothesis that a failure in 
the ubiquitin-proteasome system can be responsible for protein accumulation (Valentine 
& Hart 2003, Migheli et al. 1999).
TDP-43
The TAR DNA binding protein (TDP-43) is an ubiquitously expressed nuclear protein 
capable of binding DNA and RNA. TDP-43 is the major protein in ubiquitinated 
inclusions in neuronal cytoplasm of ALS patients, and it is usually accompanied by a 
relevant loss of such protein from the nucleus (Neumann et al., 2006). This 
sequestration would be predicted to disrupt the regulation of transcription and splicing. 
The identification of mutations (although rare) in the TARDBP gene in chromosome 1 
which resulted in increased fragmentation and toxicity to neurons, strongly supports a 
patho-physiological role for TDP-43 misaccumulation in ALS (Sreedharan et al., 2008; 
Buratti et al., 2005; Abhyankar et al., 2007).
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VAPB
A point mutation (P56S) in the vapb gene encoding an endoplasmic reticulum (ER)- 
integrated membrane protein [vesicle-associated membrane protein-associated protein B 
(VAPB)] causes autosomal-dominant ALS (ALS8; Nishimura et al., 2004). A 
pathogenic mechanism for this mutation has been suggested since the total loss of 
VAPB function in cellular response to unfolded protein, induced by one P56S mutant 
allele, could account for accumulation of unfolded and misfolded proteins in ER (Ron 
& Walter 2007; Suzuki et al., 2009).
Neuroinflammatory responses
One event, which has been proposed to contribute to the selective motor neuron 
degeneration in ALS, is the altered immune response and inflammation reaction (Appel 
et al. 1995, Poloni et al. 2000, Yi et al. 2000, Cereda et al. 2008). The autoimmunity 
implication was suggested by the presence of antibodies against voltage-gated calcium 
channels in the sporadic forms, which lead to impairment of neuronal intracellular 
calcium homeostasis (Appel et al. 1995). The anti-Fas auto-antibodies, which induce 
apoptosis in neuronal cultures (Yi et al. 2000), were also found in sera of ALS patients 
(Sengun & Appel 2003).
Glia-mediated neuroinflammation seems to play an important role among the 
mechanisms of neurodegeneration. Inflammatory cytokines have been implicated in 
many CNS disorders with an inflammatory component (Toulmond et al. 1996). 
Although contrasting results have been reported for cytokine levels in the CSF (Aimer 
et al. 2002) or plasma of ALS patients, increased concentrations of IL-6, TN Fa and 
MCP-1 suggest a neuroinflammatory contribution to the etiological pattern of the 
disease (Baron et al. 2005, Cereda et al. 2008, Ford & Rowe 2004, Moreau et al. 2005).
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In particular, TNFa is an important mediator of inflammatory and immune processes
and a TNF signalling pathway has been demonstrated to mediate both apoptotic and 
necrotic cell death (Wallach et al. 1999). Furthermore, TNF-a is up-regulated in 
neurodegenerative disorders, such as multiple sclerosis, Parkinson’s and Alzheimer’s 
diseases (Deigner et al. 2000, Lue et al. 2001) and high circulating levels of TNF and its 
soluble receptors were found in the blood of ALS patients (Cereda et al. 2008, Poloni et 
al. 2000), thus suggesting a possible involvement of this cytokine in the pathogenesis of 
motor neuron degeneration. TN Fa can also induce astrocytes to produce interleukin 8 
(EL-8, Kasahara et al. 1991), another pro-inflammatory cytokine which has been shown 
to be toxic for neurons (Maini et al. 1995). Since TNF-a has been shown to strengthen 
the glutamate-mediated neurotoxicity in human foetal neuronal cultures (Chao & Hu 
1994) and injection of kainic acid increases the level of TNF-a mRNA in rat brain 
(Minami et al. 1991), the interactions between TNF signalling and excitotoxic injuries 
could also represent a relevant contribution to motor neuron degeneration (Ghezzi & 
Mennini 2001).
1.6 Therapy and patient’s care
Many therapeutic strategies for ALS have been devised and tested in clinical 
trials over the years (Forbes et al. 2004, Liebetanz et al. 2004, Preux et al. 1996, 
Scarmeas et al. 2002), but as yet, the only agent that has been shown to confer improved 
survival in ALS is riluzole (Rilutek®; Aventis Pharma SA, France; (Bensimon et al. 
1994, Miller et al. 2007). The benefit is modest, prolonging life for an average of about 
3 months if the drug is taken for 18 months. One of the actions of riluzole is the 
inhibition of glutamate-release by acting on sodium channels. Findings of an initial trial 
in individuals with this disorder suggested that riluzole was more effective in bulbar- 
onset than limb-onset patients (Lacomblez et al. 1996). This result was not repeated in a
45
PhD Thesis, M. De Paola
INTRODUCTION - Chapter 1-1 .6  
second, larger, dose-ranging trial (Miller et al. 2007). Further studies were
recommended to investigate aspects of the potential effectiveness of riluzole in
amyotrophic lateral sclerosis. Riluzole, indeed, does not represent a cure, or even a very
effective treatment, and the search for better therapeutic agents continues. But clinical
trials in ALS are difficult and expensive to perform. Trials must involve many clinical
centres to allow enrolment of sufficient numbers for statistical validity. Recent advances
in patient care, such as assisted ventilation via nasal intermittent positive-pressure
ventilation, care in multidisciplinary teams and tube feeding have improved patient’s
survival so that it is very difficult to compare previous drug-dependent benefits to the
contemporary results. The main currently recommended interventions for the cure and
care of ALS patients are reported in the diagram in Fig. 1.6.1.
There is still no reliable surrogate marker for early disease in ALS. Most researchers
believe that therapeutic agents will be of most benefit if given early in the disease.
Various neuraxis imaging modalities, magnetic resonance imaging (MRI), diffusion
MRI, functional MRI, and single photon emission computed tomography (SPECT) have
been examined, but no specific and sensitive imaging features to allow early diagnosis
have been identified (Kalra & Arnold 2003). Likewise, no serum or CSF markers of
early disease have yet been found (Shaw & Williams 2000).
Many of the agents undergoing clinical trials in ALS have shown good effects in the 
mSODl mouse model, both in reducing the rate of disease progression and in 
prolonging survival. However, the benefits in the mouse have translated into 
clinical efficacy only in the case of riluzole. Possible reasons for this have recently been 
reviewed (Rothstein 2003) and include (1) difficulties in extrapolating equivalent 
dosesfrom mouse to man, (2) species differences in the anatomy of the motor system, 
the permeability of the blood-brain barrier, the ratio of neurons to glial cells and the
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Fig. 1.6.1 Recommended strategy for ALS patient’s care.
PEG= percoutaneous endoscopic gastrostomy. RIG=radiologically inserted gastrostomy
(modified from Radunovic et al. 2007).
immune response, and (3) the fact that the mSODl rodent models involve huge 
overexpression of the human mSODl gene (17-fold overexpression in the G85R 
mSODl mouse and 40-fold overexpression in the G93R mouse according to Jonsson et 
al. 2006) compared with the single gene dose effect in human mSODl- mediated fALS. 
There is clearly need for developing further animal models that more closely resemble 
the human disease. Many of the drug trials in the mouse model reported better results 
when agents were administered early, before the mice develop clinically apparent 
weakness, which is of questionable relevance in human ALS in the absence of an early 
identified surrogate marker for the disease. Some of the compounds assessed in 
completed and ongoing clinical trials are listed in Fig 1.6.2.
Trials of cocktails of therapies -  combining agents that act on different proposed 
mechanisms, such as minocycline, riluzole and nimodipine -  have given excellent 
results in the mouse model (Kriz et al. 2003). It seems likely that successful therapy in
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ALS will similarly involve a mix of agents, acting synergistically on various
mechanistic targets to interrupt the final common pathway of motor neuron
degeneration. In the last decade the rationale to define a therapy for ALS was to plan
clinical trials by agents that: 1) have been shown to be effective in in vitro or in vivo
models of motor neuron degeneration, such as neurotrophic agents, compounds that
support mitochondrial activity, or anti-apoptotic agents; 2) have been reported to
counteract the detrimental effect caused by stimuli that have been postulated to be
involved in ALS, such as antiglutamatergic agents, anti-inflammatory agents, calcium
regulators and antiviral drugs.
Drug Mechanism Dose and route Trial design Status/outcom e
AEOL-10150 Antioxidant Dose not known, subcutaneous Notknown Phase 1 clinical trial status: pivotal phase ll/ill 
trials planned
Brain-derived 
neurotrophic factor
Neurotrophln 25 or 100 pg/ kg Randomised, placebo-con trolled 
dose-ranging trial
Failed to  show benefit fbrprimary endpoints
(BDNF) 60,150, 400, or 
looopg/day, intrathecal
Randomised, double-blind, sequential 
das e-escalation study
Intrathecal BDNF well tolerated in doses ofup to 
150 pg/day; few patients did not permit 
conclusions on effectiveness
Ciliary neurotrophic 
factor (CNTF)
Neurotrophin o - £ * o r 5 pg/kgperday Double-blind, placEbo-controlled 
dose-ranging trial
No beneficial effect on progression; adverse 
events and deaths increased in 5 pg/kg group
15 or 30 pg/kg subcutaneous Randomised, placebo-controlled, 
dose-ranging, double-blind trial
No significant difference between CNTF and 
placebo; side-effects sufficientto limit use In 
many cases
Creatine Stabilise mitochondrial 
function
Creatine monohydrate 10 g/day Double-blind, placebo-controlled 
sequential trial
Did not have a beneficial effect on survival or 
disease progression
Gabapentin Antioocitotoxic agent 3600 mg/day Randomised, placebo-control led trial No evidence of beneficial effecton disease 
prog ression o r sympto ms
Glatiramer acetate Immunosuppressant - Randomised controlled trial Status uncertain; further studies needed
Interferon beta 1A Immunomodulatory agent 12 mill, subcutaneously, three 
times a week
Randomised, placebo-controlled trial The resultsof this pilot study suggest tha t 
interferon beta lA Is not effective
Lamotrigine Glutamate release inhibitor 300 mg/day, oral Double-blind, placebo-controlled 
crossover
No evidence of effectiveness
Mlnocydine Inhibits glial and ca^use 
activation
Up to 400 mg/ day, oral Corrqsound, with and without riluzole Status notyet dear; further trials planned
(  0N02506(Cereact) Astrocyte stabilising drug 1-2 g/day, oral Compound, with and without riluzole Results pending
Pentoxifylline Tumour necrosis factor a  
Inhibitor
1-2 g/day Double-blind, randomised 
placebo-controlled multicentre trial
Not beneficial and should be avoided in patients 
treated with riluzole
Recombinant IGF-I Neurotrophln 0-05 and 0-1 mcpkg per day, 
subcutaneous
Placebo-controlled dose ranging trial Interpretation of trial results jeopardised ty  trial 
design, further studies in progress
Riluzole Glutamate release inhibitor 100 mg/rfy, oral Placebo-controlled dose-ranging trial Modestly effective
Topi ra mate Antiexcitotoxic agent Up to Boo mg/day Double-blind placebo-controlled 
multi cent re. randomised clinical trial
Did not alterdecfine in forced vital capacity and 
amyotrophic lateral sdetosisfunctional rating 
sa le  or affect survival; further studies of 
topiramate up to 800 mg/day are notwarranted
Vitamin E Anticoddant a  tocopherol (500 mg twice a day) Randomised, placebo-control led trial No effect on survival and motor function
Xaliproden
1
Enhancement of nen/e 
growth factor gene 
expression
l a n d 2 mg/day oral Random aDocation to oneortw o dosesof 
xaliproden or placebo; two sub-studies: 
one with all patients taking riluzolg the 
otherwith no patients taking riluzole
No evidence of effectiveness
Fig. 1.6.2 Disease-modifying treatments for ALS.
(taken from Goodall & Morrison 2006)
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Anti-excitotoxic agents
Riluzole is, at present, the only drug approved from the Food and Drug Administration 
(FDA) for the treatment of ALS. Riluzole is considered to exert its protective effect in 
ALS patients by acting as an antiexcitotoxic agent (Lacomblez et al. 1996). Riluzole 
treatment can block different processes inducing the release of glutamate from 
presynaptic neurons and therefore can inhibit the glutamate-mediated overstimulation 
of postsynaptic glutamate receptor (Pratt et al. 1992, Zona et al. 1998). In two distinct 
therapeutic trials, riluzole prolonged the survival by three to six months (Bensimon et 
al. 1994, Lacomblez et al. 1996). In one of these trials the treatment slightly slowed the 
decline in the strength of limb muscle but failed to reduce others considered clinical 
parameters. In one retrospective analysis (Riviere et al. 1998) patients who received 
riluzole remained in a milder state of the disease longer than placebo-treated ALS 
patients. Further evidence, by utilizing proton density magnetic resonance spectroscopy, 
has demonstrated that patients treated with riluzole had a less marked progression of 
neuronal loss compared to the placebo treated group (Kalra et al. 1999). The effect of 
riluzole reinforced the hypothesis that glutamate-induced excitotoxicity was related to 
ALS and prompted the scientific community to plan several clinical trials using more 
specific antiglutamatergic agents.
Several other trials of agents targeted against glutamate excitotoxicity did not produce 
significant clinical improvement. Such agents included gabapentin, lamotrigine, 
dextromethorphan, L-threonine and calcium channel blockers (verapamil and 
nimodipine). This evidence suggests that the mechanism of action of riluzole is not 
exclusively related to the reduction of the glutamate-induced toxicity and that additional 
mechanisms may contribute to the actual effectiveness of this drug in ALS care.
Growth factors
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Nerve growth factors (neurotrophins) have also been investigated as disease-modifying
treatments for ALS. Neurotrophins are thought to have a key role in maintenance of
neuronal viability, suggesting the hypothesis that they might be able to rescue dying
motor neurons. Recombinant insulin-like nerve growth factor 1 (IGF-1) is a naturally
occurring peptide with multitarget neurotrophic potential on motor neurons. Two
randomised placebo-controlled trials of this peptide in patients with amyotrophic lateral
sclerosis have been completed to date, which were seriously compromised by flawed
trial design (Borasio et al. 1998, Lai et al. 1997). A Cochrane review (Mitchell et al.
2002) has been undertaken, and the effectiveness of recombinant IGF-1 for treatment of
this disorder remains unproven, although the drug might be modestly effective.
Hopefully, a current trial in North America will provide new insights into the
effectiveness of this peptide in ALS.
Ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) have 
both shown promising results in vitro and in animal models. However, findings of 
clinical trials with parenteral and (for BDNF) intrathecal administration have been 
disappointing (Bongioanni et al. 2004, Ochs et al. 2000).
Anti-inflammatory and anti-apoptotic agents
Much current interest is focused on the tetracycline antibiotic minocycline, as this has 
been the most effective agent in prolonging life in the rodent mSODl model (Kriz et al. 
2002). The exact mechanism is unclear but thought to be via inhibition of microglial 
activation and modulation of apoptosis (Yong et al. 2004). The antibiotic has good CNS 
penetration when taken orally, and clinical trials in various neurodegenerative disorders, 
including ALS, are now ongoing.
A trial of Copaxone (glatiramer acetate), widely used in the treatment of multiple 
sclerosis, is in progress. In the mSODl model, administration of the drug improved
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survival by 25% via the proposed mechanisms of increased T-cell derived interferon y
and enhanced glutamate transporter expression (Angelov et al. 2003).
Arimoclomol is one of a novel family of ‘smart drugs’, co-inducing the expression of
HSPs only under times of cellular stress. Treatment with arimoclomol after symptom
onset in mSODl mice delayed disease progression and increased survival, suggesting
that chaperone induction may be a good target for effective therapy in humans (Kieran
et al. 2004). Human trials are currently ongoing in the USA.
Symptomatological and palliative care
Palliative care is aimed at relief of symptoms and improvement in quality of life for 
patients whose disease is not responsive to curative treatment, and for their families 
(World-Health-Organization 1990), although palliative care is still perceived as the last 
resort (terminal care). Despite first attempts at establishing evidence-based guidelines, 
standards of palliative treatment in patients with amyotrophic lateral sclerosis are still 
largely based on expert opinion (Mitsumoto et al. 2005, Simmons 2005) and differ 
between countries (Borasio et al. 2001). When oral food intake becomes intolerable 
because of choking, percutaneous endoscopic gastrostomy should be undertaken 
(Kasarskis et al. 1999). In patients with a forced vital capacity less than 50%, 
gastrostomy placement should be done after institution of non-invasive ventilation 
because of the increased risk of respiratory insufficiency (Gregory et al. 2002). 
Alternatively, a radiologically inserted gastrostomy can be considered (Chio et al.
2004). Dysarthria can lead to complete loss of oral communication. Speech therapy is 
helpful initially if progression is slow. Modern computer technology can enable even 
quadriplegic patients to communicate effectively. First attempts at directly exploiting 
brain electric currents to control computers have shown encouraging results (Kubler et 
al. 2005).
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Dyspnoea can be a very distressing symptom in patients with ALS and most affected
individuals die from respiratory failure. Dyspnoeic attacks usually have a pronounced
anxiety component and are best managed by short-acting benzodiazepines (lorazepam).
Particularly in chronic dyspnoea, the feeling of shortness of breath is best treated with
morphine. Titration of the morphine dose against the clinical effect will almost never
lead to life-threatening respiratory depression (Sykes & Thorns 2003). Non-invasive
ventilation is an efficient and cost-effective palliative measure for nocturnal
hypoventilation (Mustfa et a l 2006). Other symptoms of amyotrophic lateral sclerosis
that can be relieved by appropriate drugs include muscle cramps, fasciculations,
spasticity, and drooling.
1.7 Animal models
The development of animal models for human diseases is an important scientific goal 
since they can provide valuable insights into the disease process itself. A valid animal 
model of a human disease should recapitulate the pathogenic process, present similarity 
in the clinical and pathological features of human disease, and responsiveness to 
disease-modifying events, such as treatments.
Several animal models of ALS have been proposed but so far not one is thought to be 
completely satisfactory (Borchelt et al. 1994, Gurney 1994, Pioro & Mitsumoto 1995, 
Strong & Pattee 2000). This gap is due largely to the incomplete knowledge of the 
etiology and the pathogenesis of human ALS. Furthermore unsuccessful approaches 
reflect the inevitable limitation of accuracy reproducing human diseases in species with 
a different physiology and anatomy. Anyway, studies on animal models of motor 
neurodegenerative diseases contributed to the understanding of common detrimental 
processes that lead to motor neuron death. The animal models for motor neuron
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disorders can be classified in three main categories: pharmaco-toxicological models,
animals showing spontaneous motor neuron degeneration and transgenic mouse models.
A short description of the most common animal models of ALS is reported below.
SOD1 transgenic mouse
The most characterized transgenic model of fALS is the transgenic mouse with 
Cu2+/Zn2+ superoxide dismutase (SOD1) mutation. Since 1993, when Rosen et al. 
reported the correlation between this mutation and a 20% of familial cases of ALS 
(Rosen et al. 1993), several lines of transgenic mice, and rats, carrying different point 
mutations associated to human mutations, were produced (Bruijn et al. 1997, Gurney 
1994, Wong & Borchelt 1995).
The onset of symptoms differs among the different type of mutation; however, all are 
characterized by motor neuron degeneration. On the other hand, transgenic mice 
expressing the wild type form of human SOD1 (hSODlwt) showed mild 
neuropathological alterations in lumbar motor neurons, and no neurological disorders, 
appearing phenotypically similar when compared to healthy mice (Jaarsma et al. 2000). 
The motor degenerative process follows a lumbar/cervical gradient and at the late stage 
of the disease almost all spinal motor neurons have disappeared with death commonly 
produced by respiratory failure. Degenerating motor neurons appeared highly 
vacuolized and at the end stage, the cytoplasm of motor neurons is almost empty. 
Filamentous inclusions immunopositive for ubiquitin and neurofilaments are present in 
some of the surviving neurons (Gurney et al. 1994).
Genetic strategies aimed at modifying the mutant SOD1 transgene induced the greatest 
benefits in these mice (Ralph et al. 2005, Raoul et al. 2005). Riluzole treatment only 
marginally affects disease outcome, but not onset (Gurney et al. 1996, Gurney et al. 
1998). Viral-mediated delivery of growth factors such as IGF-1 and VEGF (Azzouz et
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a l  2004, Bordet et a l 2001, Kaspar et a l  2003, Wang et a l  2002) to spinal motor
neurons substantially rescues mice, suggesting that the delivery of neurotrophic factor 
into the CNS is a key-factor for therapy in ALS. HD AC inhibitors, anti-apoptotic, anti­
inflammatory and novel anti-oxidant agents also appear effective at extending life in 
this model. However, none of these therapies completely arrests disease, suggesting
Neurofilament transgenic mice
Excessive accumulation of neurofilaments in the cell bodies and proximal axons of 
motor neurons is a major pathological hallmark during the early stages of many human 
motor neuron diseases. Transgenic mice with mutations in genes encoding for 
neurofilament proteins were produced as the first animal model of motor neuron 
degeneration. Transgenic mice that accumulate NF-L to approximately 4-fold the 
normal level in the sciatic nerve showed massive accumulations of neurofilaments in 
the motor neurons of the ventral horn of the spinal cord, swollen perikarya, and 
eccentrically localized nuclei (Xu et a l, 1993). NF-L accumulation was accompanied 
by an increased frequency of axonal degeneration, proximal axon swelling, and severe 
skeletal muscle atrophy. Transgenic mice with a genomic fragment including the 
complete human NF-H gene were also generated. Human NF-H proteins were produced 
at levels up to 2-fold the levels of endogenous mouse NF-H protein and progressively 
induced neurological defects and abnormal neurofilamentous swellings in NF-H 
transgenics, by 3-4 months of age (Cote et al., 1993). Some years later, transgenic mice 
overexpressing wild-type peripherin (a component of intermediate filament inclusion 
bodies associated with degenerating motor neurons in sALS) showed massive and 
selective degeneration of motor axons during aging (Beaulieu et a l, 1999). Remarkably, 
the onset of peripherin-mediated disease was precipitated by a deficiency of NF-L. In 
NF-L null mice, the overexpression of peripherin led to early- onset formation of
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intermediate filament inclusions and to the selective death of spinal motor neurons at 6
months of age. Formation of similar peripherin inclusions in presymptomatic transgenic
mice expressing a mutant form of superoxide dismutase linked to ALS was also
reported (Beaulieu et al., 1999).
pmn mouse
The “paralyse natural mutant” (pmn) mouse carries a recessive mutation on the 
chromosome 13 (Brunialti et a l  1995). The genetic defect in pmn mice has been 
localized to a missense mutation in the tubulin-specific chaperone E (Tbce) gene 
(Bommel et al., 2002; Martin et al., 2002). The Tbce gene encodes a protein (cofactor 
E) that is essential for the formation of primary tubulin and tubulin heterodimeric 
complexes. Isolated motor neurons from pmn mutant mice exhibit shorter axons and 
axonal swelling with irregularly structured tubulin and tau immunoreactivity, thus 
providing genetic evidence that alterations in tubulin assembly lead to retrograde 
degeneration of motor axons, ultimately resulting in motor neuron cell death. 
Neuropathological and clinical signs have an early onset (2 weeks) and a rapid 
progression of symptoms (Schmalbruch et a l  1991). Symptomatic phase begins at two 
weeks of age and evolves rapidly to death at around 40 days. Distal axonopathy is the 
most relevant sign of this pathology. Neurogenic muscle atrophy and subsequent 
paralysis are prominent (Kennel et a l  1996). In the pmn mouse both growth factors and 
pharmacological agents, including riluzole have been shown to reduce the progression 
of symptoms (Haase et a l  1998, Sagot et a l 1995). Nonetheless in pmn the mechanism 
of motor neuron death is not yet characterized, the evidence that Bcl2 overexpression 
failed to slow clinical progression and to prolong the survival, would support a non- 
apoptotic cell death process (Blondet et a l 2002).
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Wasted mouse
The wasted mouse carries a recessive mutation that has been identified as a deletion of a 
sequence of DNA on chromosome 2 that prevents the expression of the gene coding for 
the translation elongation factor E G la2  (Chambers et al. 1998). It is still unclear why 
the disruption of this protein involved in protein synthesis should produce such a 
specific neurological syndrome.
In the wasted mouse, neuropathological and clinical signs have an early onset, before 
the second week of age, and a very fast progression that leads to death within a month. 
Pronounced vacuolization is observed throughout the anterior horn region and in the 
brainstem of motor nuclei (Lutsep & Rodriguez 1989). Spinal motor neurons degenerate 
and are lost, whilst upper motor neurons appear to be unaffected. Wasted mice also 
show lymphoid hypoplasia and other immunological anomalies (Kaiserlian et al. 1986, 
Libertin et al. 1994).
Although many neuropathological hallmarks observed in the wasted mouse are similar 
to those found in human disease, the early onset of symptoms and the short time of 
survival make it extremely difficult to determine the possible effectiveness of 
pharmacological treatments.
ALS2 knockout mouse
Mutation in an ALS-related (ALS 2) gene has been identified as the cause of a rare 
autosomal recessive form of juvenile-onset ALS, also referred to as ALS2 (Ben Hamida 
et al. 1990, Hadano et al. 2001, Yang et al. 2001). In humans, the ALS2 gene is located 
on chromosome 2 at position 33.2, and encodes a protein called alsin, which is produced 
in a wide range of normal tissues, with the highest amounts in the brain and spinal cord. 
Although the function of ALS2 protein in motor neurons is unclear, it may play an 
important role in regulating cell membrane organization and the movement of
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molecules within motor neurons. Therefore, it would be expected to play a role in the
development of axons and dendrites. However, it is unclear how and why loss of alsin
function causes the ALS2-linked diseases. To fill this gap, four types of ALS2 knockout
mice have been successfully developed and studied. They are characterized by increased
susceptibility to oxidative stress and to glutamate receptor-mediated excitotoxicity (Cai
et al. 2005), age-dependent decrease in the size and number of ventral motor axons and
cerebellar Purkinje cells, astrocytosis and microglial activation in the spinal cord and
brain (Hadano et al. 2006); significantly smaller cortical motor neurons, and in addition,
marked diminution of Rab5-dependent endosome fusion activity and disturbance in
endosomal transport of IGF-1 and BDNF receptors (Devon et al. 2006). Slowed
movement without muscle weakness and progressive axonal degeneration in the lateral
spinal cord have also been shown (Yamanaka et al. 2006). Significantly, all four of
these ALS2 knockout murine models show no human ALS2-like symptoms and are not
neurologically analogous to patients with the ALS2 mutation.
Mutant dynactin mouse model
Dynein/dynactin is a motor protein complex required for fast retrograde transport along 
microtubules (Ateh et al. 2008, Schroer 2004). The disruption of this complex results in 
motor neuron disease in mice (LaMonte et al. 2002) and impairs clearance of aggregate 
prone proteins by autophagy (Ravikumar et al. 2005), which is a lysosomal pathway for 
degrading damaged organelles and aggregated proteins inside the cell.
Supporting the hypothesis that impairment of retrograde axonal transport causes motor 
neuron death, point mutations of the p i50 subunit of the dynactin gene have been 
reported in ALS patients (Munch et al. 2004). Experimentally, on the basis of this 
retrograde axonal transport impairment theory, mice overexpressing dynamitin,
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which is a subunit of dynactin, have been produced, and show disruption of the
dynein/dynactin complex, leading to inhibition of retrograde axonal transport.
Lines of mutant p i50 glued mice exhibit a rapid disease progression indicating that this
mouse model closely mimics the clinical outcomes of sALS. Moreover, these mice
share important pathophysiological alterations with the human pathology, including loss
of motor neurons, ubiquitin-positive inclusions, accumulation of neurofilaments and
astrogliosis (Laird et al. 2008).
Wobbler mouse
The wobbler mouse is one of the best characterized model of spontaneous motor neuron 
degeneration (Falconer 1956). The mutated gene responsible for the disease is 
autosomal recessive and associated with a missense mutation L967Q (Schmitt-John et 
al. 2005) in a Vacuolar-vesicular Protein Sorting (Vps54) involved in the tethering of 
vesicles retrieved between late endosomes and the Golgi apparatus (Liewen et al. 2005). 
Wobbler mice show early-onset selective motor neuron death in the cervical spinal cord 
(reviewed in Beghi & Mennini 2004). The onset of symptoms and their progression 
coincide with the rate of motor neuron loss. Glial activation (Bigini et al. 2001, Boillee 
et al. 2001, Rathke-Hartlieb et al. 1999) and upregulation of TNF-a (Schlomann et al. 
2000) have been reported in the cervical spinal cord of pre-symptomatic or early- 
symptomatic mice. Wobbler mice show a progressive atrophy of foreleg muscles 
accompanied by a marked decrease in muscular strength and motor ability. Although 
the wobbler disease was classified for a long time in the spinomuscular atrophy (SMA) 
group because no neuronal alterations were detected in the cortex, this has been refuted 
using in vivo proton magnetic resonance spectroscopy. In this study Pioro observed that 
the cell bodies and the neurites of neurons of the neocortex had a strong 
immunoreactivity for ubiquitin and an accumulation of NF-H was observed in neuronal-
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cell bodies of the cerebral cortex (Pioro et al. 1998). Although the actual loss of neurons
has not yet been demonstrated in the cortex, this result suggests that the neuronal target
in wobbler mice is not restricted to lower motor neurons but may involve other brain
areas. This finding renders this model more similar to ALS than to SMA (Pioro et al.
1998).
The wobbler mouse is a reliable model to investigate the symptomatological, 
neuropathological and biochemical alterations leading to motor neuron degeneration. 
The main etiopathological hypotheses that have been considered responsible for motor 
neuron death in humans, such as excitotoxicity, oxidative stress, deficit of trophic 
factors and accumulation of toxic proteins and aggregates, have been tested in wobbler 
mice. The results obtained have pointed out several defects that are common to the 
human disease.
The rapid progression of symptoms and the possibility to easily score the evolution of 
motor impairment make the wobbler mouse a valid tool to evaluate the efficacy of 
different pharmacological treatments. Several agents tested during recent years showed 
beneficial effects by reducing clinical progression and/or motor neuron loss. These 
include growth factors (Ishiyama et a l  2002, Mitsumoto et al. 2001) and cytokines 
(Ikeda et al. 1995a) as well as antioxidant (Abe et al. 1997, Ikeda et al. 1995b) or 
mitochondria-targeted (Ikeda et al. 2000) pharmacological treatments. Treatment with a 
TNF-binding protein (rhTBP-1) delayed both symptom progression and motor neuron 
loss (Bigini et al. 2008). Riluzole treatment slowed the progression of neuromuscular 
dysfunction and partially prevented motor neuron death in this model (Fumagalli et al. 
2006, Ishiyama et al. 2004).
Many others pharmacological treatments with different types of agents, such as steroid 
hormones, gangliosides, plasminogen activators, were reported to be active in reducing
59
PhD Thesis, M. De Paola
INTRODUCTION - Chapter 1-1.8 
the disease progression and the neuropathological alterations observed in the wobbler
mouse (Bose et al. 1999, Gonzalez Deniselle et al. 1997, Gonzalez Deniselle et al.
1999, Gonzalez Deniselle et al. 2002, Lisovoski et al. 1997, Schumacher et al. 2004).
However, despite these encouraging results in this animal model, the clinical trials of
some of these molecules had no significant effect in ALS patients.
1.8 In vitro models
The complexity of ALS etiology and the lack of clear results from human studies and 
animal models underlie the need for parallel studies on in vitro cellular models, to test 
specific intracellular events and hypotheses involved in the selective vulnerability of 
motor neurons. Several tissue culture studies using human CNS tissue have been 
performed, but they gave insufficient information about spinal cord neurons in culture 
(Gilden et al. 1975). Since the main limitations on obtaining human primary cultures of 
motor neurons are represented by the source of the tissue (the embryo), cultures of adult 
human spinal cord have been reported as explants or dissociated cultures (Erkman et al. 
1989, Kim et al. 1988). Unfortunately, these cultures are extremely fragile and their low 
viability (even in basal conditions and in presence of serum and trophic factors) did not 
produce useful results.
Because of the difficulties in studying human spinal cord cultures, the use of non­
human spinal cord cultures is considered a reliable alternative for research. Organotypic 
cultures are widely used in ALS research. While maintaining reciprocal cell interaction 
and the presence of well-differentiated motor neurons, they have two main limitations: 
an inability to perform analyses at the single cell level, and the detrimental effects of 
"experimental axotomy" on motor neurons. This form of axotomy is due to the fact that, 
in early postnatal age, the axons are already connected to their specific peripheral
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targets, and therefore, during the preparation of organotypic slices, the proximal stump
of axons remains connected to the motor neurons whereas the distal part is lost.
The possibility of performing a single cell study to avoid the problems arising from
“experimental axotomy” is obtained with immortalized cell lines. Cell-lines derived
from tumours, or from cells that are dedifferentiated and transformed in vitro, such as
the fusion product of mouse neuroblastoma with primary mouse embryonic spinal cord
neurons (Cashman et a l  1992) are mainly used. However the use of cell lines as a
model of motor neuron degeneration has not been entirely successful. This is due
mainly to the fact that these cells often appear and behave like motor neurons but they
are not motor neurons. Moreover, it is important to note that they are frequently
obtained by differentiation programs or from tumour cells which possess relevant
differences both in terms of cell biology and in their response to different external
stimuli.
For this reason, although such approaches can provide information on the basic 
mechanisms of cytotoxicity, primary cultures of motor neurons (obtained from 
embryonic rats, mice and chickens) are the most reliable and direct model to perform 
more accurate and rapid measurements on different cell death pathways and to evaluate 
the effectiveness of drug treatments.
Formation and accumulation of protein aggregates (Robertson et al. 2003), oxidative 
stress (Estevez et a l  1999, Peluffo et a l 2004, Raoul et a l  1999), energetic metabolism 
and calcium homeostasis (Ankarcrona et a l  1995, Kim et a l 2002), the role of 
glutamate-mediated excitotoxicity (Carriedo et a l 1996, Greig et a l  2000, 
Vandenberghe et a l  2000) have been analyzed in detail in cultured motor neurons. In 
vitro studies are also very important to define the metabolic interactions between 
astrocytes and neurons and their cytotoxic effects on motor neurons (Pellerin & 
Magistretti 1994, Tsacopoulos & Magistretti 1996).
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Chapter 2 - Aims and objectives
Aims
A) Glutamate-mediated excitotoxicity induces motor neuron degeneration mainly by the 
activation of ionotropic glutamate receptors with high affinity for AMPA and kainate 
(Van Den Bosch et al. 2000). Motor neurons do express these receptors even when 
maintained in cultures and in particular they show the presence of calcium-permeable 
AMPARs which were suggested to account for the high vulnerability of this type of 
cell. The present study was aimed at investigating the intracellular responses induced by 
the activation of the AMPA receptor (NBQX-sensitive) in primary cultured motor 
neurons. We previously showed that after the exposure of primary motor neuron 
cultures to equipotent concentrations of glutamate agonists inducing about 50% of cell 
death after 48 hours (chronic treatment), kainate, but not AMPA or NMD A, seems to 
induce apoptotic motor neuron death (Comoletti et al. 2001). Starting from these data, 
we investigated the main intracellular mechanisms that are induced by AMPAR 
agonists. Interactions between mediators of the inflammatory signalling and the 
AMPAR-dependent excitotoxic pathway were studied by evaluating the intracellular 
effects of two important cytokines, i.e. TNF-a and IL-8.
In light of the results obtained from the study of the AMPAR-dependent pathways we 
planned to test the effectiveness of potentially neuroprotective drugs which could 
interfere with the intracellular death mechanisms of motor neurons.
B) A second aim was to investigate the role of protein aggregation, which is one of the 
main etiological events in ALS, in in vitro motor neuron degeneration. Thus, we studied 
the effect of a-synuclein, which is responsible for protein aggregations in different 
neurodegenerative disorders (Bennett 2005), on motor neuron viability. Primary 
cultures were exposed to the fusion protein TAT-a-syn, derived by fusion of a-
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synuclein and the TAT sequence of HIV, which is membrane permeable and can be 
internalized inside motor neurons, resulting in intracellular accumulation.
Objectives
The main objectives of this study were:
1) to set up and standardize a useful in vitro model to study motor neuron features 
and responses to excitotoxic stimuli
2) to investigate the intracellular responses to treatment with AMPAR agonists
3) to study the possible contribution of mediators of neuroinflammation to motor 
neuron death which were correlated with excitotoxicity
4) to analyze the effect of intracellular aggregations of a-synuclein on motor 
neuron viability
5) to test potentially neuroprotective drugs interacting with the degenerative 
pathways
1) There are many difficulties in obtaining long term primary cultures with healthy and 
numerous motor neurons, in particular when purified cultures are needed in order to 
avoid the interaction of glial cells. Since motor neuron cultures can be obtained and 
maintained with different procedures (animal sources, purification processes, culture 
media, in vitro ageing, etc.), and the cellular sensitivity to exogenous stimuli (i.e. 
responses to pharmacological treatments) are definitely dependent on culture conditions, 
direct comparisons between the results reported by different authors can be hardly done. 
Starting from the original work of Camu and Henderson (Camu & Henderson 1992), 
many groups used a metrizamide gradient and/or the immunopanning method to obtain 
purified motor neurons from dissociated spinal cord extracts (Greig et al. 2000,
Herreros et a l  2000, Vandenberghe et al. 1998, Vargas et a l  2006), but this reagent is
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no longer available and alternative methods of purification have been reported. In
particular, the density gradient medium OptiPrep, a iodixanol solution, has been
successfully used to obtain motor neuron-enriched cell fractions (Duong et al. 1999,
Haastert et al. 2005, Misgeld et al. 2005). However, in these papers no attempt to obtain
a purified glial fraction was reported. In the present study we set up a new procedure for
the concomitant purification of motor neuron and glial fractions from the anterior horns
of mouse embryo spinal cord based on the OptiPrep gradient, and we directly compare
different types of primary motor neuron cultures (mixed anterior horn cultures, purified
motor neuron cultures and cocultures of purified motor neurons seeded on a mature glial
layer). The morphological features of motor neurons maintained under the three
different culture conditions were studied by evaluating the axonal outgrowth and the
perimeter and area of the somata of SMI32-positive motor neurons. Furthermore, the
effect of AMPAR activation induced by the agonists kainate and AMPA, considered to
play an important role in ALS etiology (Carriedo et al. 1996, Jahn et al. 2006, Mennini
2004, Van Den Bosch et al. 2000), was investigated. Immunocytochemical assays were
used to define the cellular death kinetics induced by AMPAR agonists. This enabled the
conditions (time of exposure, agonist concentration, type of culture, etc.) to be set for
the analysis of the intracellular events and to define the different drug-dependent death
rates. The death kinetics of the AMPAR agonists in mixed anterior horn cultures and
cocultures were obtained by detecting motor neuron viability after treatments.
2) The degenerative pathways induced by excitotoxic insults were studied with 
cytochemical, immunocytochemical and biochemical assays and analyzed by 
immunofluorescent microscopic methods and microphotography techniques.
Some of the fundamental events involved in the apoptotic process were evaluated: DNA 
fragmentation (detected by a DNA binding dye), the expression of phosphatidylserine
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residues on the membrane’s outer leaflet (revealed by the annexin-V binding) and the
activation of secondary apoptotic markers at early stages of motor neuron degeneration,
such as procaspase and caspase proteins (with specific antibodies against the activated
forms). Further intracellular degenerative events were analysed by studying the
mitochondrial involvement and the mitochondrial-dependent signalling. The reduction
of the mitochondrial transmembrane potential (A'PM) is an upstream apoptotic event
and is determinant for the release of the apoptotic initiating factors (AIFs), among
which cytochrome c has a pivotal role (Marchetti et a l  1996, Susin et a l  1997). The
detection of cytochrome c release was revealed using specific antibodies.
Subsequently the role of calcium intracellular influx in motor neuron degeneration was
studied. The levels of intracellular free calcium and mitochondrial calcium will be
detected after different excitotoxic insult exposures by using different fluorescent dyes
for cytosolic or mitochondrial calcium.
3) Since TNF-a has been shown to strengthen the glutamate-mediated neurotoxicity in 
human foetal neuronal cultures (Chao & Hu 1994) and injection of kainic acid increases 
the level of TNF-a mRNA in rat brain (Minami et a l  1991), the interactions between 
TNF signalling and excitotoxic injuries could represent a relevant contribution to motor 
neuron degeneration (Ghezzi & Mennini 2001). Thus, we planned to test the effect of 
TN F-a on motor neuron viability in different culture conditions. This would also 
provide information about the contribution of glial cells.
TNF can also induce IL-8, another pro-inflammatory cytokine which has been shown to 
be toxic for neurons (Brennan et a l  1995, Maini et a l  1995). The IL-8 receptor CXCR2 
is the most strongly expressed chemokine receptor on neurons and it is strongly 
upregulated in neuritic plaques in Alzheimer’s disease (Horuk et a l  1997, Xia &
Hyman 2002). Interestingly, CXCR2 and AMPAR were found to be co-expressed in
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several CNS regions (Bigge 1999, Giovannelli et a l 1998) and CXCR2 activation
through its ligand MIP-2 was demonstrated to enhance the amplitude of the spontaneous
AMPAR-mediated excitatory activity in rat cerebellar slices (Lax et al. 2002). Starting
from this evidence, the effects mediated by TNF receptors (TNFR1/2) or by the IL-8
receptor (CXCR2) activation and their interactions with the AMPAR-mediated motor
neuron degeneration were investigated.
4) On the basis of the evidence suggesting the involvement of a-synuclein in the 
pathogenesis of ALS, both by human and animal studies, we investigated the effect of 
the protein in purified cultured mouse motor neurons to clarify the role of a-synuclein 
in motor neuron degeneration. In particular, we focused on the possible neuroprotective 
or neurotoxic roles of the protein in our cellular model of neurodegeneration. To 
achieve this point a-synuclein was introduced in motor neurons by incubating cultures 
with the fusion protein TAT-a-synuclein. This was generated from the insertion of the 
sequence containing the minimal translocation domain of the HIVl protein TAT in 
frame before the N-terminal of the corresponding a-synuclein cDNA. a-Synuclein 
internalization and its effect on motor neuron viability was then investigated by 
immunochemistry and immunofluorescence using the primary antibody anti-a- 
synuclein mAb (Transduction Laboratories, Lexington, KY).
5) The identification of the intracellular mechanisms activated by AMPAR agonists 
could suggest a potential pharmacological approach aimed at interfering with different 
targets of the degenerative pathways. Thus we studied potential neuroprotective 
approaches on cultured motor neurons which were activated to die by excitotoxic 
stimuli or by inflammatory mediators.
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EPO and its derivatives
Erythropoietin (EPO) is a glycoprotein originally identified as the regulator of erythroid 
progenitor cells. EPO is induced in hypoxic conditions through the HIF-1 transcription 
factor (Semenza & Wang 1992). Different findings indicate that systemically- 
administered EPO crosses the blood brain barrier (Brines et a l  2000) and is 
neuroprotective in animal models of brain and spinal cord trauma, and ischemia 
(Cerami et al. 2002) and retinal ischemia (Junk et a l  2002). Thus, in addition to 
promoting the hematopoietic effect, EPO has protective effects in different in vitro and 
in vivo models of neurodegeneration, although the molecular mechanisms involved in 
this EPO activity are still not fully understood (for review see Chong et a l 2002). 
Starting from the evidence that EPO could prevent the death of primary cultured motor 
neurons exposed to kainate or serum deprivation (Siren et a l  2001) we investigated its 
effect on motor neuron degeneration induced by different AMPAR agonists.
Because chronic administration of EPO results in an increase in the hematocrit, which 
could have undesirable effects, for instance by increasing the risk of thrombosis, 
different nonerythropoietic molecules derived from EPO have been designed that retain 
the neuroprotective activities of EPO. One of these molecules, carbamylated EPO 
(CEPO), has proven effective in animal models of stroke, EAE, spinal cord injury, and 
diabetic neuropathy (Leist et a l  2004). Unlike EPO, CEPO does not bind to the 
classical homodimeric EPO receptor (EPOR) (Leist et a l  2004), and its neuroprotective 
action appears to require a common sequence (common p chain) of IL-3/IL-5/GM-CSF 
receptor (also known as CD131) (Brines et a l  2004), which can functionally associate 
with EPOR (Jubinsky et a l 1997). Another nonerythropoietic EPO derivative is asialo 
erythropoietin (ASIALO-EPO), which, although it binds to the classic homodimeric 
EPOR, has a short half-life in vivo and does not increase the hematocrit (an activity that 
requires persistent circulating levels of EPO) but also retains neuroprotective activities
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in vivo (Erbayraktar et a l  2003). An interesting approach to avoid the erythropoietic
activity of EPO was the use of HBP, a synthetic peptide containing the amino acid
sequence corresponding to helix B (residues 58-82) region of EPO, which is needed for
the binding to CD131. HBP lacks the regions of EPO that interact with EPOR.
In the present study, we planned to verify the effect of CEPO, ASIALO-EPO or HBP on
motor neuron viability and their potential neuroprotective activity against AMPAR-
mediated toxicity. This allowed the testing of new pharmacological approaches which
might exert protection of motor neurons without inducing undesirable effects.
Reparixin
Reparixin, an orally active CXCR1/2 inhibitor, reduces PMN infiltration and has 
protective activities in rat models of cerebral ischemia, (Garau et al. 2005, Villa et a l 
2007) and it is currently being tested in a phase 2 clinical trial for graft dysfunction after 
kidney or lung transplantation. CXCR2 is a chemokine receptor which mediates the 
effect of IL-8 (called MIP-2) in rodents. It is expressed in neurons and was suggested to 
have pathophysiological role in neurodegenerative diseases, like Alzheimer’s disease 
(Horuk et a l  1997, Xia & Hyman 2002).
The finding by Gorio and colleagues (Gorio et a l  2007) on the efficacy of reparixin in 
reducing MIP-2 concentrations, oligodendrocytes apoptosis and finally the axon 
demyelination in an in vivo model of spinal cord injury supports the possible 
neuroprotective role of CXCR2 inhibitors in the spinal cord. Since we found that MIP-2 
induced neurotoxicity in cultures, we tested the efficacy of reparixin in preventing 
motor neuron death.
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MATERIALS & METHODS
Chapter 3 - Materials
Reagents and materials that were utilized during this thesis are listed below:
• 2-mercaptoethanol, SIGMA, Italy
• ABC complex, Vector Laboratories, UK
• AMPA, Tocris, Italy
• Anti-a-synuclein monoclonal antibody (MAb), Transduction Laboratories, US
• Anti-Active capase 3 antibody, Promega, Italy
• Anti-Active caspase 9 antibody, Alexis Biochemical, UK
• Anti-annexin V polyclonal antibody (sc-8300), Santa Cruz Biotechnology Inc.,
US
• Anti-cytochrome c antibody, BP Biosciences, Italy
• Anti-EPOR polyclonal antibody (sc-5624, against the N-terminus residue of
human EPOR) and blocking peptide, Santa Cruz Biotechnology, US
• Anti-glial fibrillary acid protein (GFAP) monoclonal antibody, Immunological 
Science, Italy
• Anti-GluRl/2/3/4 antibodies, Immunological Science, Italy
• Anti-IL-8RA (sc-23811), anti-IL-8RB (sc-683) polyclonal antibodies and their 
blocking peptides, Santa Cruz Biotechnology, US
• Antimicin A, SIGMA, Italy
• Anti-oligomer polyclonal antibody (A l 1), BioSource Europe, Belgium
• Anti-TNFRl antibody, Hycult Biotechnology, The Netherlands
• Anti-TNFR2 antibody, Hycult Biotechnology, The Netherlands
• AraC, SIGMA, Italy
• B27, Invitrogen, Italy
• BDNF, Amgen, US
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• Biotinylated anti-mouse antibody, Vector Laboratories Inc.,UK
• BSA, SIGMA, Italy
• calcium green, CG5AM, fluorescent dye for cytosolic and nuclear calcium, 
Molecular Probes, Eugene, OR, US
• CD131: anti-IL-3/R p (sc 679) polyclonal antibody (raised against a peptide 
mapping at the N-terminus of the mouse EL-3 receptor p chain), Santa Cruz 
Biotechnology, US
• CPW399, synthetized by Prof. G. Campiani, University of Siena, Italy 
(Campiani et a l  2001)
• Cyclosporin A, SIGMA, Italy
• Diaminobenzidine, SIGMA, Italy
• DMEM, Invitrogen, Italy
• DMSO, SIGMA, Italy
• EDTA, Fluka Biochemical, Germany
• F I2 nutrient mix, Invitrogen, Italy
• FBS, Invitrogen, Italy
• FCS, Life Technologies, US
• Fluorescent FITC- (Alexa 488) or TRITC- (Alexa 546) conjugated secondary 
antibodies, Molecular Probes, US
• Fura-2 AM calcium indicatror, Calbiochem, Merck KGaA, Darmstadt, Germany
• GraphPad Prism version 5.01, GraphPad Software, US
• HEPES buffer solution, Invitrogen, Italy
• Hoechst 33258, SIGMA, Italy
• Horse serum, Invitrogen, Italy
• Image Tool Software (UTHSCASA), US
• JC-1, Molecular Probes, Eugene, OR, US
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• Kainic acid, Tocris, Italy
• L-glutamic acid, SIGMA, Italy
• L-glutamine, SIGMA, Italy
• NBQX, Tocris, Italy
• Neurobasal Medium, Invitrogen, Italy
• NGS, Vector Laboratories, Germany
• Olympus Fluoview Laser scanning, Japan
• OptiPrepTM was from Life Technologies Italia Sri, Milanese
• Paraformaldehyde, Merck, Darmstadt, Germany
• PBS, Invitrogen, Italy
• Penicillin/streptomycin solution, SIGMA, Italy
• Poly-L-lysine, SIGMA, Italy
• Propidium iodide, Molecular Probes, Eugene, OR, US
• Recombinant rat CXCL2/MIP-2, PeproTech, US
• Reparixin and DF1726A, Dompe pha.r.ma. s.p.a., Italy
• RHODD1, fluorescent dye for mitochondrial calcium, Molecular Probes, 
Eugene, OR, US
• SMI-32, Sternberger Monoclonals Inc., US
• SYTO 59, Molecular Probes, US
• Thioflavin-T, SIGMA, Italy
• Trypsin, SIGMA, Italy
71
PhD Thesis, M. De Paola
MATERIALS & METHODS - Chapter 4 -4 . 1  
Chapter 4 - Methods
4.1 Cell cultures
Procedures involving animals and their care were conducted in conformity with the 
institutional guidelines that comply with National (D.L. n. 116, G.U., suppl. 40, 
February 18, 1992) and International Laws and Policies (EEC Council Directive 86/609, 
OJL 358, 1, December 12, 1987; NIH Guide for the Care and Use of Laboratory 
Animals, US National Research Council, 1996). Primary cultures were obtained from 
the ventral horns of the spinal cords of 13-day-old C57 BL/6N mouse embryos or 14- 
day-old Sprague-Dawley rat embryos (Charles River, Calco, Italy). Dompe pha.r.ma. 
s.p.a. (L’Aquila, Italy) supplied 13-day-old wild-type or CXCR2-deficient (BALB/c- 
Cmkar2) mice.
Mixed anterior horn cultures
Spinal cords were dissected with microscopic surgical operations and meninges and 
other tissues (dorsal horns) were removed. The ventral horns were trypsinized and 
centrifuged through a BSA cushion (4%) for 10 min at 400xg. Cells obtained at this 
step represent mixed neuron/glia population and were seeded at a density of 50,000 
cells/cm2 into 24-mm diameter well plates on glass cover slips pre-coated with polyl- 
lysine and containing complete culture medium as follows: neurobasal medium, B27 
(2%), 0.5 mM 1-glutamine, horse serum (2%), 25 pM 2-mercaptoethanol, 25 pM 
glutamate, penicillin and streptomycin (1%), and 10 ng/mL BDNF. The same medium 
(without glutamate) was added to the cultures on 4th and 6th day in vitro. Neurobasal 
medium contains physiological concentrations of Ca2+ (1.8 mM) and Mg2+ (0.8 mM).
Purified motor neuron cultures
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As described for mixed cultures, the ventral horns were trypsinized and centrifuged
through a BSA cushion. The pellet of cells obtained at this step was suspended and
purified. The purification process of motor neurons was carried out by centrifugation of
the cell suspension through 6% OptiPrep cushion. After centrifugation at 800xg for 15
min, a sharp band (motor neuron fraction) on the top of the iodixanol cushion and a
pellet (glial fraction) were obtained. Fractions were re-suspended, centrifuged for 7 min
at 500xg on a 4% BSA cushion and re-suspended in their respective plating media.
Purified motor neurons obtained from the sharp band of the iodixanol cushion were
seeded at a density of 10,000 cells/cm2 into 24-mm well plates pre-coated with poly-1-
lysine and cultured and maintained with complete culture medium as described
above.
Glial layer
The glial feeder layer was prepared by plating the glial fraction, obtained from the 
purification process described above, at a density of 25,000 cells/cm2 into 24-mm well 
plates on glass cover slips pre-coated with poly-l-lysine. Culture medium was prepared 
with DMEM adding 0.5mM 1-glutamine, foetal bovine serum (10%), penicillin and 
streptomycin (1%), 3.6 mg/mL glucose, sodium bicarbonate (0.2%). Glial cultures were 
fed three times a week with fresh culture medium and grown at 37° C in a humidified 
incubator with 5% of CO2 . Glial cells proliferate and reach confluence after 3-4 weeks 
in vitro. At this step glial cell division was halted by the exposure to 10 pM AraC 
solution for 72 h and then replaced by fresh medium.
Cocultures o f motor neurons and glia
To obtain cocultures, purified motor neurons from the purification step were seeded at a 
density of 10,000 cells/cm2 onto a mature glial layer, pre-treated with AraC, by
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replacing the medium used for glial cultures with a suspension of motor neurons in
complete culture medium. Fresh medium (without glutamate) was added to the cultures
on 4th and 6th day in vitro.
4.2 Drug treatments
Drugs were dissolved in complete culture medium (DMSO for NBQX) and 600 pi of 
drug solutions (diluted to the appropriate concentrations in complete culture medium) 
were added to wells, after the removal of 600 pi from the total 1 mL of medium present 
in each well. Complete culture medium (or DMSO for experiments with NBQX) was 
used as vehicle and represented the control condition. Inhibition studies with 
antagonists (NBQX for AMPAR, reparixin for CXCR2) or co-treatment with 
neuroprotective drugs (EPO and its derivatives) were performed by treating cultures 
with a solution containing the different agents.
a-Synuclein treatment
On the seventh day in vitro (DIV 7) purified motor neuron cultures were incubated for 
18h with the fusion protein TAT-a-synuclein, generated from the insertion of the 
sequence containing the minimal translocation domain of the HIV1 protein TAT in 
frame before the N-terminal of the corresponding a-synuclein cDNA (Albani et al. 
2004). a-Synuclein internalization was then revealed by immunochemistry and 
immunofluorescence assays using the primary antibody anti-a-synuclein or anti 
oligomer A l l  or by the thioflavin-T staining. To investigate the effect of a-synuclein 
against H2 O2 and kainate induced toxicity, on DIV 7 motor neurons were pre-incubated 
with TAT-a-synuclein at the proper concentration for no less than 3h and then co-
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treated with TAT-a-synuclein and 100 pM H2 O2 or 50 pM kainate for 18 and 48 h
respectively. For serum deprivation, cultures were incubated for 18 h with the medium
free of serum and growth factors. The same medium was used to dilute a-synuclein
when co-treatment was needed.
Motor neuron viability
The viability of motor neurons was assayed as follows: only the SMI32-positive cells, 
with typical morphology (triangular shape, single well defined axon), large bodies 
(>20pm) and with intact axons and dendrites were counted, at a magnification of 200x, 
following the length of the cover slip in four non-overlapping pathways. This number 
was compared to the mean of SMI32-positive cells counted in control wells. In a typical 
experiment, the number of counted SMI32-positive cells in control wells was 30 + 7 (n 
= 6) in purified cultures, 45 + 9 (n = 12) in mixed anterior horn cultures or 70 + 11 (n = 
12) in cocultures.
4.3 Cytochemical staining
Cell cultures underwent common process of cell fixation and permeabilization when not 
differently specified: cells were incubated with paraformaldehyde 4% (w/v) in PBS for 
40 min, permeabilized with Triton X-100 (0.2%) for 30 min and blocked with FCS 10% 
(v/v) in PBS.
SMI 32 staining
The SMI32 antibody specifically stains the non-phosphorylated neurofilaments.. 
Incubation with the primary antibody SMI32 (1: 6000) was carried out overnight in 
blocking solution. Cells were washed and incubated with an anti-mouse fluorescent 
secondary antibody (Alexa 488/546, diluted 1: 1000) for immunofluorescent staining or
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with a biotinylated anti-mouse secondary antibody (diluted 1: 200) for 1 h at room
temperature in a dark room. The biotinylated antibody signal was amplified with avidin
and biotinylated horseradish peroxidase macromolecular complex (ABC kit method),
finally revealed with diaminobenzidine (0.5 mg/mL) and H2O2 (6 pl/10 mL).
Double staining SMI32 /active caspase-9 or -3
Fixed and permeabilized mixed anterior horn cultures or cocultures were double-stained 
with the SMI32 antibody and a specific antibody for activated caspase-9 or -3. The 
SMI32 staining assay was performed as described above. After the incubation with the 
anti-mouse secondary antibody (Alexa 488), cells were rinsed three times in PBS and 
incubated with the primary antibodies as follows. Cells were incubated overnight at 4° 
C, in a solution of PBS containing an anti-rabbit polyclonal antibody raised against the 
cleaved form of capase-9 (1:100) or capase-3 (1:100) and FBS 1%. After the incubation 
with the primary antibody and three rinses in PBS at RT, cells were incubated for 2 h at 
RT in a solution of PBS containing an Alexa-546 goat anti-rabbit secondary antibody 
(1:1000 for caspase-9 staining or 1:500 for caspase-3) and FBS (2%). For the detection 
of activated caspase-9 after 2 or 4 h treatments with lpM  AMPA the FITC-conjugated 
secondary antibody was used, being the SM B2 revealed by the Alexa-546 antibody.
Double staining annexin V /  SMI32
For the annexin V staining, cultures did not undergo the permeabilization step. Cells 
were fixed by incubation with 4% (w/v) paraformaldehyde, rinsed three times in PBS 
pH 7.4, then incubated overnight with a solution of the primary antibody anti-annexin V 
(1:500) in PBS, with 10% of normal goat serum (NGS). After that, cells were rinsed 
with PBS and incubated with an Alexa-546 goat anti-rabbit secondary antibody
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(1:1000) for 2 h at RT. After being rinsed with PBS, cells were permeabilized with 
Triton and the procedure for the staining of SMI32 was carried out as described above.
Double staining GluR2 /  SMI32
For the GluR2 staining, cells were not permeabilized. After fixation by incubation with 
4% (w/v) paraformaldehyde, cocultures were rinsed three times in PBS, then incubated 
overnight with a solution of the primary antibody anti-GluR2 (1:100) in PBS, with 10% 
FBS. After that, cells were rinsed with PBS and incubated with an Alexa-488 anti-rabbit 
secondary antibody (1:1000) for 2 h at RT. After being rinsed with PBS, cells were 
permeabilized with Triton and the procedure for the immune-fluorescent staining of 
SMI32 was performed as described above, using an Alexa-546 anti-mouse as secondary 
antibody.
Double staining SMI32 /  CXC Receptors
Mixed anterior horn cultures were double-stained with the SMI32 antibody and the 
specific antibody for CXCR1 (sc-23811) or CXCR2 (sc-683). The SMI32 staining assay 
was done as described above. After incubation with anti-mouse secondary antibody, 
cells were incubated overnight at 4 ° C with the primary antibody sc-23811 (diluted 1: 
100 in PBS) or sc-683 (diluted 1: 200 in PBS). To verify the specificity of the staining, 
parallel samples were incubated with the same solutions of primary antibodies with a 
fivefold excess of the blocking peptides. All the steps were conducted in a dark room. 
Cells were finally washed and incubated with an anti-goat (for CXCRl) or an anti­
rabbit (for CXCR2) fluorescent secondary antibody (diluted 1: 200; excitation 
wavelength 546 nm).
Double staining SMI32 /  TNF Receptors (cocultures)
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The SMI32 staining assay was done as described above. After incubation with the
Alexa-546 anti-mouse secondary antibody, cocultures were rinsed three times in TBS,
incubated for 30 min in 10% NGS and then incubated overnight at RT with the primary
rat anti-TNFRl or anti TNFR2 antibody diluted 1:100 in TBS + 1% NGS. After
incubation, cultures were washed in TBS + 10% NGS and incubated for 2 h with the
Alexa- 488 anti-rat secondary antibody (diluted 1:1000).
Double staining GFAP /  TNF Receptors (mixed anterior horn cultures)
Mixed anterior horn cultures were incubated overnight at 4 °C with the GFAP mouse 
primary antibody (1:500) diluted in PBS with 3% FBS and 0.1 % Triton X-100. After 
incubation cell were washed with PBS and 1% FCS and incubated with the Alexa-546 
anti-mouse secondary antibody for 2 h. Then TNFRs staining was performed as 
described in the previous section.
EPO and CD131 receptors
Purified motor neuron cultures were incubated overnight at 4 °C with rabbit polyclonal 
primary antibody raised against anti-Epo receptor (1:500) or anti-IL-3/R (3 (1:500) 
polyclonal antibody, in the absence or presence of an excess of relative blocking 
peptides (1:50). Next steps were carried out at room temperature. Cells were washed 
three times and then incubated for two hours in a solution of PBS containing 
biotinylated anti-rabbit (1:200) and FCS (1%). The following steps were identical to the 
SMI32 protocol (ABC kit method).
a-synuclein
Purified motor neurons were incubated overnight with the anti-a-synuclein monoclonal 
(1:100) or anti-oligomer (1 p,g/mL) antibody diluted in PBS with 1% HS. After
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washing, a proper fluorescent secondary antibody diluted 1:200 with 1% HS was added 
for lh  and cells were analysed by the fluorescent microscope.
GluRl-4
Cells were then incubated overnight at 4°C in a solution of PBS containing Triton X- 
100 (0.1%), FBS (3%) and one of the following primary antibodies:
- anti-rabbit polyclonal antibody for GluRl, diluted 1:500 
anti-mouse monoclonal antibody for GluR2, diluted 1:1000
- anti-goat polyclonal antibody for GluR3, diluted 1:1000
- anti-rabbit polyclonal for GluR-4diluted 1:200
After incubation with the primary antibody, and two rinses in PBS at room temperature, 
cells were incubated for 2 hours at room temperature in a solution of PBS containing 
FBS (2%) and Alexa-488 secondary antibody (1:1000). Images were acquired by 
confocal microscopy.
Hoechst 33258 staining
Cells were fixed overnight in Carnoy solution (3:1 methanol/acetic acid) and stained 
with Hoechst 33258 (0.1 |ig/ml in PBS; excitation wavelength of 365 nm) for 1 h at 
room temperature, then washed 10 times, 5 min each, with distilled water, air-dried 
overnight and covered with a glass cover slip.
Propidium Iodide and SYTO 59 staining
Purified motor neurons were double stained with SYTO 59 (0.5 p,M) and propidium 
iodide (PI, 10 tig/ml). SYTO 59 is a red fluorescent dye excited with the 633 line of a 
He/Neon laser and propidium iodide is excited at 488 nm with an Argon laser. The 
pseudocolour blue was chosen for SYTO 59 to distinguish between the fluorescence
79
PhD Thesis, M. De Paola
MATERIALS & METHODS - Chapter 4 - 4.3 
emission of this dye and that of PI (red). The cells were incubated ex vivo at 37 °C for
20 min with the fluorescent probes. At the end of the incubation, the cells were washed
and re-suspended in fresh buffer. Laser scanning confocal images were acquired with a
DMS IRBE SP2 (Leach) inverted microscope.
Mito Tracker staining
The cell-permanent Mito Tracker probe contains a mild thiolreactive chloromethyl 
moiety that appears to be responsible for keeping the dye associated to mitochondrial 
penetration. To stain mitochondria, non-fixed cells were incubated with a 
submicromolar concentration of Mito Tracker (100 to 500 nM, depending on the 
intensity of the staining). Orange-Mito Tracker was previously dissolved in DMSO, to 
obtain a starting concentration of 1 mM, and further diluted (1:2 to 1:10) and added at a 
ratio of 1:1000 in the culture medium, maintained at 37 °C, to reach the nanomolar 
dilution required. The culture medium was then removed and substituted, for about 30 
minutes, with the medium containing the Mito Tracker at 37 °C. After incubation the 
cells were immediately fixed. This rapid fixation is required to avoid that the Mito 
tracker probes, which passively diffuse across the plasma membrane and accumulate 
into the mitochondria, diffuse after incubation.
Cytochrome c
For cytochrome c immunostaining fixed cells were rinsed for three times in 0.1 M PBS 
pH 7.4 and then preincubated for 15 minutes at room temperature in a solution of PBS 
containing FBS (10%). After three rinses in PBS the cells were permeabilized in a 
solution of PBS containing saponin (0.1%) for 15 minutes at room temperature and then 
incubated overnight at room temperature in a solution of PBS containing an anti-mouse 
monoclonal antibody raised against cytochrome c (1:100) and FBS (5%) according to
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the method previously described by Sanchez-Alcazar and colleagues (Sanchez-Alcazar 
et al. 2001).
Thioflavin-T
The thioflavin-T binding assay was used for the detection of amyloid aggregates. 
Purified motor neurons were fixed with paraformaldehyde as reported above and then 
incubated with 0.05% thioflavin-T solution for 10 minutes (as previously reported by 
(Albani et al. 2004). Thioflavin-T reactivity was analysed by the epifluorescent 
microscope at a wavelength of 488 nm.
Microscopy analysis
Pictures of double stained cells were obtained by a laser scanning microscope (Olympus 
Fluoview microscope BX61 with a confocal system FV500). Dual excitation was used, 
488 nm (LASER Ar) and 543 (LASER He-Ne green). For the other fluorescent staining 
experiments, an optical epifluorescent microscope (Olympus BX51) coupled with an 
Olympus Camedia C-5060 digital compact camera were used. Images were analysed by 
the Olympus DPSoft software.
4.4 Intracellular calcium detection
For the detection of intracellular calcium levels ([Ca2+]i) by confocal microscopy 
techniques, cocultures were loaded with specific indicators for cytosolic and nuclear (5 
pM CG5AM) or mitochondrial (0.5 pM RHODD1) calcium for 20 min at 37°C. Then 
cultures were washed and cover slips with cells were placed in a watertight chamber 
superfused with an isotonic buffer. Images were acquired and analysed with ImageJ, a 
public domain, Java-based image processing program developed at the National 
Institutes of Health.
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For live imaging analysis , cocultures were loaded in the dark with 2.5 pM FURA-2
AM in Neurobasal medium containing 0.1% BS A and 250 pM sulfinpyrazone for 40 
min at 37°C. Cultures were then washed in Neurobasal and kept in the dark for an 
additional 30 min to allow for complete dye deesterification. Cells were alternately 
illuminated at 340 and 380 nm and fluorescence was monitored at 510 nm. Calibration 
of the fluorescence ratios was not attempted since the present study aimed at evaluating 
relative changes in [Ca2+]i following the activation of AMPAR by different stimuli 
rather than obtaining absolute values of [Ca2+]i. [Ca2+]i variations were obtained from 
the ratio between fluorescence emission that resulted from emission at 340 and 380 nm 
(Grynkiewicz et a l  1985). Intracellular calcium variations after treatments were 
recorded by an epifluorescent microscope (1X81, Olympus) equipped with a 
thermostatic chamber which maintains cultures alive during the experiments and the 
CellR software (Olympus) for live imaging.
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Chapter 5 - Culture characterization
Background
Primary motor neuron cultures have been used over the years to study different 
mechanisms of neurodegeneration implicated in ALS etiology. Mixed cultures, 
established as monolayer spinal cord extracts as well as cocultures of motor neurons 
plated over a layer of glial cells obtained from various regions of the CNS were also 
frequently used to define the metabolic interactions between astrocytes and neurons and 
their interplay in both trophic and cytotoxic condition (Pellerin & Magistretti 1994, 
Tsacopoulos & Magistretti 1996, Vandenberghe et al. 1998). Unfortunately, there are 
many difficulties in obtaining long-term primary cultures with healthy and numerous 
motor neurons, in particular when purified cultures are needed in order to avoid the 
interaction with glial cells. Since motor neuron cultures can be obtained and maintained 
with different procedures (animal sources, purification processes, culture media, in vitro 
ageing, etc.), and the cellular sensitivity to exogenous stimuli (i.e., responses to 
pharmacological treatments) are definitely dependent on culture conditions, direct 
comparisons between the results reported by different authors is difficult to achieve. 
Starting from the original work of Camu and Henderson (Camu & Henderson 1992), 
many groups used a metrizamide gradient and/or the immunopanning method to obtain 
purified motor neurons from dissociated spinal cord extracts (Arce et al. 1999, Greig et 
al. 2000, Herreros et al. 2000, Vandenberghe et al. 1998, Vargas et al. 2006), but this 
reagent is no longer available and alternative methods of purification have been 
reported. In particular, the density gradient medium OptiPrep, an iodixanol solution, has 
been successfully used to obtain motor neuron-enriched cell fractions
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(Duong et al. 1999, Haastert et al. 2005, Misgeld et al. 2005). However, in these papers
no attempt to obtain a purified glial fraction was reported.
In the present study, we have set up a new procedure for the concomitant purification of 
motor neuron and glial fractions from the anterior horns of mouse embryo spinal cord 
based on the OptiPrep gradient.
5.1 Motor neuron enrichment
The purification procedure, consisting of the separation of the cell suspension from the 
anterior horns (including both neuronal and glial cells) through 6% iodixanol cushion, 
gave a high purified motor neuron population. Among the entire cell population present 
in purified cultures (revealed by the phase contrast microscopy) 87 + 6% (n = 20) were 
SMI32-positive cells with the typical morphological features of motor neurons (for 
representative pictures see Fig. 1). Seven days after being plated over a confluent glial 
layer, the purified motor neuron fraction yielded a higher number of motor neurons 
compared to that observed in the monolayer of mixed anterior horn cultures. In a typical 
experiment, the number of counted SMI32-positive cells in control (not treated) wells 
was 45 + 9 (n = 12) in mixed anterior horn cultures while it increased to 70 + 11 (n =
12) in cocultures.
5.2 Morphological features
We have directly compared different types of primary motor neuron cultures (mixed 
anterior horn cultures, purified motor neuron cultures and cocultures of purified motor 
neurons seeded on a mature glial layer) obtained at different steps of a common process 
of cell extraction. The morphological features of motor neurons maintained under the 
three different culture conditions have been studied by evaluating the axonal outgrowth 
and the perimeter and area of the somata of SMI32-positive motor neurons. Cells were
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Figure 1. Representative pictures o f purified motor neuron cultures.
Under the experimental conditions utilized, about 90% of motor neuron 
purification was obtained. In these representative pictures, all the cells 
revealed by microscopy observation in phase contrast (A) are positive to the 
specific staining with SMI32 (B), having the appearance of large motor 
neurons. M agnification: 200X.
at
100|im
b c  4
*
*
V .
'W -  ■
*  s
*  +  
* ♦  f  #
4
'  ** .
*  .
T " 150|nm
M. * *
150jim
Figure 2. Primary m otor neuron cultures.
Different primary cultures obtained from  the ventral horns of the spinal 
cords of E l 3 mouse embryos. M otor neurons are stained with SMI32 and 
revealed with DAB. a) Purified motor neuron culture, b) M ixed anterior 
horn cultures, c) Cocultures of purified motor neurons on a glial feeder 
layer.
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maintained in culture for 8 days, and then immunostained with SMI32 as reported
above. In purified cultures the specific staining with the SMI32 antibody (Fig. 2a) and
the measurement of the axonal length (Table 1) revealed low neurite outgrowth and
small somata areas (Table 1) of motor neurons, even in the presence of growth factors.
Mixed anterior horn cultures, obtained at the first step of cell dissociation from the
ventral horns (Fig. 2b), showed a good growth and health of motor neurons as
evidenced by the significant increase in axonal and somata measures (Table 1). Motor
neurons grown in cocultures (Fig. 2c) showed further morphological improvements. In
fact, SMI32 positive cells in cocultures had significantly longer somata perimeters,
wider somata areas and increased axonal length compared both to mixed anterior horn
cultures and to purified motor neuron cultures (Table 1). Furthermore, the extensive
growth of purified motor neurons on mature glial layers allowed a better identification
of motor neurons in cultures.
TABLE I. Quantitative morphological features of motor neurons under different 
culture conditions.
Axon Length 
(pm)
Somata
Perimeter
(pm)
Somata Area
2
(pm )
Purified motor 
neuron cultures 224 ± 33 58 ± 13 207 ± 65
Mixed anterior horn 
cultures 379 ±41*** 73 ±13* 312 ±32***
Cocultures 937 ± 83***’$ 117 ± 22 *** $ 612 ± 4i***’$
Data are means ± S.D. of 15 cover slips for each condition. Five fields were analysed 
for each cover slip, and the mean values used for statistical analysis.
*p<0.05, ***p<0.001 different from purified cultures 
$p<0.001 different from mixed neuron/glia cultures 
One way ANOVA and Tukey test.
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Conclusions
We have developed a valid and useful method to concomitantly separate motor neurons 
from glial population from the same spinal cord extract. This method showed interesting 
advantages:
1) the use of a commercially available compound (OptiPrep) which can substitute for 
metrizamide and is not toxic (at least at the concentrations used to separate cell 
fractions)
2) it consists of easy procedures and cheap materials
3) it allows a highly purified motor neuron fraction to be obtained
4) it is useful to establish motor neuron-enriched cocultures
Since in recent years the use of motor neuron cocultures has provided important results 
on the intracellular mechanisms regulating the astrocyte/neuron crosstalk and on the 
toxic role of different agents involved in neurodegenerative diseases, it is clear how 
methods aimed at providing easy, cheap and rapid tools for such investigations are 
extremely interesting. Using this OptiPrep-based method we were able to compare and 
validate results on the effect of different agents and on the role of the different cell 
populations in mediating them.
We directly compared, for the first time, the main morphological properties of motor 
neurons in three different types of cultures, all coming from the same animal source 
(ventral horns of the spinal cord of E l 3 mouse embryos) and obtained at different steps 
of the same purification protocol procedure. We demonstrated that motor neurons in 
mixed anterior horn cultures or in coculture with mature glial cells have significant 
improvements in axonal length and somata perimeter and area compared to those 
maintained in purified cultures. Moreover, motor neurons in cocultures showed 
significantly better values in all the morphological properties analyzed, compared
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to mixed cultures. The main difference between these two culture conditions is the in 
vitro “ageing” of the glial population. In fact, while in mixed anterior horn cultures both 
the neuronal and the glial populations were cultured for 8 days in vitro, in cocultures the 
glial cells were maintained up to 3 weeks before the addition of motor neurons. This
t
suggests that the long-term cultured glial layer plays a fundamental role in the health 
and development of cultured motor neurons, probably due to its metabolic and trophic 
support as well as to the intercellular signalling between the different cell populations. 
To provide such a neuronal support, a physical contact between glial cells and motor 
neurons seems to be necessary, since the soluble factors released from glia have been 
demonstrated not to be sufficient to induce improvement of neuronal survival or 
morphological differentiation (Vandenberghe et al. 1998).
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Chapter 6 - AMPAR-mediated excitotoxicity
Background
Glutamate mediated excitotoxicity has been demonstrated to have an important role in 
motor neuron degeneration in ALS (Mennini 2004, Rothstein et al. 1995) and 
the AMPAR was shown to be the main receptor involved in calcium-dependent 
excitotoxic motor neuron death (Carriedo et al. 2000, Carriedo et al. 1996, Van Den 
Bosch et al. 2000). Ca2+ overloading can be an important factor to activate intrinsic 
apoptotic pathways in motor neurons. The induction of apoptosis by Ca2+ overloading 
depends on the intensity of Ca2+ influx (Orrenius & Nicotera 1994). In vitro 
experiments on rodent cerebellar granule cells (CGC) demonstrated that high doses of 
glutamate produce a typical necrosis identified by the disruption of membrane integrity, 
the collapse of mitochondria, membrane potential decay and the swelling of nuclei. On 
the other hand, milder but longer lasting excitotoxic stimulation triggered a great 
percentage of neurons following an apoptotic pattern (Ankarcrona et al. 1995). These 
results suggest that the intensity of Ca2+ influx determines the selective activation of 
different targets, finally inducing apoptotic or necrotic/lytic neuron death (Nicotera et 
al. 1997, Ankarcrona et al. 1995). The typical apoptotic events were prevented both by 
glutamate receptor antagonists and by caspase inhibitors, while neuron death induced by 
high concentrations of glutamate was only weakly reduced by caspase inhibitors (Leist 
et al. 1997).
In a previous study we demonstrated that after the exposure of primary motor neuron 
cultures to equipotent concentrations of glutamate agonists inducing about 50% of cell 
death after 48 hours (chronic treatment), kainate, but not AMP A or NMD A, seems to 
induce apoptotic motor neuron death (Comoletti et al. 2001). Starting from this 
evidence, we studied the time-course of death induced by different AMPAR agonist 
concentrations and fully analysed the intracellular death mechanisms mediated by the
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receptor activation under these different stimuli. In detail, we evaluated the activation of
different events of the apoptotic pathway after the exposure of either mixed anterior
horn cultures or cocultures to the different excitotoxins. DNA fragmentation (revealed
by Hoechst33258), activation of initiator (-9) or executioner (-3) caspases, release of
cytochrome c from mitochondria and the expression of phosphatidylserine residues on
the membrane’s outer leaflet (revealed by the annexin V binding) were all studied by
cytological staining techniques .
The downstream event of DNA fragmentation was studied after 18 h, while the 
activation of caspase-9 or -3 and the annexin V binding 6 h after treatment, when the 
effect of the low or high AMPAR agonist concentrations on motor neuron survival 
was significantly different. Finally we checked the alteration in cytosolic calcium influx 
in motor neurons exposed to different AMPAR agonist concentrations in order to 
provide a detailed description of the perturbations induced by such toxic stimuli.
6.1 Time-course of AMPAR agonist-induced motor neuron death
We firstly verified whether the AMPAR subunits were expressed on motor neurons by 
immunocytochemical identification of the AMPAR subunits. We found that all the four 
subunits are widely expressed on purified motor neurons, although with different 
distributions (Fig. 3). GluRl antibody showed a high immunofluorescence in the cell 
body, low fluorescence on dendrites, and a more intense signal in axonal terminals, 
especially in synaptic buttons. GluR2 showed a wide distribution on the whole cell 
surface, but not in the nuclear area. The subunit is moreover highly present all over the 
neuronal network. GluR3 showed a high localization in the somata, excluding the 
nuclear area. Dendrites and axons were stained with high intensity, mainly in the 
synaptic region. GluR4 induced high immunopositivity in the cell body and above
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Figure 3. AM PA receptor subunit localization on motor neurons.
Purified cultured motor neurons were stained with specific antibodies 
against G luR l (a), GluR2 (b), GluR3 (c) and GluR4 (d) subunits.
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Figure 4. AM PA receptor subunit 2 is present on motor neuron.
C ocultured m otor neurons were double-stained by SM I32 (A, red) and the 
specific antibody against G luR2 (B, green), w ithout undergoing the cell 
perm eabilization procedure. G luR2 is present both on m otor neurons 
(m erge in C) and on SM I32-negative cells (green in C).
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Figure 5. Time-course o f different AM PAR agonist concentrations.
M otor neuron viability after 6, 18 or 48h of treatment with different 
AM PAR agonist concentrations in mixed anterior horns cultures (panel A) 
or cocultures (panel B). D ata represent means + S.D. of SM I32-positive 
cells normalized for CTR. 6-9 wells for each condition have been analyzed. 
** p< 0.01 vs 0.3 pM AM PA and 5 pM KA; * p< 0.05 vs 5 pM KA; 00 p< 
0.01 vs 0.3 pM AMPA; ° p< 0.05 vs 0.3 pM AM PA and 5 pM KA. One 
w ay ANOVA and Tukey test.
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all in the axon hillock, but slight staining of neuronal arborizations was also evident.
We also detected the expression of GluR2 in SMI-32 positive motor neurons in
cocultures which were not permeabilized by Triton (see Methods for details; Fig. 4).
Our results were in agreement with previous findings on the expression of this AMPAR
subunit on motor neurons purified by different purification procedures (Comoletti et al.
2001, Greig et al. 2000, Vandenberghe et al. 1998) and with evidence of functional
GluR2-dependent properties (Van Damme et al. 2007, Van Damme et al. 2002).
The death kinetics mediated by the activation of AMPAR was evaluated by quantifying
the motor neuron viability in mixed anterior horn cultures (Fig. 5A) or cocultures (Fig.
5B) after different times of exposure (6, 18 or 48 hours) to different concentrations of
AMPA (0.3 or 1 pM) or kainate (5 or 15 pM). High AMPAR agonist concentrations (15
J
pM kainate or 1 pM AMPA) induced a relevant rate of death of SMI32-positive motor 
neurons shortly after treatment, reaching a “plateau” effect within 18 hours; while lower 
excitotoxic insults (0.3 pM AMPA or 5 pM kainate) lead to a significantly reduced cell 
death rate, progressively increasing to 50-60% death after 48 hours.
Both in mixed anterior horn cultures or in cocultures 15 pM kainate or 1 pM AMPA 
induced more than 35% of motor neuron death already after 6 hours of exposure, while 
lower concentrations triggered about 25% cell death (p < 0.01). A similar trend was 
shown after 18 hours, when higher AMPAR agonist concentrations induced between 
50% (in mixed anterior horn cultures, Fig. 5A) and 60% (in cocultures, Fig. 5B) of 
motor neuron death, while lower concentrations failed to induce more than 40% 
toxicity (p < 0.01). After 48 hours of exposure, the effect of the different AMPAR 
agonist concentrations was quantitatively similar (about 50%). Only the effect of 15 pM 
kainate (55% of cell death) was statistically different (p < 0.05) from the effect of 5 pM 
kainate (50% death) or 0.3 pM AMPA (45% death).
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Finally, we showed that co-treatment with the specific AMPAR antagonist NBQX (2
pM) significantly counteracted the motor neuron death induced both by low or high
AMPAR agonist concentrations in cocultures (Fig. 6), suggesting that the neurotoxic
effect was specifically mediated by the AMPAR, in accordance with the results
obtained in a previous study in mixed anterior horn cultures (Comoletti et al. 2001).
6.2 Neurodegenerative pathways: caspase activation
For the detection of the caspase cascade activation, mixed anterior horn cultures 
or cocultures (representative picture in Fig. 8) were double stained using specific 
antibodies against SMI32 and the activated form of caspases-9 or -3. In control 
conditions, SMB 2-positive motor neurons showed regular shape and size (Fig. 8, CTR, 
green cells) and slight activation of caspases-9 or -3 (quantified in Fig. 7A or B). After 
6 hours, treatments with low kainate or AMPA concentrations reduced the number of 
SMI32-positive motor neurons and significantly increased the percentage of activated 
caspase-9- (Figs. 7A and 8) or -3- (Figs. 7B and 8) positive cells in both culture 
conditions.
1 pM AMPA or 15 pM kainate treatments induced a severe reduction in the viability of 
SMI32-positive cells and the remaining motor neurons showed a compromised 
morphology (Fig. 8, green cells). In cocultures (Fig. 7A or B, filled bars) the SMI32 
positive cells showed a very low percentage of activated caspases-9 or -3 and in mixed 
anterior horn cultures (Fig. 7A or B, empty bars) not significant rate of caspase 
activation (probably due to the biological turnover of developing cells as well as to 
plating-dependent stress conditions) was observed after the high concentration 
treatment, suggesting that the caspase-dependent death pathway was not involved.
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Figure 6. NBQX counteracts AM PAR agonist-m ediated m otor neuron  
death.
M otor neuron viability after 48h treatm ent of cocultures with low (5 juM 
kainate) or high (1 jiM  AM PA) AM PAR agonist concentrations, alone or in 
co-treatment with 2 pM  NBQX. Data represent means ±  S.D. of SMI32- 
positive cells normalized for CTR. 6 wells for each condition were 
analyzed. *** p< 0.001 vs treatm ent without NBQX. Two way Anova and 
Bonferroni post-test.
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Figure 7. Activation of caspase-9 or -3 by AM PAR agonists.
M ixed anterior horn cultures or cocultures were exposed to different 
AM PAR agonist concentrations for 6 h and then double stained with SMI32 
and specific antibodies against the activated form  of caspases.
6 cover slips for each condition were analyzed. Only double-stained cells 
were counted. Bars represent mean percentage + SD of motor neurons 
showing activation of caspase-9 (panel A) or caspase-3 (panel B) after each 
treatm ent in mixed anterior horn cultures (empty bars) or cocultures (filled 
bars). *** p<0.001 vs CTR, 0.3 pM  AM PA and 5 pM  KA. ANOVA and 
Tukey test.
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Figure 8. Activation of caspase-9 or -3 by AM PAR agonists in 
cocultures.
Representative pictures o f motor neurons in cocultures exposed to different 
AM PAR agonist concentrations for 6 h and then double-stained by SMI32 
(green) and specific antibodies against the activated form  of caspase-9 or 
caspase-3 (red).
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Figure 9. High AMPA concentration does not induce caspase-9 
activation even at early times.
Cocultures were exposed to 1 pM  AM PA for 2 or 4 h, then double-stained 
by SM I32 and a specific antibody against the activated form of caspase-9. 
Panel A: representative pictures of double stained SMI32 (red)/caspase-9 
(green) motor neurons in cocultures. Panel B: 4 cover slips for each 
condition were analyzed. Graph bars represent the mean percentage + SD of 
SM I32-positive motor neurons (empty bars) or the percentage of double 
stained (SMI32/caspase-9; filled bars) cells present in each treatment 
condition. * p<0.05 vs CTR, ANOVA and Tukey test.
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To further verify that the lack of caspase activation after high AMPA concentration
could not be related to a masking effect by the cells that have already died, we repeated
the experiment in cocultures treated with lpM  AMPA at earlier times (2 or 4 hours).
Motor neuron death was about 20% (after 2 h) or 35% (after 4 h) and no significant
activation of caspase-9 was detected (Fig. 9B; representative pictures of stained motor
neurons in Fig. 9A). Thus, since early times of exposure, high agonist concentrations
did not induce caspase activation.
6.3 Neurodegenerative pathways: cytochrome c release
The key event in the intrinsic apoptotic pathway is represented by the release of 
cytochrome c from mitochondria into the cytosol (Neame et al. 1998). Cytochrome c is 
normally located in the space between the outer and the inner membrane of 
mitochondria. During apoptosis the pro-apoptotic molecules are activated and move into 
the mitochondria where they induce the release of cytochrome c (and other proteins) 
from the intermembrane space. Once diffused into the cytosol, cytochrome c is able to 
initiate the processing of multiple caspase activation.
In this study we verified whether treatment with AMPAR agonists induced this process. 
Purified motor neurons, were double stained with a mitochondrial dye (Mito Tracker) 
and an antibody directed against cytochrome c. Purified motor neuron cultures were 
treated with 50 pM kainate (representative of lower concentrations) or 10 pM AMPA 
(representative of the higher ones) for 4 hours; these concentrations were utilized since 
they exert an equipotent effect in inducing motor neuron death equal to 5 pM kainate or 
1 pM AMPA in mixed anterior horn cultures after 48 hours of treatment (Comoletti et 
a l  2001).
In contrast to 10 pM AMPA treated motor neurons, in which a loss of mitochondrial 
integrity and a consequent spreading of cytochrome c immunoreactivity is already
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detectable after 4 hours of treatment (Fig IOC, F), both in control and in 50 pM kainate
treated cells mitochondrial integrity was seen (Fig 10 A, B). However, in a large
percentage (quantification not done) of kainate treated motor neurons, cytochrome c
staining did not overlap with mitochondria, but homogenously diffused throughout the
whole cytoplasm (Fig 10 E). This evidence supports the hypothesis that low AMPAR
agonist concentrations can induce apoptosis by modifying mitochondrial activity and
thus, allowing the caspase-cascade activation by cytochrome c release and consequent
apoptosome formation.
6.4 Neurodegenerative pathways: phosphatidylserine externalization
We investigated also the effect of the different AMPAR agonist concentrations on a 
typical apoptotic alteration of the cell membrane such as the expression of 
phosphatidylserine residues on the membrane’s outer leaflet (revealed by the annexin V 
binding). Phosphatidylserine is normally found on the cytosolic surface of the plasma 
membrane, but it is redistributed during apoptosis to the extracellular surface by a 
protein known as scramblase (Wang et al. 2003). This event marks the cell for the 
phagocytotic process, mediated by cells possessing the appropriate receptors, such as 
macrophages (Savill et al. 2003).
Cocultures were exposed to 6 hour treatment with the different agonists, then double­
stained with SMI32 and annexin V antibodies. Semi-quantitative data, obtained by 
counting the double stained cells (SMI32/annexin V-positive cells; representative 
pictures in Fig. 11 A), showed that 5 pM kainate or 0.3 pM AMPA significantly 
increased the percentage of annexin V-positive motor neurons in cocultures, while 
higher concentrations did not induce this membrane alteration (Fig. 1 IB). After 0.3 pM 
AMPA or 5 pM KA treatment, also a high number of SMI32-negative cells were 
immunoreactive for annexin V (Fig. 11 A, red cells in the merge column), suggesting
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Figure 10. Cytochrome c release after treatm ent with low agonist 
concentration.
R epresentative pictures o f purified m otor neuron cultures double-stained 
w ith a m itochondrial dye (M ito Tracker, red signal) and an antibody 
d irected against cytochrom e c (green). A fter 6 h, 50 pM  kainate treatm ent 
(B and E) induces a d iffused release o f cytochrom e c from  m itochondria, 
com pared to control (A and D) or 10 pM  A M PA -treated cells (C and F).
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Figure 11. Low AM PA or kainate concentrations induce the 
externalization o f phosphatidylserine residues on cell membranes.
Cocultures were exposed to different AMPAR agonist concentrations for 6 
hours and then double stained with SMI32 and the specific antibody for 
annexin V. Panel A: representative pictures of double stained SMI32 
(green) / annexin V (red) motor neurons in cocultures. Both motor neurons 
(yellow in merge pictures) and SM I32-negative cells (red in merge pictures) 
showed positivity to the annexin V antibody after low concentration 
treatments. Panel B: 6 cover slips for each condition were analyzed. Bars 
represent the mean percentage + SD of double-stained (SMI32/annexinV) 
cells. *** p<0.001 vs CTR or high concentrations, ANOVA and Tukey test.
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that such apoptotic alteration did not occur only in motor neurons but rather it
represents a common response of different cell types exposed to this treatment
condition. These results confirmed that the phosphatidylserine membrane rearrangement
was induced only by the lower agonist concentrations.
6.5 Neurodegenerative pathways: nuclear fragmentation
In 1990, Clarke described nuclear fragmentation as one of the main apoptotic alteration 
in cells: “In the nucleus, dense chromatin masses appear and increase in number until 
the nucleus has become frankly pyknotic (i.e., condensed). Under high magnification, 
the DNA fragments can be seen to be packed together more closely in the regions of 
dense chromatin.” (Clarke 1990). DNA fragmentation was usually detected by TUNEL 
assay or DNA-binding dyes (i.e. Hoechst 33258) and reported as the main downstream 
event of the apoptotic process.
DNA fragmentation was studied here after 18 hours, when the effect of the low or high 
AMPAR agonist concentrations on motor neuron survival was significantly different 
(about 35% vs. 50% death, p <0.01). In mixed cultures a relevant rate of DNA 
fragmentation was detected also in control conditions (about 20%) and was maintained 
after the exposure to high agonist concentrations (Fig. 12A). On the contrary, motor 
neurons in cocultures showed a very low amount of fragmented nuclei in controls and 
no DNA fragmentation after treatment with high agonist concentrations (Fig. 12B).
After 18 hour treatment, the double staining of SMI32 and Hoechst 33258 revealed that 
5 pM kainate or 0.3 pM AMPA significantly increased the nuclear fragmentation of 
SMI32-positive motor neurons compared to both control condition, 15 pM kainate or 1 
|iM AMPA treatment, both in mixed anterior horn cultures (Fig. 12A) and in cocultures 
(Fig. 12B; representative pictures of fragmented nuclei after low concentration 
treatments in Fig. 13). Again, lower concentrations, but not the higher, clearly induced
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Figure 12. DNA fragm entation induced by different AM PAR agonist 
concentrations in m ixed anterior horn cultures or in cocultures.
M ixed anterior horn cultures (A) or cocultures (B) were exposed to 5 or 15 jitM 
kainate, 0.3 or 1 jllM  AM PA for 18 h. Cells were double-stained with SMI32 
and Hoechst 33258. 8-10 cover slips for each culture condition were analyzed 
at a magnification o f 200X. Only SM I32-positive cells were considered and 
their nuclei were analyzed at a higher magnification (600X). Nuclei that 
clearly showed fragmentation were counted. Graph bars represent the mean 
percentage + SD o f fragmented nuclei o f SMI32 positive cells in each 
treatm ent condition. *** p< 0.001 vs CTR, 15jiM KA or lp M  AMPA. One 
way ANOVA and Tukey test.
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Figure 13. Low AM PAR agonist concentrations induce nuclear 
fragm entation in SM I32-positive motor neurons.
Cocultures, treated with 0.3 pM  AM PA or 5 jllM  kainate for 18 h, were 
double-stained by SMI32 (A, B, C) and Hoechst 33258 (D, E, F). Arrows in 
pictures E and F point representative fragmented nuclei after treatments 
with respectively 0.3 pM  AMPA or 5 pM  kainate. Nuclei o f control motor 
neurons appear intact and round-shaped (arrow in picture D).
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classical apoptotic alterations, independently from the type of agonist (kainate or 
AMPA).
6.6 AMPAR activation induced cytosolic calcium alterations
To investigate possible alterations in AMPAR-dependent calcium influx we evaluated 
the intracellular Ca2+ concentrations of motor neurons exposed to different AMPAR 
agonists by two different techniques. In the first one, we tried to identify possible 
differences in cytosolic or mitochondrial Ca2+ influx in motor neurons exposed to higher 
or lower kainate concentrations. Cocultures were loaded with specific indicators for 
cytosolic and nuclear (calcium green) or mitochondrial (RHODD1) calcium. A confocal 
microscope was used to reveal alterations in calcium-dependent fluorescence in motor 
neurons (identified in cocultures by morphological criteria). Treatment with AMPAR 
agonists was performed by superfusing the solutions in a watertight chamber. Pictures 
were obtained at different times after perfusion with the agonists and maintaining the 
microscope acquisition setting steady. We found that low AMPAR agonist 
concentrations induced increases in cytosolic calcium levels. Figure 14 shows pictures 
acquired under basal conditions and 3 min after 5 pM kainate exposure. By subtracting 
the fluorescence of the basal picture from that acquired after 3 min kainate exposure, we 
revealed that calcium-dependent fluorescence was clearly increased by the excitotoxin 
both in cells showing glial phenotypes as well as in neuronal arborizations, and it was 
likely localized in the membrane compartment (Fig 14; examples of cells showing 
neuronal phenotype in the magnifications). Moreover, when we did the subtraction of 
the picture of treated cells from the basal fluorescence, we obtained a complete black 
field (Fig 14), thus confirming that calcium-dependent fluorescence was increased by 
kainate treatment. On the other hand, a higher kainate concentration (15 pM) appeared 
to induce a redistribution of intracellular Ca2+ rather than a net increase in [Ca2+]i.
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Figure 14. Effect of low AMPAR agonist concentration on cytosolic 
calcium influx (confocal microscopy).
C ocultures w ere loaded with specific indicators for cytosolic and nuclear 
calcium  (calcium  green). A lterations o f  calcium -dependent fluorescence in 
m otor neurons (identified in cocultures by m orphological criteria) were 
revealed by confocal m icroscopy after the perfusion o f 5 pM  kainate in a 
w atertight cham ber. H igher m agnification o f cells displaying neuronal-like 
phenotype is show n in the low er row.
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Figure 15. Redistribution of cytosolic calcium by treatment with high 
AMPAR agonist concentration (confocal microscopy).
C ocultures w ere loaded with specific indicators for cytosolic and nuclear 
calcium  (calcium  green). A lterations in calcium -dependent fluorescence in 
m otor neurons (identified  in cocultures by m orphological criteria) were 
revealed by confocal m icroscopy after the perfusion o f 15 pM  kainate in a 
w atertight cham ber. H igher m agnification (800X ) o f cells displaying 
neuronal-like phenotype is show n in the low er row.
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Since a slight increase in CG5AM fluorescence after 10 min of 15 pM kainate treatment
was revealed when the fluorescence of basal picture was subtracted from that acquired
after kainate treatment or when we did the inverse subtraction of pictures (basal -
kainate treatment), this would suggest that Ca2+ ions were re-localized with a different
intracellular distribution after 15 pM kainate exposure (Fig 15). With the calcium
indicator selectively sequestrated by mitochondria we also revealed a trend to an
increase in mitochondrial calcium levels, in particular after treatment with low agonist
concentrations (5 pM kainate, not shown).
The features of the confocal microscopy technique, while providing the accuracy of 
confocal microscope analysis, introduced a series of difficulties, the most important of 
which concerned time-lapse detection and quantification of the calcium influx. For these 
reasons we used a more suitable method for live imaging based on the epifluorescent 
microscopy (detailed description in section 4.4). Briefly, cocultures were loaded with 
Fura 2 AM fluorescent dye which allowed the expression of a fluorescent signal as the 
ratio between fluorescence emission at 340 and that at 380 nm. Increasing free (not 
bound, emission at 340 nm) C a2+ concentrations led to an increased 340/380 
fluorescence ratio. Here we detected the [C a2+]i variations after treatment with the 
AMPAR agonist concentrations. Traces of [C a2+]i kinetics were obtained from the time- 
lapse recordings of fields containing at least one morphologically identified motor 
neuron and some cells displaying the neuronal phenotype.
A first set of experiments were performed to evaluate and standardize the sensitivity of 
the method. In particular, we verified that motor neurons in cocultures showed 
detectable [C a2+]i variations after membrane depolarization induced by 50mM KC1 and 
tested the sensitivity of the Fura 2 AM dye in the presence of physiological (1.8 mM) or 
saturating (10 mM) extracellular [C a2+] (not shown). When the effect of the AMPAR 
agonists was studied, we could reveal rapid [C a2+]i variations after the agonist exposure
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Figure 16.
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Figure 16. AMPAR agonists evoke [Ca2+]} increase in cocultured motor 
neurons (live imaging).
C ocultures were loaded w ith Fura-2 AM  and basal [Ca2+]j levels w ere 
recorded before addition o f A M PA R  agonists. H ere fluorescent im ages 
taken at 340 nm  in basal condition or at different tim es from  0.3 (A) or 1 
)liM  (C) AM PA or 5 (B) or 15 (D) pM  kainate addition are reported.
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Figure 17. [Ca2+]j rise induced by AMPAR agonist addition.
C ocultures w ere loaded w ith Fura-2 AM  and tim e-lapse recording o f [Ca2+]j 
w ere obtained w ith a live-im aging equipm ent. T races represent the k inetics 
o f [Ca2+]j alterations in cells displaying m otor neuronal, neuronal or 
astrocytic phenotypes (defined by m orphological criteria) after low (A) or 
high (B) A M PA R  agonist concentration addition to the m edium . H igh 
agonist concentrations induce higher increase o f [Ca2+]j as the increase o f 
in tensity  R 340/380 is greater after 15 pM  KA or 1 pM  AM PA, com pared to 
that induced by  the low er concentrations.
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and for all the agonist concentrations tested (Fig 16 and 17). After exposure to high
AMPAR agonist concentrations a higher variation in [C a2+]i was detected, compared to
that revealed after treatment with the lower ones. In fact 1 pM AMPA (Fig 17B,
representative pictures obtained from the time-lapse recording in Fig 16C) or 15 pM
kainate (Fig 17B, representative pictures in Fig 16D) induced a higher (about 0.5)
increase in intensity R340/380 compared to 0.3 pM AMPA treatment (Fig 17A,
representative pictures in Fig 16A) or 5 pM kainate (Fig 17A, representative pictures in
Fig 16B) which triggered about 0.1-0.2 increase in intensity R340/3 8 0- To demonstrate
that the revealed increase in [C a2+]i was dependent on AMPAR activation, we verified
that the calcium influx induced by the AMPAR agonists was counteracted by
concomitant exposure to 2 pM NBQX (AMPAR antagonist, not shown). Interestingly,
by this method we were also able to detect a rhythmical oscillation of the calcium
concentration in astrocytes (evident in the 5 pM kainate treatment, trace from astrocyte
in pink, Fig 17A) that did not seem to be affected by the excitotoxic treatment.
Conclusions
Our data demonstrated that, in spite of a better phenotype of motor neurons in 
cocultures, there are no differences from the mixed anterior horn cultures in terms of 
sensitivity to the AMPAR-mediated neurotoxicity, excluding a possible toxic effect of 
OptiPrep on purified motor neurons. In fact, independently from the type of agonist 
(AMPA or kainate), higher concentrations induced relevant death rates after 6 hours, 
while lower concentrations induced a milder, progressively increasing effect showing 
similar concentration-dependent death curves in both culture conditions. To detect the 
effect of the different agonist concentrations on the intracellular mechanisms leading to 
motor neuron death, we considered early events of the apoptotic pathway (such as the
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activation of the caspase cascade and the membrane externalization of annexin V) and a
later event such as the DNA fragmentation. Since the death curves of the AMPAR
agonist concentrations showed the higher statistically significant differences after 6 or
18 hours exposure, we considered these as time points with the better chance of
detecting possible differences in inducing intracellular death pathways. High
concentrations of AMPAR agonists inducing more than 35% of motor neuron death
within 6 hours did not appear to activate the apoptotic mechanisms, while lower
concentrations, which induced less than 25% death, led to the activation of typical
apoptotic intracellular markers such as the cleavage of caspases-9 and -3, the expression
of phosphatidylserine residues on the membrane’s outer leaflet and the DNA
fragmentation. The lack of activation of the apoptotic death pathway by high AMPA
concentration was not related to the high death rate, since no activation of caspase-9
was found even 2 or 4 hours after treatment with 1 |liM AMPA, when motor neuron
death was only about 20%, quantitatively similar to that obtained after 6 hours of
treatment with the lower concentration, when caspase activation was shown. Thus, our
data demonstrated that the activation of the AMPAR induced by different excitotoxic
stimuli triggered specific intracellular death mechanisms, which are related neither to
the morphological differences found in motor neurons cultured with immature glial cells
(mixed anterior horn cultures) as compared to those with glial cells grown up to 4 weeks
in vitro (cocultures), nor to the type of agonist but are rather dependent on the intensity
of the initial stimulus.
Our results, demonstrating that the two AMPAR agonist concentrations tested here were 
able to trigger rapid [C a2+]; increase of different amplitude, led to the hypothesis that the 
higher [C a2+]i variation induced by the high AMPAR agonist concentrations (1 pM 
AMPA or 15 pM kainate) was the triggering event leading to the rapid, non-apoptotic 
motor neuron death shown in this toxic condition (see section 6.1). On the other hand,
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low AMPAR agonist concentrations induced a lower [C a2+]i variation, which could
allow the motor neuron to recover from this perturbation or to start the programmed cell
death mechanism in case of a persisting unbalanced situation. This finding fits very well
with the evidence reported in literature supporting the fact that sustained or excessive
AMPAR-mediated Ca2+ influx, together with excessive mitochondrial Ca2+ loading (Sen
et al. 2008) and lower buffering capacity (Alexianu et a l  1994, Reiner et al. 1995) of
motor neurons are the key factors which could account for their selective vulnerability
to excitotoxicity.
Finally, although we did not examine this event carefully, the repeated low-amplitude 
calcium-dependent spikes shown by astrocytes in cocultures could be bona fide 
considered, in accordance with the literature (Parri & Crunelli 2001, Parri & Crunelli 
2003, Parri et al. 2001), as spontaneous [C a2+]i oscillations which account for the 
intrinsic astrocytic activity also taking place in control conditions and independently 
from the neuronal activity or excitotoxic stimuli.
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Chapter 7 - Neuroinflammation and excitotoxicity
7.1 Tumor Necrosis Factor-a
Background
The inflammatory response occurs in several brain trauma and neurological diseases. 
Cells that more actively participate to this process in the CNS are microglial cells and 
astrocytes, for this reason this response is often indicated as reactive gliosis (Raivich et 
al. 1999). Microglial cells are functionally related to peripheral tissue macrophages and, 
like macrophages in other tissues, resting microglia appears to participate in the immune 
surveillance of the nervous system (Eglitis et a l 1987). In response to injury, microglial 
cells modify their physiology and rapidly transform from a resting into an activated 
state. This is the triggering event of a series of cell alterations making microglial cells 
able to remove neural debris through phagocytosis.
The cellular modifications occurring in reactive astrocytes also play an important role in 
neuroinflammation. The morphological transformation from protoplasmic to fibrillary 
astrocytes in the neural parenchyma can be tightly controlled by several factors, 
including cytokines, which regulate different steps in this activation response (Lucas & 
Hohlfeld 1995). The release of cytokines can activate cellular pathways leading to the 
death of motor neurons. In addition diffusible factors released from dying neurons can, 
in turn, activate resting astrocytes (Viviani et a l 2000). Recent findings suggest that 
glial cells (astrocytes and microglia) play a role in motor neuron degeneration (Barbeito 
et al. 2004, Rao & Weiss 2004, Sargsyan et a l  2005). Although contrasting results have 
been reported for cytokine levels in the cerebrospinal fluid or plasma of ALS patients, 
high concentrations of IL-6 , TNF and MCP-1 suggest a neuroinflammatory component 
(Baron et a l  2005, Cereda et a l  2008, Ford & Rowe 2004, Gallo et a l  1994, Joerg 
Stuerenburg et a l  1999, Krieger et a l  1992, Moreau et a l  2005, Poloni et a l  2000, 
Sekizawa et a l  1998, Wilms et a l 2001). Inflammatory reactions have been implicated
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in several pathogenic mechanisms of motor neuron diseases (Appel et al. 1995, Cereda
et al. 2008, Poloni et al. 2000) and the TNF signalling pathway has been demonstrated
to mediate both apoptotic and necrotic cell death (Wallach et al. 1999). Since TNF-a
has been shown to strengthen the glutamate-mediated neurotoxicity in human foetal
neuronal cultures (Chao & Hu 1994) and injection of kainic acid increases the level of
TNF-a mRNA in rat brain (Minami et al. 1991), the interactions between TNF
signalling and excitotoxic injuries could represent a relevant contribution to motor
neuron degeneration (Ghezzi & Mennini 2001).
Starting from these data, the present studies were aimed at investigating the effect 
mediated by exogenous TN F-a on motor neurons and its interaction with AMPA- 
mediated motor neuron degeneration. The contribution of glia to such an effect was 
elucidated by comparing motor neuron viability in different culture conditions and by 
detecting the TNF receptor localization in cocultures.
7.1.1 Effect of TNF-a treatment on motor neuron cultures
In a first set of experiments, mixed anterior horn cultures were treated with different 
concentrations of TN F-a alone or in co-treatment with 1 pM or 0.3 pM AMPA for 48 
hours. TNF-a (tested at 1, 10 or 100 ng/mL) did not induce any toxic effect on SMB 2- 
positive motor neurons (Fig 18) and did not affect the rate of motor neuron death 
induced by AMPA concentrations (Fig 19). Pre-treatment with the cytokine was also 
performed in order to verify whether a longer period of incubation was required. 
Cultures were pre-treated with 10 or 100 ng/mL TNF-a for 72 hours before 0.3 pM 
AMPA was added and treatment extended for a further 48 hours. Also with this protocol 
TNF-a showed no effect on motor neuron viability (not shown).
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Figure 18. TNF-a treatment does not affect motor neuron viability in 
mixed anterior horn cultures.
M ixed anterior horn cultures w ere treated w ith different concentrations o f 
T N F -a  and then stained with SM I32. 6 cover slips for each condition w ere 
analyzed. Bars represent the m ean percentage + SD o f SM I 32-positive 
cells. T reatm ents do not induce significant effect at any tested 
concentration.
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Figure 19. TNF-a treatment does not affect the neurotoxic effect of 
AMPAR agonists in mixed anterior horn cultures.
M ixed anterior horn cultures w ere treated w ith 10 ng/m L T N F -a  alone or in 
co-treatm ent w ith 0.3 or 1 jaM A M PA  for 48 h. Bars represent the m ean 
percentage + SD o f  SM I 32-positive cells in each treatm ent condition. TNF- 
a  treatm ent is not effective at any tested condition .
*** p < 0.001, ** p< 0.01 vs C TR  or 10 ng/m L T N F -a . A N O V A  and Tukey 
test.
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We then tested 10 ng/mL TNF-a and its interactions with AMPAR agonist
concentrations in cocultures to verify whether the confluent and mature glial layer
would affect the cytokine effect. When cocultures were exposed to the cytokine for 48
hours, a significant motor neuron death (29.2 + 8  %, p < 0.01 vs. control; Fig 20A) was
observed. The addition of 0.3 or 1 pM AMPA induced about 35% or 47% of motor
neuron death respectively when used alone, and these effects were significantly
attenuated (by 16 or 15% respectively) by TNF-a co-treatment (Fig 20A) indicating an
interaction between the two compounds. Indeed the toxic effect of TNF was no more
evident in the presence of AMPA concentrations (Fig 20A) and the presence of TNF
resulted in protection against AMPA-induced neurotoxicity.
Similar results were obtained if cocultures were pre-treated with 10 ng/mL TNF-a for 
72 hours before the 48 hour incubation. In this case the cytokine toxicity was enhanced 
to about 50% of motor neuron death when used alone (Fig 20B). A significant 
interaction between TN F-a and AMPA was detected (p < 0.001, Two Ways Anova), 
since the co-treatment with cytokine decreased the toxicity of 0.3 or 1 pM AMPA from 
38% or 52% (when used alone) to 22% or 38% (if in co-treatment with 10 ng/mL TNF- 
a) of motor neuron death respectively (Fig 20B).
Further studies on the specific contribution of glial cells to TNF-a-mediated toxicity 
were done by conditioning the confluent glial layer with exposure to the cytokine for 72 
hours before seeding motor neurons and establishing the cocultures. The number of 
motor neurons grown in cocultures with conditioned glia was significantly lower (3 7 % 
less, p<0.001; Fig 21) than that of motor neurons on control (not treated) glia.
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Figure 20. TNF-a induces motor neuron death in cocultures and 
significantly interacts with AMPAR agonist treatment.
Panel A: cocultures w ere treated with 10 ng/m L T N F -a  alone or in co ­
treatm ent w ith 0.3 or 1 jliM  A M PA  for 48 h. Panel B: cocultures w ere pre­
treated w ith 10 ng/m L  T N F -a  (w here present) for 72 h and then incubated 
w ith AM PA (in co-treatm ent w ith the cytokine w here indicated) for further 
48 h. Bars represent the m ean percentage + SD o f SM I 32-positive cells in 
each treatm ent condition. *** p < 0.001, ** p< 0.01 vs CTR or 10 ng/m L 
T N F -a . Tw o w ay A N O V A  and Bonferroni post tests, F int p < 0.001.
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Figure 21. TNF-a conditioned glia reduces motor neuron survival in 
cocultures.
Purified  m otor neurons w ere seeded over a control confluent glial layer 
(CTR) or over a g lial layer pre-treated with 10 ng/m L TN F-a for 72 h 
before the estab lishm ent o f cocultures. 1 w eek old cocultures w ere then 
stained by SM I32 and positive m otor neurons w ere counted. Bars represent 
the m ean percentage + SD o f SM I 32-positive cells in each treatm ent 
condition.
*** p < 0.001 vs CTR. A N O V A  and Tukey test.
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7.1.2 TNF receptor expression in motor neuron cultures
Since TNF-a exerted neurotoxicity only when mature glial cells were in the cultures, 
we verified the expression of TNF receptors in cocultures (4 weeks old glia) or in mixed 
anterior horn cultures (1 week old glia). In experiments with cocultures, motor neurons 
were plated over conditioned (pre-treated with 10 ng/mL TN F-a for 72 hours; Fig 22 E, 
F, G, H) or control (not treated; Fig 22 A, B, C, D) mature glial layers. Then, they were 
double-stained by SMI32 (red, Fig 22 A, E, C, G) and TNFR-1 (Fig 22 B, F) or TNFR - 
2 (Fig 22 D, H) antibodies. Both TNFR-1 and -2 showed a low immunostaining in 
motor neurons, but were highly localized in SMI32-negative cells (Fig 22 B, D), 
suggesting that glial cells express the two receptors. Conditioned glial cells did not 
affect this trend of expression and both TNFR-1 (Fig 22 F) and -2 (Fig 22 H) antibodies 
gave a similar pattern of immunofluorescence, with SMB 2-negative cells being 
intensively stained.
In another set of experiments, mixed anterior horn cultures were double-stained by 
GFAP (revealing the astrocytes) and by the TNFR-1 antibody. Despite the presence of a 
high number of GFAP-positive glial cells (Fig 22 I, in red), the staining of TNFR-1 
could not be revealed (Fig 22 J), suggesting that in this culture condition (1 week of in 
vitro aging) glial cells did not yet express TNFR-1.
Conclusions
We reported here evidence that the in vitro ageing of the glial population is the 
determinant for eliciting TNF-a-mediated neurotoxicity and protection against the 
AMPAR-mediated motor neuron death (when comparing the results obtained in mixed 
anterior horn cultures to those in cocultures). We revealed high immunoreactivity of 
TNF receptors in 4 week old glial cells (used in cocultures), while we could not obtain 
evidence for the presence of the receptors on glial cells grown in vitro for 1 week
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Figure 22. TNFRs are expressed in cocultures, but not in mixed 
anterior horn cultures.
C ocultures w ere estab lished  over control (not treated) or 10 ng/m L T N F -a- 
treated glial layer. A fter 1 w eek from  the establishm ent o f cocultures, they 
w ere double-stained by SM I32 (red, A, C, E, G) and TNFR1 (green, B, F) 
or TN FR2 (green D, H). Both the receptors are expressed in cocultures by 
m otor neurons and by SM I32-negative cells, independently  from  the 
presence o f control or conditioned glia.
In picture I and J, 1 w eek old m ixed anterior horn cultures w ere double­
stained by G FA P (red, I) and TNFR1 (green, J). TNFR1 is not expressed in 
this culture condition.
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(mixed anterior horn cultures). Consistently, when tested on motor neuron survival,
even at high concentrations (100 ng/mL) TN F-a was ineffective in mixed anterior horn
cultures. On the other hand, when a mature glial layer was present (cocultures) TNF-a
treatment induced motor neuron death both if present in the incubation medium and
after withdrawal from previous 72 hour pre-treatment. Experiments with conditioned
glia (pre-treated with the cytokine) demonstrated that the activation of the glial cells by
10 ng/ml TNF-a induced a neurotoxic phenotype that affected motor neurons
subsequently added to the glial cultures even if they were not directly exposed to the
cytokine.
We also documented a significant interaction between the effect mediated by TNF-a 
and the AMPAR-dependent toxicity in cocultures, while no interaction was present in 
mixed anterior hom cultures. We showed, in fact, that 10 ng/mL TNF-a exerted 
neuroprotective effect by significantly reducing the motor neuron death induced by 
different AMPA concentrations. Also the TN F-a neurotoxicity was significantly 
reduced by co-treatment with the AMPAR agonist.
Taken together these data are in accordance with the results described in the literature 
demonstrating the central role of glia in mediating TNF-a-dependent neurotoxicity and 
protection against excitotoxic insults, and clearly indicate that this effect is dependent 
on the presence of mature glial cells expressing the TNF receptors. Activated glial cells 
may in turn induce a toxic effect on neurons probably by the release of toxic mediators, 
or, alternatively, trigger neuroprotective mechanisms such as the TNF-mediated 
stabilization of neuronal [Ca2+]i (Cheng et al. 1994), suggesting the importance of the 
strict cross-talk between neurons and glia.
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7.2 Interleukin-8
Background
The presence of chemokine receptors has been described in the CNS (for review, see 
(Cartier et al. 2005). In particular, the chemokine receptor CXCR2, which mediates the 
recruitment and activation of polymorphonuclear (PMN) and other leucocytes by IL - 8  
at the site of tissue damage during inflammatory reactions, is the most strongly 
expressed chemokine receptor on neurons and is upregulated in Alzheimer disease 
(Horuk et al. 1997, Xia & Hyman 2002). CXCR2 is also expressed on oligodendrocytes 
and its ligands are present in multiple sclerosis lesions, meaning that there are CXCR2- 
mediated effects also in a disease that is not typically associated with PMN infiltration 
and suggesting that chemokines may do more than just mediate recruitment of 
inflammatory cells (Omari et al. 2006, Omari et al. 2005). The few data published on 
the trophic or toxic effects of CXCR1/2 and their ligands in neuronal cultures are 
controversial. IL- 8  enhanced the survival of hippocampal cultures in vitro, possibly by 
an indirect effect mediated by increased astroglial and microglial proliferation (Araujo 
& Cotman 1993). IL - 8  also showed neuroprotective activity against NMDA and (3- 
amyloid-induced toxicity in mixed cortical cultures (Bruno et al. 2000). A protective 
effect of IL- 8  against apoptosis induced by low potassium-containing medium was 
reported in cerebellar granule cells (Limatola et al. 2002, Limatola et al. 2000). 
However, other reports have shown that EL-8  has detrimental effects such as induction 
of Tau phosphorylation (Xia & Hyman 2002) and of pro-apoptotic proteins in primary 
neurons (Thirumangalakudi et al. 2007).
To study the role of chemokines acting via CXCR2 in motor neuron diseases, we 
investigated the effect of the CXCR2 ligand MIP-2 (CXCL2; homologue of EL- 8  in 
rodents) on primary motor neuron cultures, both as mixed anterior horn cultures and as
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purified motor neurons from rat embryos. To specifically address the role of CXCR2, 
we also used motor neurons from wild-type and CXCR2-deficient mice.
7.2.1 IL8 receptor CXCR1/2 expression on motor neurons
We verified the presence of the two IL- 8  receptor homologues in rodents (i.e. CXCR1 
and CXCR2) on motor neurons in mixed anterior horn cultures. Figure 23 shows the 
double-staining of mixed anterior horn cultures labelled with SMI32, selectively 
identifying motor neurons, and with the anti-CXCRl or anti-CXCR2 antibody. Both 
antibodies labelled the entire cell population, i.e. neurons and glial cells. However, 
while the staining for CXCR2 (Fig 23 F) was completely prevented by incubation with 
an excess of the specific blocking peptide (Fig 23 H), we could not demonstrate the 
specificity of CXCR1 staining (Fig 23 B) with its blocking peptide (Fig 23 D). The anti- 
CXCR2 antibody intensely stained glial cells and seemed to label the entire motor 
neuronal cell (Fig. 23 E, F), both in the soma and in the arborizations.
7.2.2 Neurotoxic effect mediated by CXCR2 activation
We investigated the effect of recombinant rat MIP-2 in mixed anterior horn cultures. 
Figure 24 shows that MIP-2 induced dose-dependent neurotoxicity triggering about 
50% motor neuron death at 12.5 nM. The boiled protein had no effect even at the 
highest concentration (12.5 nM), indicating that the neurotoxic effect was not due to a 
contaminant (Fig 24). MIP-2, at 12.5 nM, was toxic also to purified motor neuron 
cultures (41 + 6.5 % death, p<0.001; fig 25) indicating that the toxicity was due to a 
direct effect on motor neuron. Experiments performed with the human chemokine (IL- 
8 ) gave similar results, not significantly different from those obtained with MIP-2 (not 
shown). To see whether the in vitro neurotoxicity of MIP-2 was specifically mediated 
by CXCR2, we studied the effect of chemokine on mixed anterior horn cultures
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Figure 23. CXCR1 and CXCR2 distribution in motor neurons.
M ixed anterior horn cultures w ere double-stained w ith SM I32 (green, A , C, 
E  , G) and the specific antibodies for CXCR1 or CX C R 2 (red, B , D , F , H). 
CXCR1 and CX CR2 w ere revealed by prim ary antibody sc -2 3 8 1 1 ( B ,
D ) or sc-683 ( F , H ) respectively , as described in M ethods.
D, H: CXCR1 and C X C R 2 staining after incubation w ith an excess of 
specific blocking peptides.
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Figure 24. Dose-response effect of MIP-2 on motor neuron viability 
in mixed anterior horn cultures.
Viability of SM I32-positive motor neurons in mixed anterior horn cultures 
after 48 hour treatment with different M IP-2 concentrations. Data are 
expressed as the percentage of SMI32-positive cells normalized over 
controls, and are means + SD of 8  replicates from  4 independent 
experiments.
*** p < 0.001 vs control; f f t  p < 0.001 vs boiled solution, ANOVA and 
Tukey test.
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Figure 25. Toxic effect o f M IP-2 on motor neuron viability in purified 
motor neuron cultures.
Viability of SM B  2-positive motor neurons in purified motor neuron 
cultures after 48 hour treatment with 12.5 nM MIP-2. Bars represent the 
percentage o f SM I32-positive cells normalized over controls, and are means 
+ SD of 8  replicates from  4 independent experiments.
*** p < 0.001 vs control (no MIP-2), ANOVA and Tukey test.
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prepared from individual CXCR2 - / -  or control (both CXCR2 -/+  and CXCR2 +/+)
mouse embryos. As expected, 12.5 nM MIP-2 induced motor neuron death in cultures
from wild-type mice. Primary cultures from the spinal cords of CXCR2-deficient mouse
embryos developed like those from wild-type mice and motor neurons did not differ in
terms of morphology or SMI32 staining. However, 12.5 nM MIP-2, incubated for 48 h,
was not toxic for motor neurons from CXCR2 knock-out embryos, but induced 30-40%
death in those from control or heterozygous embryos (Table II).
TABLE II. Effect of MIP-2 on mouse mixed anterior horn cultures (% of motor 
neuron viability)
MIP-2 MIP-2 + reparixin
Wild type mice (+/+) 6 8  ±  22 (5) * 8 6  ± 14 (3) §
(+/-) mice 58 ±11  (10) ** 95 ± 19 (5) §
CXCR2 KO mice (-/-) 100+16(3) —
Mixed anterior horn cultures from single mouse embryos were incubated for 48 h with 
12.5 nM MIP-2, in the presence or absence of 10 jjM  reparixin.
Data represent means + SD of individual culture preparations, the number of replicates 
is given in parenthesis.
* p< 0.05, ** p<0.01: different from -/- mice (ANOVA and Tukey test)
§ p<0.0021, different from MIP-2 alone (ANOVA paired test)
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Conclusions
These results are the first demonstration of a toxic effect of a CXCR2 ligand on motor 
neurons. We showed MIP-2 dose-dependent neurotoxicity both in mixed anterior horn 
cultures and in purified motor neuron cultures, indicating a direct toxic effect of 
CXCR2 activation on the motor neuron, without the involvement of glial cells. We 
confirmed the presence of CXCR2 receptor on motor neurons, but could not document 
the specific immunostaining for CXCR1, in agreement with earlier reports showing 
CXCR2, not CXCR1, being expressed at high levels in some CNS regions, including 
motor neurons in the anterior horn of the human spinal cord (Horuk et al. 1997). The 
lack of effect of MIP-2 in mixed anterior horn cultures from CXCR2-deficient mice 
further indicated that the toxicity was specifically mediated by this receptor.
This finding supports the hypothesis that high IL - 8  levels during inflammatory reactions 
could exert also a direct neurotoxicity mediated by CXCR2 on motor neurons.
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Chapter 8 - Protein aggregation and excitotoxicity: the dual role of a-synuclein
a-Synuclein is a small (14 kDa) protein mainly expressed in the brain and 
predominantly concentrated in presynaptic nerve terminals. At physiological 
concentrations a-synuclein is an unfolded protein with no ordered secondary structure 
but it is well known that it can undergo polymerisation into fibrils associated with the 
formation of toxic aggregates (Moran et al. 2001). Overexpression of a-synuclein 
resulted in cytotoxicity while at nanomolar concentrations it protected neurons against 
serum deprivation, oxidative stress and excitotoxicity. Stable a-synuclein transfected 
neuronal cell lines have been shown to be protected from toxic insults such as H2O2 and 
the mitochondrial toxin MPP+ (Hashimoto et a l 2002, Jensen et al. 2003). NGF- 
differentiated PC 12 cells have been shown to be protected from H2O2 , 6 -OH DA and 
serum deprivation if previously incubated with the fusion protein TAT-a-synuclein 
(Albani et al. 2004). Finally a-synuclein protected rat primary cortical and hippocampal 
neuronal cells from death induced by serum deprivation and SHSY-5Y, GT1-1 and 
NGF-differentiated PC 12 cells againstFLC^, glutamate and serum deprivation 
treatments (Seo et al. 2002).
a-synuclein aggregates are associated with several neurodegenerative disease including 
Parkinson’s disease, Alzheimer’s disease, Lewy body dementia, multiple system 
atrophy and recently also to ALS (Bennett 2005). Aggregates of a-synuclein have been 
observed in neuronal spheroids, astrocytes, Schwann cells and in corticospinal axon 
tract fibers and glia in brain and spinal cord of ALS patients (Doherty et al. 2004, 
Mezey et al. 1998). In addition an increased expression of a-synuclein has been 
detected in the anterior horn of the spinal cord of SODG93A transgenic mice, an animal 
model of ALS (Chung et al. 2003).
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On the basis of such evidence, suggesting the involvement of a-synuclein in the
pathogenesis of ALS, we investigated the effect of the protein in motor neuron
degeneration by using purified cultured motor neurons.
8.1 a-Synuclein insertion and effect on motor neurons
On the seventh day in vitro (DIV 7) cultures were incubated for 18h with the fusion 
protein TAT-a-synuclein, generated from the insertion of the sequence containing the 
minimal translocation domain of the HIV1 protein TAT in frame before the N-terminal 
of the corresponding a-synuclein cDNA (Albani et al. 2004). Motor neurons treated 
with 100 nM or higher TAT-a-synuclein concentration showed a dose-dependent 
decrease in viability (p < 0.001 at all a-synuclein >100 nM concentrations tested,
Fig 26 A). Lower concentrations (tested up to 10 nM) did not affect motor neuron 
viability. From the dose-response curve (Fig 26 B) the calculated EC50 was 107 + 22 
nM. a-Synuclein internalization was then investigated by immunofluorescent assay 
using the primary antibody anti-a-synuclein. Immunofluorescence confirmed the typical 
fine punctate a-synuclein staining (Fig 27 A) previously observed in neuronal cells by 
Quilty and colleagues (Quilty et a l 2003). Even in control conditions, motor neurons 
were intensively labelled for a-synuclein throughout the cell body and processes with a 
patch-like distribution typical of the cytoskeleton constitutive proteins. For this reason it 
was not possible to quantify the further contribution of the exogenous a-synuclein, even 
when a lower concentration of primary antibody or the DAB staining was used (not 
shown). We obtained very similar results by using the anti-oligomer antibody which 
showed the same punctate staining observed with the antibody for the monomeric form 
of the protein, with no differences between control and a-synuclein-treated motor 
neurons (Fig 27 B). Although it was not a specific staining of a-synuclein, we clearly
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Figure 26. Dose-dependent neurotoxicity of a-synuclein.
A fter 1 week in culture, purified  m otor neurons w ere exposed to different 
concentrations of the fusion protein T A T -a-synucle in  for 18 h and then 
stained by SM I32. Panel A: bars represent the m ean percentage + SD o f 
SM I 32-positive cells obtained from  6 replicates for each condition.
* * * p < 0.001 vs control (no a -sy n ), A N O V A  and T ukey test. Panel B 
shows the dose-response curve o f  a -syn . D ata w ere fitted w ith the one site 
com petition equation built in G raphPad Prism  5.01; each point represents 
mean + standard deviation  o f 6 replicates from  3 independent experim ents. 
The calculated EC 50 is reported.
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Figure 27. Intracellular a-synuclein visualization.
A fter 1 w eek in culture, purified m otor neurons w ere exposed to 100 nM a -  
syn for 18h and then stained by different im m unocytochem ical assay.
Panel A: m otor neurons stained by the a -sy n  m onoclonal antibody for the 
detection o f m onom eric a -sy n  form. Panel B: m otor neurons stained by the 
A l 1 antibody for the olygom eric a -sy n  form. Panel C: m otor neurons (in 
phase contrast, upper row ) labeled by the T hioflavin-T  assay (low er row), 
revealing the am yloid  aggregates. Only the T hioflav in-T  assay revealed 
increased aggregates after 100 nM  a-sy n  treatm ent.
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identified increased fluorescent signal in a-synuclein-treated motor neurons compared
to control by the thioflavin-T binding assay (Fig 27 C), which detects amyloid
aggregates, demonstrating intracellular protein accumulation.
8.2 Protective effect of low a-synuclein concentration
Since previous evidence demonstrated that nanomolar concentrations of a-synuclein 
resulted in neuroprotection against different cytotoxic stimuli, we also examined in our 
model whether low a-synuclein concentrations could preserve motor neurons from 
death. Thus we investigated the effect of the protein against serum deprivation, H2O2  or 
kainate induced toxicity. Purified motor neuron cultures were pre-incubated with 50 nM 
TAT-a-synuclein for 3h on DIV 7 and then they were co-treated with TAT-a-synuclein 
and 100 pM H2O2 or 50 pM kainate for 18 or 48h respectively (treatments known to 
induce about 50% of motor neuron death in our experimental condition). 50 nM TAT- 
a-synuclein protected motor neurons from H2O2 - mediated toxicity (approximately 
20% viability increase, Fig 28). Quite surprisingly, a-synuclein, at the same 
concentration shown to be effective on oxidative stress-dependent toxicity, did not 
protect motor neurons from excitotoxicity, since the percentage of motor neuron death 
induced by 50 pM kainate was not significantly altered by co-treatment with the fusion 
protein (Fig 28). For serum deprivation, after the pre-incubation with TAT-a-synuclein 
cultures were treated with the protein dissolved in serum free-medium for 18 hours.
Here different nanomolar concentrations of the protein were tested, but none exerted 
any neuroprotective effect (Fig 29).
139
120-.
100 -
£  8°-
n
cs
>  60 -
Z
2
G
Figure 28. a-Synuclein is protective against H20 2- but not kainate- 
induced motor neuron death.
A fter 1 w eek in culture, purified  m otor neurons w ere pre-treated  by 50 nM  
a -sy n  for 3 h and then co-incubated  with a solution o f the protein added o f 
100 pM  H20 2 or 50 pM  K A  for further 18 h or 48 h respectively. Then, 
m otor neurons w ere stained by SM I32. Bars represent the m ean percentage 
+ SD o f 6 replicates from  3 independent experim ents.
* * * p < 0.001 vs control; ° p < 0.05 vs 100 pM  H20 9 alone, A N O V A  and 
Tukey test.
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Figure 29. a-Synuclein does not affect the motor neuron death 
occurring after serum deprivation.
A fter 1 w eek in culture, purified m otor neurons w ere pre-treated by 50 nM  
a -sy n  for 3 h and then incubated w ith a solution o f the protein diluted in 
m edium  free o f serum  and grow th factors for further 18 h. Then, m otor 
neurons w ere stained by S M B 2. Bars represent the m ean percentage + SD 
o f 6 replicates from  3 independent experim ents.
* * * p < 0.001 vs control, A N O V A  and T ukey test.
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Conclusions
Our experiments provide evidence to support a dual concentration-dependent effect of 
a-synuclein in cultured motor neurons, in accordance with what has been reported in 
other cell cultures (Albani et al. 2004, Seo et al. 2002). Our data indicated that TAT-a- 
synuclein displayed neuroprotective effect against oxidative stress at 10 nM. At the 
same concentrations effective against H2O2 , TAT-a-synuclein was not able to 
counteract cell death induced by 50 jiM kainate or serum deprivation. This suggests that 
the a-synuclein-dependent protective effect in motor neurons could be mediated by 
specific events which are mainly involved in oxidative stress conditions but do not have 
a fundamental role in excitotoxicity or serum deprivation. Conversely, as the 
concentration of the protein increased, a toxic effect was shown and motor neuron 
viability significantly decreased with an EC50 about 100 nM. We failed to specifically 
verify whether this toxicity was dependent on the accumulation of the protein in motor 
neurons, although amyloid aggregates were likely to be present in the toxic conditions 
(100 nM a-synuclein for 18 hours), as revealed by the thioflavin-T assay. Whether the 
toxic effect revealed in primary motor neuron cultures is dependent on protein 
accumulation inside these specific cells remains to be elucidated.
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Chapter 9 - Pharmacological approaches
An important aim of this research project was to test pharmacological compounds that 
might exert neuroprotection by interfering with the mechanisms of death that I analysed 
in vitro. Thus, the results obtained in primary motor neuron cultures brought us to test 
agents acting at different steps of the death pathways or on specific receptors with 
neurotoxic features. In particular we obtained interesting evidence for a protective effect 
by two classes of compounds: 1) erythropoietin (EPO), a hematopoietic growth factor 
which prevented the apoptotic cell death induced by AMPAR agonists, and its non- 
erythropoietic derivatives (CEPO, ASIALO-EPO and HBP) 2) reparixin, an orally 
active CXCR1/2 inhibitor counteracting the toxicity induced by MIP-2.
9.1 Erythropoietin and its derivatives
Background
EPO is a glycoprotein originally identified as the regulator of erythroid progenitor cells. 
EPO is induced in hypoxic conditions through the hypoxia-inducible factor 1 (HIF-1) 
transcription factor (Semenza & Wang 1992). Systemically administered EPO crosses 
the blood brain barrier (Brines et al. 2000) and showed neuroprotection in different 
models of neurodegenerative disease, including experimental autoimmune 
encephalomyelitis (EAE; Agnello et al. 2002, Savino et al. 2006), cerebral ischemia 
(Siren et al. 2001), and diabetic neuropathy (Bianchi et al. 2004). Its mechanism of 
action is not completely understood: in addition to its anti-apoptotic effect (Siren et al. 
2001), EPO inhibits CNS inflammation (Agnello et al. 2002, Villa et al. 2003), 
enhances neurogenesis in animal models of stroke and EAE (Wang et al. 2004, Zhang 
et al. 2005), and augments BDNF expression in vivo and in vitro (Viviani et al. 2005, 
Wang et al. 2004). Thus, in addition to promoting a hematopoietic effect, EPO showed 
protective effects in different in vitro and in vivo models of neurodegeneration. Since
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chronic administration of EPO results in an increase in the hematocrit, which could
increase the risk of thrombosis, different non-erythropoietic molecules retaining the
neuroprotective activities of EPO have been derived from EPO. One of these molecules,
carbamylated EPO (CEPO), has proven effective in animal models of stroke,
EAE, spinal cord injury, and diabetic neuropathy (Leist et al. 2004). Unlike EPO,
CEPO does not bind the erythropoietic receptor EPOR (Leist et al. 2004), and its
neuroprotective action appears to require the common P chain of IL-3/IL-5/GM-CSF
receptor (also known as CD131) (Brines et al. 2004), which can functionally associate
with EPOR (Jubinsky et al. 1997). Another non-erythropoietic EPO derivative is asialo
erythropoietin (ASIALO-EPO), which, although binding to EPOR, has a short half-life
and does not increase the hematocrit (an activity that requires persistent circulating
levels of EPO) but also retains neuroprotective activities in vivo (Erbayraktar et al.
2003).
HBP is a synthetic peptide, fragment of EPO, lacking the regions of EPO that interact 
with EPOR, but mimicking the helical structure of the full-length protein that interacts 
with CD 131 (Brines et al. 2008). In fact the peptide contains the amino acid sequence 
corresponding to helix B (residues 58-82) which is needed for the binding to CD131.
In this study we investigated the effect of EPO on motor neuron death elicited by two 
different stimuli that seem to play a relevant role in inducing or enhancing the 
progressive loss of motor neurons in ALS: neurotrophic factors withdrawal and 
AMPAR-mediated excitotoxicity. Moreover we tested if EPO analogues with no effect 
on hematopoiesis (ASIALO-EPO, CEPO and HBP) retain the neuroprotective effect of 
the parent compound.
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9.1.1 EPO is neuroprotective against apoptotic death induced by low AMPAR
agonist concentrations or by serum/BDNF deprivation
We first verified the presence of EPOR in mixed anterior horn cultures. The double 
staining of SM B2 and the specific antibody for EPOR revealed that EPOR was present 
both on motor neurons (Fig 30 C, merge staining) and on SMB2-negative cells (Fig 30 
C, red label). In particular, it stained motor neurons both on cell bodies and 
arborizations, and seemed to be located both in the membrane and in the cytosol. To 
assess if repeated EPO treatments modify the expression or the distribution of EPORs 
on motor neurons, purified cultures were treated with EPO (2.5 pmol/mL) for 5 days. 
The staining revealed no difference in the intensity and distribution of EPORs in EPO- 
treated cells compared with vehicle-treated cells (not shown), indicating that EPO, in 
the experimental conditions tested, neither downregulated nor upregulated EPOR.
For experiments on the effect induced by EPO treatment, cell death was induced on the 
sixth day in culture by incubating mixed anterior horn cultures for 48 hours with 5pM 
kainate (low AMPAR agonist concentration) or 1 pM AMPA (high AMPAR agonist 
concentration). EPO (2.5 pmol/mL) or vehicle was added to the cultures 72 hours before 
induction of cell death, and treatment continued for the 48 hours of exposure to the 
AMPAR agonists. The viability of motor neurons in mixed anterior horn cultures was 
significantly reduced after treatment with 5 pM kainate and returned to control values in 
cells treated with 2.5 pmol/mL EPO (Fig 31 A). The survival of untreated cultures 
exposed to EPO was above control values (128 + 38 n.s.; Fig 31 A), demonstrating the 
neurotrophic effect of EPO, possibly related to reduced spontaneous apoptosis.
1 pM AMPA caused 50% of cell death and EPO was not effective at protecting motor 
neurons from this excitotoxicity stimulus (Fig 31 A). These results indicate a selective 
effect of EPO against the AMPAR-dependent apoptotic cell death. The effect of EPO 
was concentration-dependent between 0.25 and 2.5 pmol/mL (concentration that
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Figure 30. Motor neurons express EPO and CD131 receptors.
M ixed an terior horn cultures w ere double-stained by SM I32 (green, A, D) 
and the specific antibody against EPO R  (B) or the (3 chain com m on to IL-3, 
IL-5, and G M -C SF receptors (E). C and F are the m erged pictures. C o­
incubation w ith an excess of the respective blocking peptides com pletely  
abolishes the specific staining o f anti-EPO R  and an ti-IL -3R  p antibodies 
(not show n). Scale bar: 25 pm.
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Figure 31. EPO counteracts the motor neuron death induced by low, 
but not the higher, AM PAR agonist concentrations
Panel A : m ixed an terior horn cultures pre-treated  w ith 2.5 pm ol/m L EPO  
for 72 h and then co-treated  w ith the cytokine and 5 pM  KA or 1 pM  
A M PA  for further 48 h. *** p<0.001 vs control.
Panel B: m ixed anterior horn cultures pre-treated  w ith 2.5 pm ol/m L EPO 
for 72 h and then co-treated  w ith the cytokine and 5 pM  KA or 1 pM  
AM PA for further 18h .  * * * p <  0.001 vs other treatm ent condition.
C-F: Syto59 (blue) and PI (red) double-stain ing in purified m otor neuron 
cultures. C ontrol cells are im perm eable to PI and do not show  DNA 
fragm entation (C). K ainate treated cells undergo to a m assive DNA 
fragm entation and nuclear shrinkage thus rem aining im perm eable to PI (D). 
A M PA  treated m otor neurons show ed a m assive PI penetration 
accom panied by nuclear enlargem ent (E). EPO  com pletely  counteracts the 
effect produced by kainate treatm ent (F). Scale bar C-F, 20 pm .
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produced full protection against kainate toxicity), with an ED50 of about 1.25 pmol/mL.
Figure 32 shows SMI 32-positive motor neurons in mixed anterior horn cultures
exposed to different treatments. After 72+48 hour treatment, 2.5 pmol/mL EPO
produced a clear neurotrophic effect, increasing the neurite outgrowth and the number
and differentiation of motor neurons (Figure 32 B) compared to control conditions (Fig
32 A). EPO was also neuroprotective when associated with 5 pM kainate (Figure 32 D)
restoring motor neurons in number and morphology, which were highly compromised
by the treatment with the agonist alone (Fig 32 C).
Since in this experimental condition only low AMPAR concentrations, but not the 
higher, induced caspase activation and nuclear fragmentation (see Chapter 6 , sections 
6 .2/6.5), further experiments were performed to investigate the effect of EPO on the 
specific apoptotic intracellular events.
After 18 hours, the high percentage of SMI32-positive motor neurons showing nuclear 
fragmentation induced by 5 pM  kainate treatment was significantly reduced by pre­
treatment with 2.5 pmol/mL EPO (Fig 31 B). lpM  AMPA treatment confirmed that no 
significant nuclear fragmentation was triggered compared to control condition, and EPO 
treatment did not affect this result (Fig 31 B).
In order to define whether DNA fragmentation was actually related to an exclusively 
apoptotic mechanism, double staining experiments using the fluorescent nucleic acid 
dyes SYTO 59 and propidium iodide (PI) were done. Fig 31 C shows the pattern of 
staining for PI (red) and SYTO 59 (blue) in purified motor neurons in basal condition. 
As for Hoechst 33258 staining the nuclei in control condition displayed a physiological 
morphology with homogeneous distribution of the nuclear dye, no PI staining was 
observed in these cells (Fig 31 C). Although low concentration kainate treatment 
produced a marked nuclear fragmentation and shrinkage (Fig. 31 D), motor neurons did 
not lose membrane integrity, as indicated by the lack of PI staining. Following the
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Figure 32. Neurotrophic and neuroprotective effect o f EPO on SMI 32- 
positive motor neurons in mixed anterior horn cultures.
M ixed anterior horn cultures stained by SMI32 after different treatments.
A: motor neurons in control cultures, well defined morphologically. B: 
mixed anterior horn cultures after treatment with EPO (2.5 pmol/mL) alone 
for 5 days. Large cell bodies with long axons and increased num ber of 
SMI32-positive motor neurons were shown. C: cultures treated for 48 h 
with 5 pM kainate. D: effect o f EPO (added 72 h before and during the 48 h 
of exposure to kainate) on cultures treated with kainate.
Scale bar = 40 pm.
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treatment with 1 pM AMPA, purified motor neuron exhibited marked cytoplasmic PI
positivity and an increased nuclear size without fragmentation (Fig 31 E). Both are 
common features of necrotic death. EPO counteracted kainate-induced nuclear 
fragmentation of motor neurons (Fig 31 F) but was ineffective when a non-apoptotic 
cell death was triggered with high AMPAR agonist concentrations (not shown).
For the detection of caspase activation, mixed anterior horn cultures were double 
stained using specific antibodies against SMI32 and the activated form of caspase-3 and 
caspase-9. The quantification of SMI32-positive cells co-expressing the activated 
caspase-3 motor neurons in mixed anterior horn cultures, 6  hours after excitotoxic 
exposure, further confirmed the involvement of apoptosis in motor neurons treated with 
5pM kainate and the selective anti-apoptotic role of EPO (Fig 33 A). On the other hand 
lpM  AMPA did not induce caspase-3 activation in SMI32-positive cells (Fig 33 A). 
Similarly to caspase-3, low AMPAR agonist concentration treatment increased the 
number of activated caspase-9 in SMI32 positive cells above control conditions and 
EPO reverted this effect (Fig 33 B). As expected, 1 pM AMPA treatment did not raise 
the mean number of activated caspase-9 positive motor neurons (Fig 33 B). The pattern 
of expression of either activated caspase-3 or activated caspase-9 in SMI 32-positive 
cells is shown in figure 33 C-E and figure 33 F-H respectively. The ratio between the 
percentage of activated caspase-3 positive cells and the percentage of activated caspase- 
9 positive cells, 6  hours after 5 pM kainate treatment, is about 3. Although this 
discrepancy may be due to a different sensitivity of antibodies used to reveal the two 
caspases, it is more likely that kainate-treated motor neurons did not have a 
synchronous activation of the apoptotic pathway. Therefore, it is possible that, 6  hours 
after kainate treatment, motor neurons which underwent early apoptotic activation 
already express both activated caspase-9 and caspase -3, whereas in motor neurons 
where apoptosis is slower only the cleaved form of caspase-3 can be detected.
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Figure 33. EPO antagonizes the caspase activation induced by low  
AM PAR agonist concentrations.
M ixed  anterior horn cultures p re-treated  w ith EPO  (2.5 pm ol/m L ) for 72 h 
and then exposed for further 6 h to low (5 pM  KA) or high (1 pM  A M PA ) 
A M PA R  agonist concentrations (alone or in co-treatm ent w ith the cytokine) 
w ere double-stained by SM I32 and the antibody for activated  capase-3 (A) 
or -9 (B). H istogram s show  the percentage o f  SM I32-positive cells 
d isplaying activation of caspase-3 (A) or -9 (B).
*** p < 0.001 vs control and the other treatm ent condition.
C-E: co-localization of activated  caspase-3 (green, D) in SM I32 positve 
cells (red, C) after kainate treatm ent.
F-H : co-localization o f activated  caspase-9 (green, G) in SM I32 positve 
cells (red, F) after kainate treatm ent. Scale bar C-H, 40 pm.
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To test the neuroprotective properties of EPO on the cell death triggered by a different
toxic condition, we investigated the effect of the cytokine on motor neuron viability in
purified motor neuron cultures after 18 hours of serum deprivation. Under these toxic
conditions motor neuron viability was significantly reduced and EPO completely
reversed this toxicity (% cell viability in control condition: 100.0 + 7.8; in serum-
deprived cells: 67.4 + 4 *** p < 0.001; in serum-deprived cells + EPO: 107.3 + 4.9 n.s.),
confirming previous published results (Siren et al. 2001).
The percentage of apoptotic nuclei, as revealed by DNA staining with Hoechst 33258, 
was hugely increased compared to control values and 2.5 pmol/mL EPO significantly 
reduced the percentage of apoptotic nuclei in serum-deprived cultures (Fig 34 A).
After the staining of purified motor neurons by the specific antibody, the number of 
motor neurons expressing activated caspase-3 was increased 6  hours after serum 
deprivation and was significantly reduced by EPO treatment (Fig 34 B). Figure 34 
shows representative pictures of purified motor neuron cultures incubated with Hoechst 
33258, panels C-E, and immunostained to detect the activated caspase-3, panels F-H. In 
control condition a high number of nuclei displayed physiological morphology (Fig 34 
C). In addition a very low number of cells positive for the activated form of caspase-3 
can be detected (Fig 34 F). Purified motor neurons showed a marked increase in 
fragmented nuclei after serum deprivation (Fig 34 D). In this condition the number of 
activated caspase-3 cells was also greatly increased (Fig 34 G). EPO alone did not 
produce any significant difference either in Hoechst 33258 binding or in activated 
caspase-3 immunostaining compared to control conditions (not shown). Representative 
pictures showing the effect of EPO in reducing nuclear fragmentation and caspase-3 
activation after serum deprivation are in Fig 34, panels E and H respectively.
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Figure 34. EPO antagonizes the nuclear fragmentation occurring after 
serum/growth factor deprivation.
M ixed an terior horn cultures w here pre-treated  (w here present) w ith EPO  
(2.5 pm ol/m L) for 72 h and then deprived o f serum  and grow th factors for 
fu rther 18 h w ere double-stained by SM I32 and H oechst 33258 (A) or 
activated  capase-3 (B). H istogram s show  the m ean percentage + SD (6 
rep licates from  3 independent experim ents) o f SM I32-positive cells 
d isplaying nuclear fragm entation (A) or activation o f caspase-3 (B).
*** p < 0.001 vs control and EPO  treatm ent, A NO V A  and Tukey test.
C-E: H oechst 33258 staining in purified  m otor neuron cultures. In basal 
conditions high percentage o f nuclei show s good m orphology (C); serum  
w ithdraw al drastically  increases the nuclear fragm entation (D); EPO 
treatm ent restores the nuclear m orphology (E).
F-H : activated caspase-3 im m unostain ing. In basal condition very few  cells 
show  activation of caspase-3 (F); serum  deprivation increases the 
im m unoreactiv ity  for activated caspase-3 antibody (G); EPO  treatm ent 
d rastically  reduces the num ber o f  active caspase-3 positive cells revealed in 
serum  deprivation condition (H). Scale bar, C-E, 20 pm : F-H , 40 pm.
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9.1.2 Effect of non-erythropoietic EPO derivatives
We extended the in vitro studies on motor neuron cultures to different non-
erythropoietic EPO derivatives, i.e. ASIALO-EPO, CEPO and to the EPO fragment
HBP. We initially verified if the CD131 receptor was expressed in mixed anterior horn
cultures. Cells were double-stained with SMI32 and the specific antibody for CD131.
CD 131 showed a pattern of expression similar to that of EPOR, being both in motor
neurons (Fig 30 F, merge staining) and in SMI32-negative cells (Fig 30 F, red) which
were intensively stained by the antibody.
Under the same treatment schedule used for EPO (added to mixed anterior horn cultures 
3 days before treatment and re-added with the glutamate agonist), both ASIALO-EPO 
and CEPO, tested at 100 ng/mL (equimolar concentration of EPO), significantly 
prevented the 5 pM kainate-induced motor neuron death (Table III).
To detect whether the EPO region that interact with CD 131 was sufficient to induce 
neuroprotection, we tested the synthetic peptide HBP. HBP (100 ng/mL), used with the 
pre-treatment schedule, exerted potent neuroprotective activity comparable to EPO and 
to CEPO since it completely blocked the neurotoxic effect of 5 pM kainate (Table HI).
Conclusions
We have shown here that EPO protects motor neurons from two different stimuli 
suggested to be responsible for human ALS: neurotrophic factors deficiency and 
excitotoxicity. Under the experimental conditions utilised in the present study, 
activation of the apoptotic pathway by serum deprivation or treatment with low kainate 
concentrations was clearly shown by DNA fragmentation and nuclear condensation, 
activation of caspase-3 and, mainly upon kainite exposure, caspase-9 cleavage. On the 
contrary, high AMPA concentration did not activate apoptotic motor neuron death (as 
shown in detail in Chapter 6 ). The neuroprotective effect of EPO was exerted
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TABLE III. Effect of kainate treatment on motor neuron viability in the absence 
or presence of EPO derivatives.
% motor neuron viability after 5 pM kainate
(No. replicates) Without EPO derivatives
With EPO 
derivatives
Asialo-EPO (12) 58 ± 11 91 ± 12***
CEPO (15) 42 ± 12 67 ± 19 **
HBP (6) 57 ±9 104 ± 12 ***
Viability of motor neurons in mixed neuron/glia cultures after 48 h of incubation with 
kainate (5 pM). When present, EPO derivatives (100 ng/mL) were added to motor 
neuron cultures 72 h before treatment and re-added with kainate. Data represent mean ± 
SD of SMI32-positive cells, normalized to control. For all EPO derivative treatment
Fintp < 0.001.
***p < 0.001, ** p < 0.01 vs. condition without EPO derivatives, Two-way ANOVA 
and Bonferroni post tests.
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exclusively against the apoptotic motor neuron death through the inhibition of the
intrinsic apoptotic pathway. This selective mechanism of protection has been
characterized in our study either by evaluating the effect on cell survival or
investigating the different features of cell death in all experimental conditions we
utilized. In addition, we reported that in basal conditions, the 5 day-treatment with EPO
produced a neurotrophic effect, increasing the neurite outgrowth and the number on
SMI32 positive motor neurons in mixed anterior horn cultures. A similar effect was
obtained in purified motor neurons (Siren et al. 2001) and it is likely related to a
decrease in spontaneous apoptosis. The reduction below control values of the
percentage of apoptotic nuclei and of activated caspase-3-positive cells further support
this hypothesis. However, EPO treatment did not produce significant protection when
motor neurons were exposed to a high concentration of AMPA that triggers a non-
apoptotic cell death pathway. Our data demonstrate EPO protection against low
AMPAR agonist concentration but not the higher concentrations in cultured motor
neurons. These discrepancies could be related to the type of death induced by
excitotoxins, depending on their concentration.
The in vivo utilization of chronic EPO treatment may be limited by modification of 
receptor expression and by the specific death pathway followed by neurodegeneration. 
However, the most important limitation is due to EPO activity on the hematocrit that 
could produce serious side-effect in patients. Thus, different non-erythropoietic 
molecules retaining the neuroprotective activities of EPO have been derived from EPO. 
We tested here two non-erythropoietic EPO derivatives, CEPO and ASIALO-EPO and 
a synthetic CD131 binding fragment of the protein, HBP, on AMPAR-mediated 
toxicity. They all exerted a potent neuroprotective effect on primary cultured motor 
neurons following stimulation of AMPA receptors by low concentrations of kainate.
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These results indicate that such molecules, devoid of hematopoietic activity, could exert
tissue-protective effects similar to EPO, thus offering a potential pharmacological
approach to the pathology.
9.2 Reparixin
As previously demonstrated (Chapter 7.2) CXCR2 activation induces direct toxicity on 
motor neurons. The finding of increased IL - 8  levels in the CSF of ALS patients (23+9 
pmol/mL in ALS vs. 16+5 pmol/mL in controls, p = 0.0026; CSF obtained by 38 ALS 
patients or 18 subjects with non-inflammatory neurological diseases; De Paola et al., in 
preparation) suggests that CXCR2-mediated neurotoxicity may represent an important 
contribution to a disease mainly characterized by motor neuron degeneration. Thus, the 
development of pharmacological strategies aimed at the limitation or inhibition of the 
CXCR2-mediated effect would represent a major advancement for the prevention of 
neuronal death in this toxic condition.
Reparixin, is a new small-molecule inhibitor of human CXCR1/R2 and rat 
CXCR2 receptor activation. Structural and biochemical data are consistent with a non­
competitive allosteric mode of interaction between CXCL8  receptors and reparixin L- 
lysine salt, which by blocking CXCR1 and CXCR2 in an inactive conformation 
prevents the activated receptor-induced intracellular signal transduction cascade and cell 
response. We tested here reparixin (as L-lysine salt) efficacy on motor neuron death 
induced by MIP-2 (see Chapter 7, section 7.2) and verified that it specifically exerted its 
effect by inhibiting CXCR2.
9.2.1 Neuroprotective effect of reparixin
Mixed anterior horn cultures or purified motor neuron cultures were exposed to MIP-2 
at a concentration previously demonstrated to induce neurotoxicity (12.5 nM, see
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Chapter 7, section 7.2.2) for 48 hours. When indicated, co-treatments were performed
by simultaneously adding the reparixin solution. Figure 35 shows that reparixin (1-10
pM in mixed cultures) counteracted the toxicity of 12.5 nM MIP-2, both in mixed (Fig
35 A) and purified (Fig 35 B) rat motor neuron cultures, with an IC 50 of 1 pM . To
demonstrate that the protective effect of reparixin specifically involved CXCR1/2, we
also tested DF1726A, which is structurally related to reparixin but is not active on IL - 8
chemotaxis in human PMN at a wide range of concentrations (10- 5  -10 - 8  M; Bertini et
a l, unpublished data). DF1726A, under the same conditions used for reparixin in mixed
cultures (10 pM for 48 h), did not protect motor neuron cultures from the toxicity of
12.5 nM MIP-2 (Fig 35 A). To support the specific neuroprotective action of reparixin
against the CXCR2-mediated toxicity, we tested its effect on AMPA receptor-mediated
motor neuron death. Under the experimental conditions used (48 h, 5 pM ), kainate
induced about 50% death in mixed anterior horn cultures and this was not affected by
10 pM reparixin (Fig 36). Similarly, in purified motor neurons, reparixin did not
counteract the effect of 50 pM kainate (45 + 4 and 52 + 1% kainate-induced death in the
vehicle- and reparixin-treated groups, respectively).
Conclusions
We demonstrated here for the first time that reparixin specifically prevented the MIP-2- 
induced death of motor neurons in vitro. This effect is not mediated by glial cells since 
reparixin was neuroprotective also in purified motor neuron cultures. This finding 
supports the encouraging results from the literature showing reparixin-dependent 
neuroprotection also in in vivo models (Gorio et al. 2007, Villa et al. 2007) and suggests 
that this drug could exert important pharmacological effects in addition to its anti­
inflammatory properties.
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Figure 35. Reparixin is neuroprotective against M IP-2-induced toxicity in 
both mixed and purified m otor neuron cultures.
M ixed anterior horn cultures ( A ) or purified motor neurons ( B ) were 
exposed for 48 h to a toxic concentration ( 1 2 . 5 n M ) o f  M IP-2 alone 
or with different concentrations o f reparixin (100 nM  to 10 pM  ).
The reparixin analogue DF1726A was also tested in mixed cultures (A).
Data are expressed as the mean percentage + SD of 6  replicates from  3 
independent experiments.
* p < 0.05, * * p < 0.01, * * * p < 0.001 vs control; f t  P < 0.01, f t f  p < 0.001 
vs 12.5 nM  M IP-2 alone, ANOVA and Tukey test.
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Figure 36. Reparixin does not prevent the kainate-induced motor 
neuron death in mixed anterior horn cultures.
M ixed anterior horn cultures were exposed for 48 h to 5 pM  kainate alone 
or with 10 pM  reparixin. Data are expressed as the percentage of SMI32- 
positive cells normalized over controls, and are means ±  SD of 8  
replicates from  4 independent experiments. *** p < 0.001 different from  
control and reparixin alone, ANOVA and Tukey test.
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The most striking evidence when facing ALS is the lack of effective or at least 
encouraging treatments for fighting the disease. Interventions aimed at prolonging the 
patient’s survival by a few months or palliative care applications represent an attempt 
to patch up the problem rather than to offer real solutions. The deficiency of valid 
pharmacological therapies is the consequence of the failures in elucidating the 
triggering events underlying the pathology and of the still incomplete information 
coming from the use of animal models. Most of the pharmacological studies are 
performed in vivo on the SOD 1 transgenic mouse that, although being a valid model of 
the familiar form of ALS, brings mutations representing only 2% of the ALS cases in 
humans and is anyway poorly functional for pharmacokinetic studies. Moreover, the 
latest epidemiological studies describe ALS as a disease in continuous evolution, 
showing new features in terms of disease progression, course and incidence when 
compared to data from the previous decade (Beghi et al. 2007). These are clearly related 
to the evolution of human life-style. ALS is currently considered to be an age-related 
disease, with cigarette smoking being the only risk factor supported by fairly good 
epidemiological evidence (Beghi et al. 2007). New clusters of people with increased 
ALS incidence have been discovered, different from those already known, to introduce 
new unknown, possibly environmental factors for the onset of ALS. All this evidence 
makes the therapeutic solution even more difficult to be successful. Thus, parallel in 
vitro and in vivo studies on both patient’s specimen and animal models are required in 
order to discover the mechanisms activated in motor neurons under such peculiar toxic 
conditions. Among all the different in vitro models, primary cultures have been the most 
used over the years and have provided a huge amount of valid and useful information on 
the physiological and pathological role of the neural population.
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In the present study primary motor neuron cultures were used to investigate the role of 
AMPAR-dependent excitotoxicity in motor neuron death. The effects of TNF-a and JL- 
8 were also considered in order to study the interaction between the neuroinflammatory 
response and the excitotoxic damage. Finally we evaluated the role of protein 
aggregation by analyzing the effect of a-synuclein accumulation in motor neurons. In 
order to propose valid pharmacological approaches for this pathological condition, 
different compounds interacting with the considered death pathways were tested.
Excitotoxicity
Glutamate-induced excitotoxicity is the best-characterized factor in the pathogenesis of 
ALS and AMPA/kainate receptors mainly mediate calcium-dependent motor neuron 
death in such toxic conditions (Carriedo et al. 2000, Carriedo et al. 1996). We reported 
here a successful approach to the in vitro study of AMPAR-mediated intracellular 
events occurring in motor neurons when exposed to different excitotoxic stimuli. We set 
up and standardized an easy and quick model of cocultures of purified motor neurons 
and glial cells which showed significant improvement in motor neuron health and 
survival compared to other previously reported methods. This allowed a detailed study 
of the AMPAR-mediated neurodegenerative mechanisms as well as other important 
events related to the AMPAR-dependent pathways, which occur in ALS. The main 
objective of this study was to fully analyze the effect of AMPAR agonists on the main 
events activated during apoptotic cell death, i.e. mitochondrial cytochrome c release, 
activation of the caspase cascade, externalization of the phosphatidylserine residues on 
the outer membrane surface and DNA fragmentation. This cell death pathway appears 
to occur in both ALS animal models and patients (Cleveland & Rothstein 2001, 
Friedlander 2003, Pasinelli et al. 2000). The expression of the anti-apoptotic protein 
Bcl-2 is decreased, whereas that of the pro-apoptotic protein Bax is increased in the
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spinal cord of ALS patients and of transgenic mSODl mice (Martin 1999, Vukosavic et 
al. 1999). After a death stimulus, cytosolic Bax translocates to mitochondria (Gross et 
al. 1998, Wolter et al. 1997) where it can promote the release of cytochrome c. 
Immunocytochemical evidence of cytochrome c translocation in motor neurons of 
spinal cords from sALS patients or from transgenic mSODl mice has been reported and 
it occurs in parallel with the neurodegenerative process in the animal model (Guegan et 
al. 2001). Activation of caspases is likely to participate in the neurodegenerative process 
of ALS, since caspase-1, -3, -7 and -9 are activated in spinal cords from affected 
transgenic mSODl mice (Guegan et al. 2001, Pasinelli et al. 1998, Pasinelli et al. 2000, 
Vukosavic et al. 2000).
A dual role of glutamate in triggering either necrosis or apoptosis with time and 
concentration dependence has been reported in cerebellar granule cell cultures 
(Ankarcrona et al. 1995). Consistently, here we clearly demonstrated that, also in the 
motor neuron, the main cellular target of ALS, AMPAR agonists can induce different 
intracellular death pathways depending on the intensity of the initial stimulus.
In fact, when low AMPAR agonist concentrations (inducing less than 25% motor 
neuron death within 6 hours) were used, we could observe activation of the apoptotic 
machinery in motor neurons, starting from the earlier events such as the mitochondrial 
cytochrome c release and the following activation of the caspase cascade, up to the 
latest, including chromatin condensation and DNA fragmentation externalization and re­
arrangement of phosphatidylserine composition of the outer membrane. On the other 
hand, higher concentrations, triggering more than 35% death after 6 hour treatment, do 
not induce any significant effect on the different apoptotic events considered in the 
study, compared to control conditions.
A key triggering factor, dependent on the intensity of the initial stimulus to the AMPAR 
and able to lead to the activation of different patterns of death, is the amount of
163
PhD Thesis, M. De Paola
DISCUSSION
intracellular calcium influx and resulting compromised calcium homeostasis. When 
Ca2+ influx is slow and relatively moderate in quantity the pathway involving protease 
cleavage is activated. On the other hand, stronger glutamatergic stimulation can produce 
a massive Ca2+ influx which reduces the functionality of different organelles such as 
mitochondria and the endoplasmic reticulum thus provoking such a fast decay in 
cellular activity that the cells, which might be triggered to undergo apoptosis, are 
instead forced to die by necrosis (Volbracht et al. 1999). The role of [Ca2+]i in 
AMPAR-mediated excitotoxicity was studied in vitro by exposing neurons to high 
AMPAR agonist concentrations rapidly triggering neuron death (Arundine & Tymianski 
2003, Carriedo et al. 2000, Van Damme et al. 2003, Van Den Bosch et al. 2000, 
Vandenberghe et al. 2000). Motor neurons were more sensitive to Ca2+ - dependent 
degeneration after exposure to kainate or AMPA than other neurons (Arundine & 
Tymianski 2003, Carriedo et al. 2000, Van Damme et al. 2003, Van Den Bosch et al. 
2000, Vandenberghe et al. 2000). Kainate or AMPA induced a selective rise in 
cytoplasmic Ca2+ concentration, reactive oxygen species and mitochondrial Ca2+ 
overload in motor neurons (Carriedo et al. 1996, Sen et al. 2008, Van Den Bosch et al. 
2000), suggesting that mitochondria are one of the main targets of AMPAR-dependent 
calcium influx. Recently, mitochondrial failure in buffering the kainate-dependent 
persistent increase of cytosolic calcium was reported and this was partially attributed to 
the lower density of such organelles in motor neurons (Grosskreutz et al. 2007).
Here we detected the [C a2+]i variations induced by different AMPAR agonist 
concentrations able to activate specific intracellular pathways leading to motor neuron 
death. We revealed that higher AMPAR agonist concentrations induce higher AMPAR- 
dependent intracellular calcium influx compared to lower concentrations, thus causing a 
severe alteration in calcium homeostasis and possible rapid non-apoptotic degeneration. 
By contrast, lower AMPAR agonist concentrations trigger a milder increase in [C a2+]i
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which could allow the cell to activate secondary intracellular events and the complex 
apoptotic machinery under persistent toxic conditions.
Pharmacological treatments with EPO were performed against AMPAR-dependent 
motor neuron death since this compound has shown interesting neuroprotective 
properties in different models of neurodegenerative disease (Agnello et al. 2002, 
Bianchi et al. 2004, Savino et al. 2006, Siren et al. 2001, Viviani et al. 2005, Wang et 
al. 2004).
We showed here that EPO treatment protects motor neurons from two different stimuli 
suggested to be responsible in human ALS: neurotrophic factors withdrawal and 
excitotoxicity. However, the neuroprotective effect of EPO was exclusively exerted 
against the apoptotic motor neuron death occurring after serum deprivation or treatment 
with low AMPAR agonist concentrations through the inhibition of the intrinsic 
apoptotic pathway. This selective mechanism of protection has been characterized in 
our study either by evaluating the effect on cell survival or investigating the different 
features of cell death in all experimental conditions we utilized. In addition, we reported 
that in the basal condition, the repeated treatment with EPO produced a neurotrophic 
effect, increasing the neurite outgrowth and the number on SMI32-positive motor 
neurons in mixed anterior horn cultures. A similar effect was reported in the literature 
also in purified motor neurons (Siren et al. 2001) and it is likely related to a decrease in 
spontaneous apoptosis rather than to an increase in the number of new cells. This is 
consistent with other reports that EPO does not stimulate cell proliferation in neuronal 
cultures (Siren et al. 2001). We showed here reduction below control values of the 
percentage o f apoptotic nuclei and of activated caspase-3 positive cells upon EPO 
treatment which lends further support for this hypothesis. However, we did not detect 
any significant protection by EPO when motor neurons were exposed to a higher 
concentration of AMPA that triggers non-apoptotic cell death . The effect of EPO on
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excitotoxicity in cellular models in vitro is somewhat confusing: protection against 
glutamate exposure was reported in cultured hippocampal and cortical neurons 
(Morishita e t  al. 1997) and in cortical neurons exposed to NMD A (Bernaudin e t  al. 
1999). Conversely, it has also been reported that EPO protects cortical neurons from the 
toxicity induced by AMPA, but not by glutamate or NMDA (Sinor & Greenberg 2000). 
These discrepancies could be related to the type of death induced by the different 
concentrations. Along those lines, our present data report EPO protection against low, 
but not high, AMPAR agonist concentrations indicating the specific prevention of 
apoptotic motor neuron death .
EPO has been tested in vivo and found to be active on acute spinal cord injuries, such as 
ischemia (Celik e t  al. 2002) or trauma (Gorio e t  al. 2002) where excitotoxicity plays an 
important role. However, studies aimed at testing the effect of EPO in the mSODlG93A 
mouse model reported controversial results. In 2007, Koh and colleagues showed that 
EPO was protective in this model in that it delayed symptom onset, rotarod failure and 
endpoint, and also by prolonging the symptom duration. Its protective effects might be 
achieved through inhibition of both motor neuron death and inflammation (Koh et al., 
2007). Noteworthy, in the same year Grunfeld et al. found a modest delay in disease 
onset in female mice only, without an effect on survival after EPO treatment. The 
hematocrit rose to a similar extent in female and male treated mice supporting the 
authors' conclusion that the effect of EPO on motor function was sex specific and not 
secondary to an unequal effect on hematocrit (Grunfeld et al., 2007). Firm conclusions 
on whether EPO was neuroprotective in this mouse model were not possible from that 
study since the study sample size was small and the mice were unequally distributed 
between the treatment and control groups (20 and 14 respectively).
Another group of investigators published that EPO did not preserve motor neurons in 
the mSOD!G93A animal model of ALS (Grignaschi et al., 2007). There were several
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methodological differences between the two EPO studies. These include use of different 
forms and dosages of EPO and different routes of administration: subcutaneous versus 
intraperitoneal. While treatment was initiated at approximately the same age in both 
studies, Grignaschi et al. utilized a slight variation in rotarod task, administered 
treatment more frequently, and also measured hematocrit more frequently. Treatment by 
Grignaschi et al. significantly increased mice hematocrit compared to Grunfeld et al., 
yet finding no preservation of spinal cord motor neurons and no sex-specific effects. 
Both groups report a delay in the decline of rotarod performance. Grignaschi et al. 
conclude that increased oxygen delivery to muscles may be responsible for this effect 
on rotarod performance. Neither group reported an effect on survival.
The effect of chronic EPO treatment may be limited by modification of receptor 
expression and by the specific death pathway followed by neurodegeneration. However, 
the most important limitation is due to EPO activity on hematocrit that could produce 
serious side-effects in patients. Thus, we also successfully tested different non- 
erythropoietic EPO derivatives that could be more suitable for chronic therapeutic 
strategies. ASIALO-EPO, CEPO and the synthetic CD131-binding-fragment HBP all 
showed potent anti-apoptotic properties against AMPAR-dependent motor neuron 
death similar to those observed for EPO. The in vivo protective effect of CEPO has 
already been described for spinal cord compression, diabetic neuropathy, and 
experimental autoimmune encephalomyelitis (Leist et al. 2004). Furthermore, we found 
that CEPO, and, to a lesser extent, ASIALOEPO, could exert neuroprotective effects in 
a model of chronic motor neuron degeneration (the wobbler mouse) and reduce 
inflammation in the anterior horn of the spinal cord without increasing hematocrit levels 
(Mennini et a l  2006).
HBP is small peptide and has proteolytic features which, presumably, confer a very 
short plasma half-life to the peptide. Nevertheless HBP has been found to be protective
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in a rat model of middle cerebral artery occlusion in which EPO (Brines et al. 2000), 
ASIALO-EPO (Erbayraktar et al. 2003), and CEPO (Leist et al. 2004) have previously 
been shown to produce strong protective effects. Recently, the tissue protective effect of 
HBP has also been demonstrated in vivo in a variety of other models, including 
ischemic stroke, diabetes-induced retinal edema, and peripheral nerve trauma (Brines et 
al. 2008). The results of these experiments showed that the tissue-protective activities of 
EPO are mimicked by small, non-erythropoietic peptides that recapitulate a portion of 
EPO’s three-dimensional structure acting on CD131, thus suggesting this receptor and 
related pathways as possible therapeutic targets.
Neuroinflammatory mediators
Inflammatory reactions have been implicated in several pathogenic mechanisms of 
motor neuron diseases, including ALS (Appel et al. 1995, Cereda et al. 2008, Poloni et 
al. 2000, Yi et al. 2000). In particular, high concentrations of IL-6, TNF and MCP-1 
were detected in the cerebrospinal fluid or plasma of ALS patients, suggesting a 
neuroinflammatory component (Baron et al. 2005, Cereda et al. 2008, Ford & Rowe 
2004, Gallo et al. 1994, Joerg Stuerenburg et al. 1999, Krieger et al. 1992, Moreau et 
al. 2005, Poloni et al. 2000, Sekizawa et al. 1998, Wilms et al. 2001). Thus, our 
investigation about possible interactions between the effect of important mediators of 
the inflammatory response, such as TNF-a and IL-8, and the excitotoxic injury in motor 
neurons could be of great relevance for the understanding of such ALS pathogenic 
mechanisms.
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TNF-g
Previous findings reported a dual effect of TNF-a on excitotoxic neuronal damage. 
TNF-a had a neuroprotective effect against AMPAR-mediated excitotoxicity in 
organotypic hippocampal slice cultures (Bernardino et al. 2005) and showed 
anticonvulsant effects against kainate-induced seizures (Balosso et al. 2005). 
Furthermore it induced a neuroprotective effect against excitotoxic insults by promoting 
the maintenance of calcium homeostasis (Cheng et al. 1994) or the activation of the 
transcription factor NF-kB (Marchetti et al. 2004). On the other hand it strengthened 
glutamatergic synaptic transmission by increasing the surface expression of AMPA 
receptors (Beattie et al. 2002, Stellwagen et al. 2005) and human neuronal cell lines 
showed increased susceptibility to kainate after TNF-a treatment. Furthermore, the 
combination of glutamate and TNF-a provoked an amplified neurotoxic effect mediated 
by the AMPAR in the rat spinal cord (Hermann et al. 2001).
We reported here that TNF-a treatment induced motor neuron death only in cocultures, 
where a mature glial cell layer was present. We also documented a significant 
interaction between the effect mediated by TNF-a and the AMPAR-dependent toxicity 
in cocultures, while no effect was revealed in mixed anterior hom cultures. This 
evidence demonstrates that the in vitro aging of the glial population is a determinant for 
eliciting TNF-a-mediated neurotoxicity and protection against the AMPAR-mediated 
motor neuron death. Many authors have associated the dual effect of TNF-a with its 
interaction with its two different receptors. In particular, using mice lacking TNF-a 
receptors or selective stimulation of TNFR1 by human TNF-a, Bernardino and 
colleagues (Bernardino et al. 2005) defined the selective involvement of TNF-a 
receptor subtypes in the opposite effects of the cytokine on AMPA-induced cell death. 
Namely, that the neuroprotective effect was mediated by TNFR2, whereas TNFR1
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mediated exacerbation of the AMPA toxicity. In accordance, TNFR1 has been 
implicated in cell death by a variety of authors (Fontaine et al. 2002, Stellwagen et al. 
2005, Yang et al. 2002), while TNFR2 was suggested to mediate neuronal survival 
(Balosso et al. 2005, Fontaine et al. 2002, Marchetti et al. 2004). Thus, the mechanisms 
modulating the expression of these two receptors and the subsequent intracellular 
signal(s) may determine neuronal responsiveness to TNF-a and its interaction with 
excitotoxicity.
We frequently revealed high immunoreactivity of TNF receptors in 4 week old glial 
cells (used in cocultures), while we could not document the presence of the receptors on 
glial cells grown in vitro for 1 week (mixed anterior horn cultures), suggesting that both , 
the neuroprotection and the neurotoxic effect induced by TNF-a on motor neurons are 
dependent on the functional expression of its receptors.
EL-8
Chemokines were reported to have direct effects on neurons. In particular, the EL-8 
receptor CXCR2 is expressed in neurons and may play a pathophysiological role in 
neurodegenerative diseases, like Alzheimer disease (Horuk et al., 1997; Xia et al.,
2002). In the present study we aimed at verifying the role of CXCR2 on motor neuron 
degeneration. The few data that have been published on the trophic or toxic effects of 
CXCR1/2 and their ligands were obtained from experiments on neuronal cultures 
distinct from motor neurons, and they are controversial. EL-8 enhanced the survival of 
hippocampal cultures in vitro, possibly by an indirect effect mediated by increased 
astroglial and microglial proliferation (Araujo et al., 1993). IL-8 also showed 
neuroprotective activity against NMDA or p-amyloid-induced toxicity in mixed cortical 
cultures (Bruno et al., 2000). A protective effect of MEP-2 (CXCR2 agonist in rodent) 
against apoptosis induced by low potassium-containing medium was reported in
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cerebellar granule cells (Limatola et al., 2000, 2002). However, other reports found that 
IL-8 has detrimental effects such as induction of Tau phosphorylation (Xia et al., 2002) 
and of pro-apoptotic proteins in primary neurons (Thirumangalakudi et al., 2007). This 
is the first report of a toxic effect of a CXCR2 ligand on motor neurons. We found that 
MIP-2 induced dose-dependent neurotoxicity in mixed anterior horn cultures and 
purified motor neuron cultures, indicating a direct toxic effect of CXCR2 activation on 
the motor neuron, without the involvement of glial cells. We also confirmed the 
presence of CXCR2 receptors on motor neurons, but could not document specific 
immunostaining for CXCR1, which is in agreement with earlier studies showing that 
CXCR2, but not CXCR1, is expressed at high levels in certain CNS regions including 
motor neurons in the anterior horn of the human spinal cord (Horuk et al., 1997). The 
lack of effect of MEP-2 on mixed anterior horn cultures of CXCR2-deficient mice 
further indicated that the toxicity is specifically mediated by this receptor. The present 
finding of direct neurotoxicity induced by CXCR2 activation on motor neurons suggests 
new pathogenic mechanisms for ALS. The direct role of CXCR2 ligands in neuronal 
death in vivo is indicated by the fact that intrahippocampal injection of MIP-2 results in 
the apoptotic cell death of hippocampal neurons (Kalehua et al. 2004).
Preliminary studies on the spinal cord of wobbler mice indicated high levels of CXCR2 
ligands (De Paola, in preparation), further supporting a possible role of this chemokine 
receptor in vivo. These results not only add a new piece to the picture of the complex 
relationships between inflammatory molecules and CNS diseases, but also open the way 
to new therapeutic avenues.
We reported a possible pharmacological approach to the prevention of CXCR2- 
mediated neurotoxicity by testing the effect of reparixin, an orally active CXCR1/2 
inhibitor which has been shown to reduce PMN infiltration and have protective activity 
in rat models of cerebral ischemia (Garau et al., 2005; Villa et al., 2007). It is currently
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being tested in a phase-2 clinical trial for graft dysfunction after kidney or lung 
transplantation. We found that reparixin specifically prevented the MIP-2-induced death 
of motor neurons in vitro. The finding by Gorio et al. (Gorio et al., 2007) of the efficacy 
of reparixin in reducing MIP-2 concentrations, oligodendrocyte apoptosis and axon 
demyelination in an in vivo model of spinal cord injury supports the possible 
neuroprotective role of CXCR2 inhibitors in the spinal cord. These results may 
be relevant not only for ALS, where chemokines released from activated glial cells can 
contribute to motor neuron degeneration, but also for other diseases associated with 
a secondary loss of motor neurons, including spinal cord injury and multiple sclerosis.
Protein aggregation
We also performed initial attempts to elucidate the effect of a-synuclein accumulation 
in cultured motor neurons, since protein accumulation represents an important event of 
ALS aetiology. The discovery of a-synuclein in Lewy bodies in PD (Polymeropoulos et 
al. 1997, Spillantini et al. 1997) was followed quickly by its detection in cellular 
inclusions in several other neurodegenerative diseases including cortical Lewy body 
dementia (Baba et al. 1998, Spillantini et al. 1998), multiple system atrophy (Arima et 
al. 1998, Fujiwara et al. 2002, Gai et al. 1999, Tu et al. 1998, Wakabayashi et al.
1998a, Wakabayashi et al. 1998b), Hallervorden-Spatz syndrome, now called 
neurodegeneration with brain iron accumulation type 1 (Arawaka et al. 1998, Saito et 
al. 2000, Wakabayashi et al. 1999), and amyotrophic lateral sclerosis (Mezey et al. 
1998). Aggregates of a-synuclein have been observed in neuronal spheroids, astrocytes, 
Schwann cells and in cortico-spinal axon tract fibers and glia in brain and spinal cord of 
ALS patients (Doherty et al. 2004, Mezey et al. 1998). In addition an increased 
expression of a-synuclein has been detected in the anterior horn in the spinal cord of 
SODG93A transgenic mice, an animal model of ALS (Chung et al. 2003).
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Our experiments provided evidence of a dual neuroprotective/neurotoxic effect of oc- 
synuclein in cultured motor neurons which is concentration-dependent. a-Synuclein, 
targeted into the motor neuron by the HIV 1 protein TAT, exerted a neuroprotective 
effect against oxidative stress, but not AMPAR-dependent excitotoxicity or serum 
deprivation, at nanomolar concentrations. Conversely, at micromolar concentrations, a- 
synuclein induced motor neuron death, likely caused by intracellular protein aggregates, 
as revealed by the thioflavin-T assay. These results are in accordance with what has 
been reported in other cell cultures (Albani et al. 2004, Seo et al. 2002).
Conclusions
In fulfilment of the objectives of this research project we have provided a wide range of 
information on in vitro motor neuron degeneration. In an earlier phase we set up and 
established an easy and reproducible new method for the culture of motor neurons and 
glial cells which allowed the study of the single cell type as well as the interactions 
between the two neural populations. We then reported consistent insights into the 
activation of different intracellular mechanisms when motor neurons were exposed to 
some of the main toxic conditions that are relevant in ALS aetiology, i. e. excitotoxicity, 
oxidative stress, serum deprivation, neuroinflammation and protein aggregation. These 
data add a new understanding within the complex network of events occurring in 
affected motor neurons. Furthermore this in vitro model allows to obtain further 
information about the fine pathways activated in degenerating motor neurons under 
different toxic conditions. Even if already important by themselves such basic results 
about the mechanisms used by motor neurons to die have acquired a greater relevance 
to our understanding of how cell death might be prevented. In fact, to complete the 
research outcomes we successfully tested different compounds which could prevent or 
counteract motor neuron death, induced by toxic agents, by interfering with the
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intracellular death pathways that we previously elucidated. Such pharmacological 
approaches are well supported by results from in vivo studies on animal models and 
suggest potential therapeutic applications for the treatment of ALS.
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Appendix I
Appendix I - Main external contribution to the work of thesis
Part of the thesis experiments availed of the important collaboration of external 
colleagues and researchers.
- Studies on calcium imaging by confocal microscopy were performed in 
collaboration with Prof. Daniela Curti and Dr. Farncesca Botti, Department of 
Molecular and Cellular Physiological and Pharmacological Sciences, University 
of Pavia, Italy and with the technical facilities of the University of Pavia.
- CXCR2-deficient mice were provided by Dompe, Dompe Research Centre, 
Dompe pha.r.ma s.p.a., and embryo genotyping was performed in collaboration 
with the Department of Experimental Medicine, University of L ’Aquila, 
L ‘Aquila, Italy.
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